<PAGE> 1
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
[X] Annual Report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the fiscal year ended September 30, 1996
or
[ ] Transition Report pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934 for the transition period from ________________
to ________________
Commission file number 1-11091
SYBRON INTERNATIONAL CORPORATION
(Exact name of registrant as specified in charter)
<TABLE>
<S> <C>
WISCONSIN 22-2849508
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
411 EAST WISCONSIN AVENUE 53202
Milwaukee, Wisconsin (Zip Code)
(Address of principal executive offices)
</TABLE>
Registrant's telephone number, including area code: (414) 274-6600
Securities registered pursuant to Section 12(b) of the Act:
<TABLE>
<CAPTION>
NAME OF EACH EXCHANGE
TITLE OF EACH CLASS ON WHICH REGISTERED
- --------------------------------------------- ---------------------------------------------
<S> <C>
Common Stock, par value $0.01 per share New York Stock Exchange
</TABLE>
Securities registered pursuant to Section 12(g) of the Act: NONE
Indicate by check mark whether the registrant: (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. YES [X] NO [ ]
Indicate by check mark if disclosure of delinquent filers pursuant to Item
405 of Regulation S-K is not contained herein, and will not be contained, to the
best of registrant's knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to this
Form 10-K. [ ]
The aggregate market value of the voting stock held by non-affiliates of
the registrant, based upon the closing sale price of the registrant's Common
Stock on December 2, 1996 as reported on the New York Stock Exchange, was
approximately $949,546,000. Shares of Common Stock held by each executive
officer and director and by each person known to beneficially own more than 5%
of the outstanding Common Stock have been excluded in that such persons may be
deemed to be affiliates. This determination of affiliate status is not
necessarily a conclusive determination for other purposes.
At December 2, 1996, there were 46,989,194 shares of the registrant's
Common Stock outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Certain portions of the registrant's Proxy Statement for its Annual Meeting
of Shareholders to be held January 22, 1997 have been incorporated by reference
into Part III of this Form 10-K.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
SYBRON INTERNATIONAL CORPORATION
TABLE OF CONTENTS
TO
1996 ANNUAL REPORT ON FORM 10-K
<TABLE>
<CAPTION>
ITEM PAGE
---- ----
<S> <C> <C> <C>
PART I
1 Business............................................................. 1
2 Properties........................................................... 14
3 Legal Proceedings.................................................... 15
4 Submission of Matters to a Vote of Security Holders.................. 16
Executive Officers of the Registrant................................. 17
PART II
5 Market for Registrant's Common Equity and Related Stockholder
Matters............................................................ 18
6 Selected Financial Data.............................................. 19
7 Management's Discussion and Analysis of Financial Condition and
Results of Operations.............................................. 19
8 Financial Statements and Supplementary Data.......................... 30
9 Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure............................................... 57
PART III
10 Directors and Executive Officers of the Registrant................... 57
11 Executive Compensation............................................... 57
12 Security Ownership of Certain Beneficial Owners and Management....... 57
13 Certain Relationships and Related Transactions....................... 57
PART IV
14 Exhibits, Financial Statement Schedules and Reports on Form 8-K...... 58
Signatures........................................................... 59
</TABLE>
i
<PAGE> 3
SYBRON INTERNATIONAL CORPORATION
CROSS REFERENCE SHEET
<TABLE>
<CAPTION>
HEADING(S) IN PROXY STATEMENT FOR
FORM 10-K ANNUAL MEETING OF SHAREHOLDERS
ITEM NO. TO BE HELD JANUARY 22, 1997
----------------------------------- ---------------------------------------------------
<S> <C> <C>
10. Directors and Executive Officers Election of Directors
of the Registrant Section 16(a) Beneficial Ownership Reporting
Compliance
11. Executive Compensation Executive Compensation
Election of Directors -- Directors' Compensation
12. Security Ownership of Certain Security Ownership of Certain Beneficial Owners
Beneficial Owners and Management and Management
13. Certain Relationships and Related Not applicable.
Transactions
</TABLE>
ii
<PAGE> 4
PART I
ITEM 1. BUSINESS
GENERAL
Sybron International Corporation is a leading manufacturer of value-added
products for the laboratory and professional orthodontic and dental markets in
the United States and abroad. The Company's laboratory business provides plastic
labware, microscope slides, consumables, temperature control apparatus and water
purification systems to industrial, academic, clinical, governmental and
biotechnology laboratories. The Company's orthodontic and dental businesses
provide orthodontic appliances and related products to orthodontists and a
diversified line of consumable products to dentists. The Company has been
pursuing a growth strategy designed to increase sales and enhance operating
margins. Elements of that strategy include emphasis on product line extensions,
new product introductions, acquisitions and international growth. The Company's
net sales have increased from $383 million in fiscal year 1992 to $674 million
in fiscal year 1996. In fiscal year 1996, foreign and United States export sales
represented approximately 36% of the Company's net sales.
The term "Company" as used herein refers to Sybron International
Corporation and its subsidiaries, and their respective predecessors, unless the
context otherwise requires. The Company's fiscal year ends on September 30. All
references to "1994", "1995" or "1996" reference the fiscal year ended September
30, 1994, 1995 or 1996, respectively, unless the context otherwise requires. All
references to shares, stock prices and earnings per share have been adjusted to
reflect the two-for-one stock split issued on December 15, 1995.
The Company's laboratory business is operated through three subsidiaries
and their affiliates. Nalge Nunc International Corporation ("NNI") develops,
manufactures, and markets a diversified line of reusable and disposable plastic
labware, high quality bio-pharmaceutical packaging products, recreational
containers, industrial products such as plastic tubing, sanitary tubing and
fittings, and environmental testing containers. Erie Scientific Company ("Erie")
develops, manufactures, and markets microscope slides, cover glass, consumables
used in clinical laboratories and thin glass mirrors. Barnstead Thermolyne
Corporation ("Barnstead/ Thermolyne") develops, manufactures and markets
precision heating, stirring, measuring, analytical and temperature control
apparatus and water purification systems to industrial, clinical, academic,
governmental and biotechnology laboratories.
The Company's orthodontic and dental businesses are operated through Sybron
Dental Specialties, Inc. ("Sybron Dental Specialties"), its two subsidiaries and
their affiliates. Ormco Corporation ("Ormco") develops, manufactures and markets
a broad line of orthodontic appliances including bands, brackets, wire,
adhesives, and ancillary equipment used during the course of orthodontic
treatment. Kerr Corporation ("Kerr") develops, manufactures and markets a broad
range of consumable products for use in restorative, prosthetic, and endodontic
dentistry.
NNI, Erie, Barnstead/Thermolyne and Sybron Dental Specialties, including
Kerr and Ormco, are referred to herein collectively as the "Operating
Subsidiaries".
The Company, a Wisconsin corporation, is the successor by merger in January
1994 to Sybron Corporation, a Delaware corporation. The merger was accomplished
to change the Company's corporate domicile from Delaware to Wisconsin. Sybron
Corporation, originally named Sybron Acquisition Company, was formed in 1987. In
1987, through an indirect wholly-owned subsidiary, Sybron Acquisition Company
acquired all of the outstanding shares of a company known at the time as Sybron
Corporation (the "Acquired Company") in a leveraged buyout transaction (the
"Acquisition").
In 1986, when the previous Sybron was taken private in a leveraged buyout
transaction, management initiated programs to reduce corporate and subsidiary
expenses, rationalize certain production facilities, sell certain operating
businesses and effect selective acquisitions. The company was then resold in
1987 in a second leveraged buyout transaction. After the 1987 buyout, the
company focused on maximizing cash flow in order to repay debt incurred in
connection with the Acquisition. In 1992 the Company was taken public and the
proceeds of the initial public offering were used to retire a portion of the
Acquisition debt. The balance of the Acquisition debt was refinanced in 1993
when the Company put in place a bank credit facility which, in
1
<PAGE> 5
addition to refinancing existing debt, provided the Company with a line of
credit designed to allow the initiation of a more aggressive acquisition
program. This program, together with operating strategies which have been
consistently executed since the 1986 transaction, is designed to expand and
strengthen the Company's worldwide sales and operating margins. Key elements of
the Company's strategy are as follows:
Competitive Focus. The Company has focused product development,
manufacturing and marketing efforts on increasing the range of specialty
and value-added laboratory, orthodontic, and dental products offered, as
well as on increasing the range of end users for such products.
New Product Introductions. Each of the Operating Subsidiaries has
consistently developed and introduced new products which have contributed
significantly to net sales. The Company believes that new product
introductions enable the Operating Subsidiaries to maintain their
competitive positions.
Acquisitions. Since July 1993, when the Company expanded its strategy
of growth through acquisitions, the Company and its Operating Subsidiaries
have made twenty-nine acquisitions in the United States and abroad,
including ten completed in 1996 and two completed in fiscal 1997 through
December 2, 1996. See Note 14 to the consolidated financial statements in
Item 8 of this Annual Report. The Operating Subsidiaries have been able to
use their existing distribution channels to market many of the acquired
product lines. Other synergies, such as the elimination of duplicative
administrative functions or the combining of manufacturing operations, have
been achieved with certain of these acquisitions.
International Growth. The Company has devoted significant resources to
international manufacturing, sales and marketing efforts in order to
capitalize on international sales opportunities. As a result of those
efforts, foreign and United States export sales have grown since 1986, from
$75.2 million in the twelve months ended September 30, 1987 to $244.5
million in 1996. In 1994, 1995 and 1996, foreign and United States export
sales represented approximately 35%, 36% and 36%, respectively, of the
Company's net sales. The international efforts have allowed the Company to
maintain its percentage of foreign and United States export sales to total
sales, despite the increase in acquisitions which have been more
predominantly domestic in nature. See Item 7, "Management's Discussion and
Analysis of Financial Condition and Results of Operations."
Successful execution of the strategic elements described above resulted in
a significant expansion of the business in 1996. Of the $155.3 million growth in
sales, approximately $26.9 million was generated from internal growth with the
balance coming from acquired businesses. Acquisition growth has been more
significant within the laboratory segment of the business than the dental
segment due to the fact that the worldwide market for laboratory products is
substantially larger than that for orthodontic and dental products.
Historically, the Company's net sales have been rather evenly distributed
between the laboratory and dental segments. In 1996 the laboratory segment grew
to 58.5% of net sales, with the dental segment representing 41.5%. The Company
intends to pursue its acquisition strategy in both the laboratory and dental
segments but, due to the disproportionate magnitude of these markets, expects to
continue to see a greater level of opportunity for growth in the laboratory
segment. In addition to the growth contributed from acquired businesses, the
Company has been able to realize cost benefits derived from the elimination of
duplicative costs in manufacturing and administrative areas. In April 1996, the
Company announced a restructuring to realize such benefits from the
acquisitions. An after-tax restructuring charge of $6.1 million was recorded
which is expected to generate annual savings on an after-tax basis of $2.4
million.
The description of the Company's business included in this Item 1,
Management's Discussion and Analysis of Financial Condition and Results of
Operations in Item 7 and other portions of this report contain statements that
could be deemed to be forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Those statements concern,
among other things, the intent, belief or current expectations of the Company or
its management with respect to the Company's operating and growth strategies,
the Company's capital expenditures, financing, regulatory matters pertaining to
the Company specifically and the industry in general, industry trends,
competition, risks attendant to foreign operations, reliance on key
distributors, environmental matters, legal proceedings and other factors
affecting the Company's financial condition or results of operations. Such
forward-looking statements involve certain risks and uncertainties, many of
which are beyond the Company's control, that could cause actual results to
differ
2
<PAGE> 6
materially from those contemplated in the forward-looking statements. Factors
which could cause or contribute to such differences include, but are not limited
to, those discussed in connection with such statements as well as those
described in the section entitled "Cautionary Factors" in Item 7 of this Annual
Report.
CERTAIN FINANCIAL INFORMATION
The following table sets forth net sales by Operating Subsidiary and
business segment for the years indicated.
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
--------------------------------
1994* 1995* 1996*
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Laboratory Segment:
NNI................................................. $114,405 $137,296 $220,352
Erie................................................ 59,070 74,062 110,747
Barnstead/Thermolyne................................ 50,276 57,039 63,225
-------- -------- --------
Subtotal....................................... 223,751 268,397 394,324
-------- -------- --------
Dental Segment:
Sybron Dental Specialties........................... 215,953 250,803 280,133
-------- -------- --------
Total Net Sales................................ $439,704 $519,200 $674,457
======== ======== ========
</TABLE>
- ---------------
* Includes acquired companies' sales since their effective dates of acquisition.
Other financial information about business segments and foreign operations
is included in Note 15 to the Company's consolidated financial statements in
Item 8 of this Annual Report, and such information is incorporated herein by
reference.
Management is not aware of any definitive market share information for the
laboratory and professional orthodontic and dental markets. Any such information
contained in this Annual Report has been developed by the Company from internal
sources and, in the case of certain estimates regarding Sybron Dental
Specialties, are based in part on information published by independent parties
or trade associations. The market share information presented herein reflects
the Company's current estimates and no assurance can be given regarding the
accuracy of such estimates.
LABORATORY SEGMENT
NNI
General: NNI, headquartered in Rochester, New York, represents the
combination of Nalge Company ("Nalge") and the Nunc group of companies ("Nunc").
Nalge, a manufacturer of reusable and disposable plastic labware products used
in general, industrial and research labs, was founded in 1949. Nunc, a
manufacturer of plastic labware used in biotechnology, medical research and
diagnostics, was founded in 1953 and acquired by the Company in July 1995. Nunc
was combined with Nalge to form NNI in order to take advantage of the marketing,
manufacturing and technological synergies between the companies. As used herein,
"NNI" means Nalge and its operations prior to the Nunc acquisition, and the
combined operations of Nalge and Nunc after the Nunc acquisition.
As a result of the Nunc acquisition and others made by NNI since the
expansion of the Company's acquisition program in 1993, NNI has significantly
broadened its product line. In addition, NNI formed its Nalge Process
Technologies Group ("NPT") in 1996, placing part of its existing industrial
business and certain of its acquisitions under a single management structure.
NPT is designed to address the sanitary fluid transport needs of biotechnology,
pharmaceutical and other industries.
Products: NNI's NALGENE(R) (Nalge) brand product line includes plastic
labware products for general laboratory purposes. This product line consists of
approximately 4,900 items including reusable products (bottles, carboys,
graduated ware, beakers and flasks) and disposable products (microfiltration and
cryogenic storage products). Other NALGENE products include products for
critical packaging applications (bottles
3
<PAGE> 7
for packaging of diagnostic reagents, media and specialty chemicals), consumer
products (containers, bicycle bottles and recreation containers for outdoor
camping) and plastic tubing and tanks (PVC, dairy and silicone tubing, and
corrosion-resistant tanks from 5 to 1,000 gallons in capacity). NALGENE
laboratory products are typically sold at prices ranging from $5 to $1,000. In
general, these products are designed to offer the scientist or laboratory
technician a more durable, safer and less expensive alternative to labware
products made of glass or other materials. NNI also sells I-CHEM(R)
environmental containers.
NNI's NUNC(@) brand product line consists of high quality plastic labware
used in biotechnology, medical research and diagnostics. NUNC products are
complementary to NALGENE labware products because they principally address
scientific research needs not addressed by the NALGENE products. NUNC products,
which are used for the propagation, analysis and storage of cells, are comprised
of tissue culture products, molecular biology products, storage and
transportation products and immunology products. Tissue culture products include
Cell Factories and NUNCLON(@) Flasks for use in cell culture and production of
biomaterials. A line of culture inserts is used to perform toxicological testing
of drugs and cosmetics where large numbers of samples are analyzed. NUNC
molecular biology products provide the necessary tools for fast, convenient and
safe recombinant DNA work and neurochemistry analysis. This product group
includes space-saving well plates and a multi-purpose OmniTray which are
compatible with laboratory robotics. These types of products are standard in
virtually every clinical and life science laboratory. Storage and transportation
products are used for safe handling, storage and transport of biological
samples. Immunology products are used in assay procedures in clinical
laboratories. Screening for HIV or hepatitis and tissue typing are examples of
commonly-performed immunological analyses. The diverse NUNC product line
includes a selection of product configurations and surface finishes to
accommodate a variety of immunological techniques.
NPT was formed to address the needs of biotechnology, pharmaceutical and
other industries for sanitary fluid transport. NPT takes advantage of the
combined expertise of certain acquired companies and NNI's industrial business.
The NPT product line includes plastic tubing and tanks from NNI's industrial
product line; silicone tubing and non-metallic fittings for the pharmaceutical,
semi-conductor and biotechnology industries from Sani-Tech, Inc. ("Sani-Tech"),
acquired in February 1995; pipe and tubing for ultra-pure applications from
Acutech Plastics, Inc. ("Acutech"), acquired in January 1996; hoses, fittings
and accessories used in fluid and gas transport applications from Flexible
Components, Inc. ("Flexible Components"), acquired in July 1996; and sanitary
stainless steel fittings from Pure Fit, Inc. ("Pure-Fit"), acquired in October
1996.
New Products. NNI's product development efforts are focused on expanding
product offerings for domestic and international laboratory and packaging
markets, and developing specialty products for new markets. Product development
for new markets emphasizes products that are capable of generating gross margins
consistent with its labware products, primarily by exploiting NNI's expertise
with plastic resins and molding processes. NNI periodically evaluates new grades
of resins, new resins, and innovative equipment and molding technologies as part
of its new product development effort. Recent NALGENE product introductions
include a new array of acrylic laboratory safety products (including a Beta
apron, shielded pipette rack and stand and Beta lock boxes), lab organizers,
self-venting safety wash bottles, fluorinated solvent wash bottles, autoclavable
carboys, barbed bulkhead fittings, Top Works(TM) fluid transfer systems, and a
micropackaging vial. Recent NUNC product introductions include Mutidishes and
MicroWell(TM) Plates, Lockwell(TM) Immunoassay modules, GeNunc(TM) trays and
holders, Nucleolink(TM) strips, Sonic Seal Slide Wells and Tissue Culture
Chamber Slides.
In addition, NNI has added a new line of silicone tubing and a complete
line of non-metallic fittings and accessories through the acquisitions of
Sani-Tech, Acutech, Flexible Components and Pure-Fit. During the last three
fiscal years, NNI has supported its new product development with research and
development expenditures of approximately 3% of its annual net sales.
Markets; Distribution. The Company estimates that the worldwide labware
market comprises in excess of 150,000 industrial, academic, clinical,
governmental and biotechnology laboratories. NNI believes that it has the
leading share of the domestic reusable plastic labware market in which its
NALGENE general labware products compete, and that it has the leading share of
the domestic market for disposable microporous filter units. NALGENE(@) labware
products are marketed through approximately 45 domestic and 60
4
<PAGE> 8
international labware distributors. Four distributors, Fisher Scientific
("Fisher"), VWR Scientific ("VWR"), the industrial products division of Baxter
Scientific Products ("Baxter Industrial"), and Curtin Matheson Scientific, Inc.
("CMS"), accounted for 53% and 50% of NALGENE product sales in 1994 and 1995,
respectively. In 1995, Fisher, VWR, Baxter Industrial and CMS consolidated into
two distributors as a result of Fisher's acquisition of CMS and VWR's
acquisition of Baxter Industrial. The two remaining distributors, Fisher and
VWR, accounted for 54% and 18% of NALGENE and NUNC product sales, respectively,
in 1996. Laboratory supply distributors offer a wide variety of supplies,
apparatus and instruments for the laboratory, primarily through catalogs. As end
users rely heavily on these catalogs in identifying suitable products and making
purchase decisions, the amount of catalog space provided and the number of
product items listed for a particular vendor are critical marketing variables.
The distributor consolidation led to soft sales for core labware products in
1995 and the first half of 1996 as the two remaining major distributors
rationalized their distribution systems. NNI's competitive advantages afforded
by its long-standing relationships with Fisher and VWR has continued after the
consolidation and the number of NNI's labware products offered by these two
remaining major distributors continues to be among the highest of any of NNI's
competitors. The Nalge-Nunc combination was designed to give both the NALGENE
and NUNC product lines a more significant presence with the major distributors.
NUNC products are very strong in Europe and are the worldwide leaders in
handling, storage and transport systems for biological samples. NUNC products
entered the United States market in 1987 and have not achieved the same market
presence as the NALGENE products. European markets in which NUNC products
participate have evolved somewhat differently in recent years than the
corresponding United States market. The conversion of laboratory equipment from
glass to plastic started later in Europe. While plastic labware makes up
approximately 60% of the market in the United States, the European labware
market remains approximately 70% glass. This is the result of generally lower
glass prices in Europe, as well as substantially less marketing of plastic
products. Both markets are expected to show continued growth in demand for
plastic labware. NUNC products are distributed in much the same way as NALGENE
products, through a combination of distributors and catalogs. In the United
States, NALGENE and NUNC products are sold through the same dealer network. In
Europe, NUNC products are distributed through a line of exclusive distributors
in all countries except Germany, where NNI maintains its own sales force.
NNI also maintains its own sales force in the United States and abroad to
help its dealers sell both NALGENE and NUNC products. NNI has a 60 person sales
force in the United States, a 12 member sales force in Germany and a 9 member
sales force supporting NNI products in other parts of Europe and the rest of the
world.
NPT's products are marketed primarily through distributors. NNI's packaging
products are marketed through distributors domestically and on a direct basis
internationally. NNI's consumer products are sold through distributors and
directly to retailers.
International. A significant portion of NNI's growth during the past five
years has come from its international markets. For the five years ended
September 30, 1996, NNI's foreign and United States export sales grew at a
compound annual rate of 32%, from approximately $16 million in fiscal 1991 to
approximately $76 million in 1996. In 1996, NNI's international sales increased
by 121% over 1995, primarily due to the full year effect of the NUNC
acquisition. Approximately $44 million, or 64%, of NUNC product sales in 1996
were to international markets.
Competition. NNI believes that its principal competitive advantages include
the ability to define specific customer needs and to develop products to address
those needs, the breadth and depth of its product lines, its expertise in
plastic molding technology and its significant brand recognition. Historically,
plastic labware was introduced as an alternative to glass labware. Accordingly,
NNI competes primarily with glass labware manufacturers on the basis of the
durability, safety and light weight of plastic versus glass. NNI competes with
plastic labware manufacturers on the basis of product design, quality, the
breadth and depth of its product lines and customer service capabilities. NNI's
principal competitors differ by product line, and NNI believes that no single
competitor offers a comparable mix of product lines, or breadth or depth within
individual product lines. NNI's principal competitors for NALGENE general
laboratory products are Corning Costar, Inc. ("Corning/Costar"), Millipore
Corporation, Wheaton Industries, Incorporated, and Kautex Werke
5
<PAGE> 9
Reinhold Hagen A.G. NNI's principal competitors for the NUNC products are
Corning/Costar, Becton Dickinson and Company ("Becton Dickinson"), Greiner,
Dynatech, Sarstedt and Eppendorf.
ERIE
General. Erie, founded in 1934 and headquartered in Portsmouth, New
Hampshire, has historically been a developer, manufacturer and marketer of
microscope slides, cover glass, diagnostic slides and other industrial thin
glass products for sale in the United States and abroad. Through several
acquisitions, Erie has broadened its product base to include electrophoresis
products used in molecular biology research, precision thermometers and
hydrometers for laboratories, stains, fixatives and supplies for histology and
cytology laboratories, liquid standards and reagents used with clinical
diagnostic and testing equipment, consumable histology products, and thin glass
mirrors.
Erie has achieved a high degree of vertical integration in the slide and
mirror production processes. Erie's wholly-owned subsidiary in Switzerland, Erie
Electroverre S.A. ("Electroverre"), a manufacturer of thin white glass, sells
approximately 94% of the glass it manufactures to Erie's worldwide operations.
Through this subsidiary, Erie is able to exercise control over the quality of
its glass and is ensured a continuous supply of the type of thin glass
Electroverre manufactures. Approximately every six years, the sheet glass
furnace at Electroverre must be fully rebuilt, a process which takes
approximately 10 weeks. The process was last completed in the fourth quarter of
fiscal 1994 and is next scheduled to begin in the fourth quarter of fiscal year
2000. Because Erie's employees have considerable experience with this
maintenance procedure, no significant problems occurred during the most recent
rebuild. Prior to the start of a rebuild, Erie increases inventory levels of
sheet glass which it draws upon during the rebuild period.
Products. For the most part, Erie's products are used in standard
laboratory applications such as cytology, histology and hematology as well as in
biotech research laboratories. Products include plain microscope slides and
cover glass, both of which are disposable, disposable and reusable value-added
slides, electrophoresis equipment, precision thermometers and hydrometers,
consumable stains, fixatives and supplies used in histology and cytology
laboratories, consumable liquid standards and reagents, and consumable histology
products.
Plain microscope slides are the familiar clear rectangular glass plates
used to hold specimens for examination under a microscope and cover glasses are
the smaller, thinner glass plates used on the microscope slides to cover
specimens for protection during examination. Over the past several years, Erie
has pursued a product strategy that emphasizes value-added microscope slides,
which typically have higher margins than its plain slides. Value-added products
include SUPERFROST(R) and COLORFROST(R) brand printed slides, which provide an
indelible marking surface and are disposable; SUPERFROST(R) Plus adhesion
slides, which are electrically charged in a way which causes cells to adhere to
them and are disposable; and disposable and reusable diagnostic slides which are
customer designed and printed to customer specifications for use in diagnostic
test kits. The SUPERFROST(R), COLORFROST(R) and SUPERFROST(R) Plus slides all
represent significant advancement over regular slides because they increase
laboratory technician efficiency in the marking and subsequent identification of
the slides and in preparing the slides for tissue adhesion. Therefore, they are
increasingly used as alternatives to plain slides.
Precision thermometers and hydrometers are measuring instruments used in
laboratories. Erie entered this business through the acquisition of Ever Ready
Thermometer Co., Inc. ("ERTCO") in November 1994. Electrophoresis products are
used in molecular biology research. Erie entered this business through the
acquisition of Owl Scientific, Inc. ("Owl") in January 1995. Stains and
fixatives are products used to fix and stain specimens so that their
characteristics can be observed. These products, which are often used in
conjunction with microscope slides, were added through the acquisition of
Richard-Allan Scientific Company ("Richard-Allan") in May 1995 and Stephens
Scientific, Inc. ("Stephens") in July 1996. In September 1995, Erie added liquid
standards and reagents used with clinical diagnostic and testing equipment
through its acquisition of New England Reagent Laboratory, Inc. ("NERL") and, in
November 1995, it added another line of standards and calibration verification
and quality control materials through its acquisition of CASCO Standards, Inc.
("CASCO"). In September 1995, it added consumable histology products, such as
tissue cassettes used for biopsies, through its acquisition of the Secure
Medical Products product line ("Secure").
6
<PAGE> 10
In February 1996, Erie acquired The Naugatuck Glass Company ("Naugatuck"),
a manufacturer of thin glass mirrors principally used in the cosmetic industry.
Naugatuck uses the same type of thin glass for its mirrors as Erie uses in the
manufacture of microscope slides.
New Products. Erie's product development efforts are focused on giving its
basic products characteristics which allow lab technicians to reduce the cost of
their procedures, developing specialty products for laboratory applications, and
adapting its products for use in new technologies. In 1994, Erie completed the
development and introduction of Super Cell(TM) Culture Slides for the bio-tech
tissue culture market. Since October 1994, Erie added to its product offering
with the acquisitions of ERTCO, Owl, Richard-Allan, NERL, CASCO, Secure,
Naugatuck and Stephens. Erie also acquired the Gold Seal(R) microscope slide
product line from Becton Dickinson, an original equipment manufacturer. Although
Erie previously supplied Becton Dickinson the microscope slides for this product
line, the acquisition provided Erie the opportunity to sell this line through
its own distribution channels.
Markets; Distribution. The Company believes Erie is the leading producer of
microscope slides sold in North America and that Erie has a significant
international market share. During each of the years 1994, 1995 and 1996,
approximately 95%, 95% and 96%, respectively, of Erie's domestic slides and
cover glass were produced under private label, and during 1994 and 1995
approximately 62% and 60%, respectively, of those slides were sold to the
clinical division of Baxter Scientific Products ("Baxter Clinical"), CMS and
Fisher, who resell the slides and cover glass to laboratories via their direct
sales forces. In 1996, after the major dealer consolidation discussed above, and
after Erie began selling the Gold Seal(R) product line through its distributors
rather than to Becton Dickinson, 77.8% of its slides and cover glass were sold
to two distributors, Allegiance Corp. ("Allegiance") (the successor to Baxter
Clinical) and Fisher. In 1996, 70% of Erie's consolidated domestic sales of all
products were to Allegiance and Fisher. The consolidation of the major
laboratory distributors affected Erie's net sales in 1995 and 1996, but not to
the same extent as NNI's and Barnstead/Thermolyne's because Erie sold more to
Baxter Clinical (in 1995) and Allegiance (in 1996), which, unlike Baxter
Industrial, was not consolidated with VWR. Owl and ERTCO, however, sold their
products to Baxter Industrial, which was acquired by VWR. Because Erie is now a
full-line supplier of consumables to clinical laboratories as a result of its
acquisitions, Erie believes it has reduced the risk of any negative consequences
that could result from the consolidation of the largest laboratory distributors.
International. In addition to Electroverre, Erie owns Gerhard Menzel
Glasbearbeitungswerk GmbH & Co. K.G. ("Menzel"), a German manufacturer of slides
and cover glass, and Erie Scientific Kft, which has a manufacturing facility in
Hungary. Erie also has a joint venture with operations in Hong Kong which cuts
glass for the Asian watch crystal industry. In 1996, foreign and United States
export sales represented approximately 22% of Erie's net sales. Despite
declining in 1992 and 1993, for the five years ended September 30, 1996, Erie's
foreign and United States export sales grew at a compound annual rate of 4.6%
from approximately $19.9 million in 1991 to approximately $24.9 million for
1996.
Competition. The Company believes Erie's principal competitive advantages
include its product quality, the breadth of its product offerings, economics
associated with vertical integration, cost effective processes and its long time
relationships with key industry distributors. As a full-line supplier of
consumables to clinical laboratories, Erie has maintained a critical level of
importance to its distributors and gained visibility across all its product
lines. Erie's microscope slide and cover glass production processes utilize
state of the art automated glass cutting machinery and slide finishing
equipment. In the North American microscope slide market, Erie competes on the
basis of product features and quality, the breadth of its product line, price
and customer service. The Company believes Erie has a more complete slide
product offering on the basis of quality and product features than any of its
competitors in the slide business. In the European microscope slide market, Erie
competes primarily on the basis of price, as value-added products have not
achieved acceptance levels in Europe comparable to North America. Erie's
principal competitors are Chase Instruments Corp., Surgipath, Inc., Shandon (a
division of Life Sciences Inc.), Bio-Rad, Inc., Hoefer-Pharmacia and certain
other European and Asian companies.
7
<PAGE> 11
BARNSTEAD/THERMOLYNE
General. Barnstead/Thermolyne, headquartered in Dubuque, Iowa, is the
successor of Thermolyne Corporation, founded in 1942, and Barnstead Company,
founded in 1878. Barnstead/Thermolyne develops, manufactures, and markets
precision heating, stirring and temperature control apparatus, water
purification systems, liquid handling equipment, strip chart recorders,
spectrophotometers, fluorometers and replacement parts for these products. These
products are marketed primarily to laboratories in the United States and abroad
through independent distributors.
Products. Thermolyne heating, stirring and temperature control apparatus
include hot plates, stirrers, heating tapes, muffle furnaces, incubators,
dri-baths, and cryogenic storage apparatus, which are fundamental to basic
procedures performed in the laboratory. These products are marketed in a wide
variety of product sizes, temperature ranges and control features and are
typically priced between $100 and $4,000.
Barnstead systems are used to produce ultra-pure water, the most common
reagent used in laboratories. Because the water purity requirements of end-users
differ, Barnstead offers a full range of systems which incorporate distillation,
deionization, reverse osmosis, ultraviolet oxidation, absorption or filtration
technologies for purifying water. The majority of these systems are priced
between $100 and $4,000. Barnstead/Thermolyne believes it offers a broader range
of water purification systems than any of its principal competitors and believes
that its ability to manufacture systems using all major water purification
technologies provides a significant competitive advantage.
An important element of the Barnstead/Thermolyne product strategy has been
the incorporation of replacement parts and filters which are used to extend the
useful life of the products. Barnstead deionization systems include disposable
deionization cartridges which have a finite capacity for contaminants and must
be periodically replaced to maintain acceptable purity levels. Thermolyne
products incorporate replaceable components, including heating elements and
control units. Cartridges and replacement parts have higher gross margins than
most other Barnstead/Thermolyne products.
Barnstead/Thermolyne has added to its product line from time to time
through acquisitions. In 1994 it added bottle top dispensers, positive
displacement micropipettors, and small mixers used in biomolecular research
through its acquisition of Labindustries, Inc. In 1995 it added PMC(TM) brand
programmable hot plate/stirrers, TURNER(R) brand fluorometers and
spectrophotometers, and LINEAR(TM) brand strip chart recorders through its
acquisition of Biomolecular, Inc.
New Products. Barnstead/Thermolyne devotes considerable resources to the
identification, development and introduction of new products. In recent years
Barnstead/Thermolyne has introduced a number of new products that have
contributed significantly to sales. Examples of recently introduced products
include the further expansion of the EASYpure(R) line of pure water products,
two new LABQUAKE(R) brand shaker/rotators, new purification cartridges for
equipment manufacturers, a new line of asphalt ashing furnaces and several
original equipment manufacturer dri-baths for life science customers. During the
past three fiscal years, Barnstead/Thermolyne has supported its new product
development with research and development expenditures of approximately 3% of
its annual net sales.
Markets; Distribution. The Company estimates that the worldwide labware
market comprises in excess of 150,000 industrial, academic, clinical,
governmental and biotechnology laboratories. Barnstead/Thermolyne believes that
it has significant shares of the domestic laboratory markets for hot
plates/stirrers, muffle furnaces, water deionization purification systems and
water distillation purification systems. Barnstead/ Thermolyne products are sold
through approximately 50 domestic and 90 international laboratory supply
distributors. Baxter, CMS, Fisher and VWR accounted for approximately 51% and
47% of Barnstead/ Thermolyne's net sales during 1994 and 1995, respectively, and
Fisher and VWR accounted for approximately 41% of Barnstead/Thermolyne's net
sales during 1996. The consolidation of these major distributors led to some
disruption in Barnstead/Thermolyne's laboratory business in 1995, and this
softness continued for the first half of 1996 as the two remaining major
distributors rationalized their distribution systems. As end users rely heavily
on distribution catalogs and known trademarks, such as BARNSTEAD(R),
THERMOLYNE(R), LABINDUSTRIES(R), PMC(TM), TURNER(R), and LINEAR(TM), in
identifying suitable products and making purchase decisions,
Barnstead/Thermolyne believes that the long-standing marketing cooperation
between
8
<PAGE> 12
Barnstead/Thermolyne and its distributors, including the two major distributors,
continues to represent an important competitive advantage. The number of
Barnstead/Thermolyne products offered in the distributor catalogs is among the
highest of any of its competitors.
International. Barnstead/Thermolyne has developed a network of
international distributors. In addition, Barnstead/Thermolyne believes that it
has been able to consistently meet the needs of specific regions and countries
through the modification of product designs and the provision of special product
labeling. In fiscal year 1996, United States export sales represented
approximately 23% of Barnstead/Thermolyne's net sales. For the five fiscal years
ended September 30, 1996, Barnstead/Thermolyne's United States export sales grew
at a compound annual rate of 8%, from approximately $9.9 million in 1991 to
approximately $14.8 million in 1996.
Competition. Barnstead/Thermolyne believes that its principal competitive
advantages include the breadth and depth of its product lines, product quality,
its significant brand recognition, price, and its extensive network of
distributors. Barnstead/Thermolyne's principal competitors differ by product
line, and Barnstead/ Thermolyne believes that no single competitor offers a mix
of product lines, or breadth or depth within individual product lines,
comparable to Barnstead/Thermolyne. Barnstead/Thermolyne's principal competitors
are Corning/Costar, Millipore Corporation, and Lindberg/Blue M (owned by General
Signal Corp.).
DENTAL SEGMENT
SYBRON DENTAL SPECIALTIES
Sybron Dental Specialties' headquarters is located in Orange, California.
Because the Sybron Dental Specialties' businesses are operated through its
subsidiaries, Kerr and Ormco, the businesses of those subsidiaries are described
below.
KERR
General. Kerr, founded in 1891, develops, manufactures, and markets a broad
range of consumable dental products, including restorative materials (which
include amalgam alloys, composites, cavity liners and ancillary products),
curing lights, impression materials, endodontic instruments and materials,
dental burs, preventive products, laboratory products and infection control
products. Kerr's sales are made primarily through dental distributors serviced
by approximately 92 sales representatives worldwide.
Products and Markets. Kerr's major product groups include endodontic
instruments and materials, impression materials, composite filling materials and
bonding agents, amalgam alloys and amalgamators, dental burs, curing lights,
infection control products and material used in the dental lab. Kerr believes
that it is among the market leaders domestically in each of these product
groups. Products recently acquired in these areas include dental curing lights
of Demetron Research Corp. ("Demetron") in December 1993, infection control
products of Metrex Research Corporation ("Metrex") in March 1995, infection
control products of Micro-Aseptic Products, Inc. ("Micro-Aseptic") in July 1996,
infection control products and restorative materials of E & D Dental Products,
Inc. in August 1996, and dental laboratory products of belle de st. claire, inc.
("Belle") in November 1995. Kerr also manufactures and markets products
specifically for the jewelry industry. Although many of Kerr's traditional
products are long time industry standards and in the mature phase of their
cycles in developed markets, there is significant growth potential for these
products in developing markets such as Latin America, Asia and Eastern Europe.
In addition, as dental materials evolve, they can present growth opportunities
through their impact on the techniques and products used by the average dentist.
The Company expects modest growth in the domestic market for traditional
products; this should be augmented by the demand for new products that make the
dentist more efficient. Kerr introduced a new impression material, Extrude
PS(TM), directed toward that end in 1996. The product has a unique delivery
system designed to minimize waste while providing better operator control. Kerr
is committed to growing market share through product development and promotional
activities.
New Products. Kerr commits considerable resources in an effort to meet the
needs of today's dentist, and it considers its product development program to be
of importance in maintaining its market position.
9
<PAGE> 13
Approximately 2% to 3% of annual net sales is dedicated to new product
development. With each major product group requiring diverse technical
expertise, Kerr is well positioned to take advantage of various market trends.
Recently introduced products such as Tytin FC(TM) (a dental alloy), Nexus(TM)
Luting Agent (a universal luting agent), Extrude PS(TM), and Optilux(TM) 500 (a
new curing light), have significantly contributed to Kerr's net sales.
The addition of Micro-Aseptic to Metrex has benefited Kerr's infection
control product line. The acquisition of Belle has broadened Kerr's dental
laboratory product line.
Distribution. Kerr's dental products are sold both domestically and
internationally through distributors. The Company has approximately 42 sales
representatives in the United States and approximately 50 abroad dedicated to
dental sales. Kerr also sells infection control products into the medical market
through a nationwide group of independent manufacturer representatives who sell
through dealers to end users. The mission of the Kerr dental sales force and the
independent manufacturer representatives is to provide training and technical
support to dealers and help pull the Kerr products through the dealer network.
International. Kerr's international efforts accounted for approximately
46%, 46% and 45% of Kerr's overall sales in 1994, 1995 and 1996, respectively.
The percentage of Kerr's international sales dropped slightly in 1996 because
the sales of Kerr's acquisitions have been domestically oriented. In addition to
the United States, Kerr has manufacturing facilities in Canada and Italy. As the
economies in the emerging markets of Eastern Europe, South America and the Far
East develop, so will their need for dental products. Kerr is well positioned to
take advantage of this trend due to its extensive experience in selling
internationally and the quality of its existing international dealer network.
For the five years ended September 30, 1996, Kerr's foreign and United States
export sales grew at a compound annual rate of 6.6% from approximately $56
million in fiscal 1991 to approximately $77 million in 1996.
Competition. Kerr believes its principal competitive advantages include the
breadth of its product lines, brand name recognition, and its programs to
educate the dentist regarding techniques and products. Kerr's principal
competitors are GC America, Inc., 3M Corporation, Dentsply International Inc.,
Espe GmbH & Co., and Ivoclar.
ORMCO
General. Ormco, founded in 1960, develops, manufactures, and markets a
broad line of orthodontic appliances and related products for sale in the United
States and abroad. Ormco provides the orthodontist with the bands, brackets,
wires, adhesives and ancillary supplies used during the course of orthodontic
treatment.
Products. Ormco offers a broad range of orthodontic appliances in the
following major product groups: brackets, bands and buccal tubes, wires and
elastomeric products. Brackets, bands, buccal tubes and wires are manufactured
from a variety of metals to exacting specifications for standard use or to meet
the custom specifications of a particular orthodontist. Elastomeric orthodontic
products include power chains to consolidate space and rubberbands. Ormco also
manufactures and markets a line of orthodontic instruments and instruments for
microscopic endodontics, and distributes adhesives and general supply products
manufactured by others. Ormco's subsidiary, Allesee Orthodontic Appliances,
Inc., manufactures custom-made positioners, retainers and other accessories for
the orthodontist.
New Products. Ormco devotes considerable resources to the identification,
development and introduction of new products. During the past three fiscal
years, Ormco has supported its new product development with research and
development expenditures of approximately 2% to 3% of its annual net sales.
Ormco believes the direct contact of its sales force with orthodontists
facilitates the identification and verification of market trends and new product
opportunities. Ormco works closely with orthodontists to improve existing
products and develop new products primarily through its Champion program through
which selected orthodontists assist Ormco in designing, developing and
ultimately educating users on new product and technique innovations. In recent
years, Ormco has introduced a number of new products which have contributed
significantly to Ormco's net sales. Examples of recently introduced products
include Optimesh(TM) and Spirit(TM) MB brackets, advanced wires and the
Orthos(TM) treatment system.
The acquisition of Excellence in Endodontics, Inc. ("EIE") in April 1995
introduced Ormco to a new line of products. EIE is a leading innovator in the
development of techniques and instruments for microscopic
10
<PAGE> 14
endodontics. The acquisition of Analytic Technology Corporation in October 1995
added a manufacturer of equipment used in endodontic treatment. These products
were placed under Ormco management because they are suited to Ormco's marketing
techniques.
Markets; Distribution. The Company believes that Ormco is the leading
manufacturer and marketer of orthodontic and related products in the world.
Although the market for Ormco's traditional products is relatively mature
domestically, the market continues to experience growth in the adult population.
The Company believes that the international market for orthodontic products
presents a significant growth opportunity as worldwide awareness of dental
aesthetics grows.
Ormco's products are marketed by approximately 62 direct salespersons in
the United States, Canada, Australia, Switzerland, Germany, Japan, Mexico and
New Zealand and by dealers and distributors internationally. Ormco's direct
sales force, its dealers and distributors are supported by trade journal
advertising, trade shows, seminars and telemarketing.
International. In addition to its direct distribution of products in
Australia, New Zealand, Canada, Germany, Switzerland, Japan and Mexico, Ormco
has exclusive distributors in key European markets such as France, Italy and
Spain. Foreign and United States export sales represented approximately 45%,
46%, and 47% of Ormco's net sales for fiscal years 1994, 1995 and 1996,
respectively. For the five fiscal years ended September 30, 1996, Ormco's
foreign and United States export sales grew at a compound annual rate of 13.6%
from $27 million in 1991 to $51 million in 1996.
Competition. Ormco believes its principal competitive advantages include
significant expertise in new product development and marketing, product quality,
a high level of customer service, and its ability to develop and implement new
manufacturing and marketing techniques. Ormco competes primarily on the basis of
new product offerings, product quality, and the level of customer service.
Ormco's principal competitors are Unitek (owned by 3M Corporation), "A" --
Company Orthodontics, GAC Orthodontics and American Orthodontics.
COMPETITION
As described above, the Company has numerous competitors in its laboratory
and dental businesses, a number of which have substantially greater financial
and other resources than the Company. There can be no assurance that the Company
will not encounter increased competition in the future.
BACKLOG
Total backlog orders at September 30, 1994, 1995 and 1996 were
approximately $11.3 million, $12.5 million and $26.7 million, respectively. All
1996 backlog orders are expected to be filled within the current fiscal year.
RESEARCH AND DEVELOPMENT
The Company has a number of research and development programs in its
various businesses. The Company considers these product development programs to
be of importance in maintaining its market position. The amounts spent on
research and development activities in 1994, 1995 and 1996 were approximately
$9.5 million, $11.0 million and $13.7 million, respectively.
EMPLOYEES
The Company employed approximately 5,700 persons at September 30, 1996,
approximately 488 of which are covered by collective bargaining agreements. The
Company believes that its employee relations at each subsidiary and at its
corporate offices are generally good. Kerr's hourly employees at the Romulus
facility are members of the United Autoworkers Union, Barnstead/Thermolyne's
hourly employees are members of the International Brotherhood of Electrical
Workers, and NNI's hourly employees at its Naperville, Illinois facility are
members of the International Brotherhood of Teamsters. The labor contracts at
Kerr, Barnstead/ Thermolyne and NNI expire on January 31, 1998, March 1, 1998,
and December 20, 1998, respectively.
11
<PAGE> 15
PATENTS, TRADEMARKS AND LICENSES
The Company's products are sold under a variety of trademarks and trade
names. The Company's subsidiaries own all of the trademarks and trade names that
the Company believes to be material to the operation of its businesses,
including the KERR(R) trademark, the NALGE(R) and NALGENE(R) trademarks, the
NUNC(TM) and NUNCLON(R) trademarks, Erie's SUPERFROST(R) and COLORFROST(R)
trademarks, the THERMOLYNE(R) and BARNSTEAD(R) trademarks and the ORMCO(R)
trademark, each of which the Company believes to have widespread name brand
recognition in its respective field and all of which the Company intends to
continue to protect. The Company's subsidiaries also own various patents,
including the United States patents for the marking surface of Erie's
SUPERFROST(R) and COLORFROST(R) slides, both of which expire in 2001, employ
various patented processes and from time to time acquire licenses from owners of
patents to apply patented processes to their operations. Except as referred to
above, the Company does not believe any single patent, trademark or license is
material to the operations of its business as a whole.
MEDICAL DEVICE REGULATION
Certain of the Company's products are medical devices which are subject to
regulation by, among other governmental agencies, the United States Food and
Drug Administration (the "FDA"). Pursuant to the Federal Food, Drug, and
Cosmetic Act (the "FDCA"), the FDA regulates virtually all phases of the
manufacture, sale, and distribution of medical devices, including their
introduction into interstate commerce, their manufacture, advertising, labeling,
packaging, marketing, distribution and recordkeeping. Pursuant to the FDCA and
FDA regulations, certain facilities of Erie, NNI, Kerr, Ormco, and
Barnstead/Thermolyne are registered with the FDA as medical device manufacturing
establishments.
Medical devices are classified into either Class I, II or III. Class I and
II devices are not expressly approved by the FDA. However, pursuant to section
510(K) of the FDCA, the manufacturer or distributor of a Class I or II device
that is initially introduced commercially on or after May 28, 1976, must notify
the FDA of its intent to commercially introduce the device through the
submission of a premarket notification (a "510(K) Notice"). Before commercial
distribution can commence, the FDA must review the 510(K) Notice and clear the
device for commercial distribution. The FDA normally has 90 days to review the
510(K) Notice and grant or deny clearance to market on the basis that it is
substantially equivalent to a device marketed before May 28, 1976.
Alternatively, the FDA may postpone a final decision and require the submission
of additional information, which may include clinical data. If additional
information is required, review and clearance of a 510(K) Notice may be
significantly delayed. In order to clear a Class I or II device for marketing,
the FDA must determine, from the information contained in the 510(K) Notice and
any additional information that is submitted, that the device is substantially
equivalent to one or more Class I or II devices that are legally marketed in the
United States. Certain Class I devices are exempt from the 510(K) premarket
notification requirement and manufacturers of such products may proceed to
market without any submission to the FDA. If a device is not considered
"substantially equivalent", it is regulated as a Class III medical device. In
general, a Class III medical device must be expressly approved by the FDA for
commercial distribution pursuant to the submission of a premarket approval
application ("PMA"). A PMA must contain, among other information, substantial
information about the manufacture of the device and data from adequate and
well-controlled clinical trials that demonstrate that the device is both safe
and effective. The PMA approval process is substantially more complex and
lengthy than the 510(K) premarket notification process.
A medical device, whether cleared for marketing under the 510(K) pathway or
pursuant to a PMA approval, is subject to ongoing regulatory oversight by the
FDA to ensure compliance with regulatory requirements, including, but not
limited to, product labeling requirements and limitations, including those
related to promotion and marketing efforts, current good manufacturing practice
requirements, recordkeeping, and medical device (adverse reaction) reporting.
Dental mercury is currently regulated by the FDA as a Class I device (not
exempt from the 510(K) premarket notification requirement), and amalgam alloy is
regulated as a Class II device. In February 1993, FDA reported to its Dental
Products Advisory Panel that it planned to regulate encapsulated mercury and
amalgam alloy, like those sold by Kerr, as a single Class II device. At the same
time, the FDA planned to propose the reclassification of dental mercury as a
Class II device, so as to conform to the Class II designation
12
<PAGE> 16
for amalgam alloy and to the planned Class II designation for encapsulated
mercury and amalgam alloy. In October 1994, the FDA's Dental Products Panel of
the Medical Devices Advisory Committee voted unanimously to recommend
reclassification of dental mercury from Class I to Class II. Currently, the FDA
is preparing a proposal for the reclassification of mercury from Class I to
Class II and for a Class II designation for encapsulated mercury and amalgam
alloy. Class II devices, unlike Class I devices, may be subject to performance
standards or special controls. At this time, there are no performance standards
or special controls applicable to mercury or to encapsulated mercury and amalgam
alloy, although it is possible that the FDA could propose special controls
during the reclassification process. With a Class II designation, the amalgam
products would not be subject to the PMA process.
All dental amalgam filling materials, including Kerr's dental amalgam
products, contain mercury. The use of mercury in various products, including
dental amalgams, is being examined by various groups and U.S. and foreign
governmental agencies as a part of an effort to reduce the amount of mercury
discharged into the environment. One foreign government agency, as a result of a
study it conducted, has proposed a plan which would discontinue the use of
amalgams once a suitable alternative is found.
In addition to the environmental concerns about mercury in dental amalgams,
certain groups have expressed concerns about health effects allegedly caused by
the mercury in amalgams. These groups are active in lobbying state, federal and
foreign lawmakers and regulators to pass laws or adopt regulatory changes or
recommendations regarding alleged potential health risks of dental amalgams. To
date these efforts have resulted in restrictions on or recommendations against
the use of amalgams in certain clinical situations by health authorities in some
countries, even though such health authorities point out there is no scientific
evidence to suggest that amalgam is causing illness in the general population.
Such actions have been taken to reduce human exposure to mercury where other
safe and practical alternatives to dental amalgam exist. In the United States,
the FDA's Dental Devices Panel, the National Institute of Health, and the United
States Public Health Service have each indicated that the use of amalgams does
not cause verifiable adverse effects in patients who have amalgam fillings. All
of these agencies have recommended further research on the subject and, in large
part because of their initiatives, research with respect to potential health
effects of dental amalgams is ongoing at various places around the world.
ENVIRONMENTAL MATTERS
The Company's operations entail a number of environmentally sensitive
production processes and compliance with environmental laws and regulations
along with regulations relating to workplace safety is a significant factor in
the Company's businesses. The Company's domestic facilities are subject to
federal, state and local laws and regulations concerning, among other things,
solid and hazardous waste disposal, air emissions and waste water discharge, and
the Company's foreign facilities are subject to local laws and regulations
regarding the environment. The Company's operations are also subject to
regulation relating to workplace safety, both in the United States and abroad.
Violations of any of these laws and regulations or the release of toxic or
hazardous materials used in the Company's operations into the environment could
expose the Company to significant liability. Similarly, third party lawsuits
relating to environmental and workplace safety issues could result in
substantial liability. The Company believes that it is in substantial compliance
with all applicable environmental and workplace safety laws.
See Item 3, "Legal Proceedings", Note 13 to the consolidated financial
statements of the Company contained in Item 8 of this Annual Report, and Item 7,
"Management's Discussion and Analysis of Financial Condition and Results of
Operations -- General".
RAW MATERIALS
The Operating Subsidiaries purchase a wide range of raw materials and
supplies from a number of suppliers and do not rely on sole sources to any
material extent. The Company does not foresee any significant difficulty in
obtaining necessary materials or supplies.
13
<PAGE> 17
RISKS ATTENDANT TO FOREIGN OPERATIONS
The Company conducts its business in numerous foreign countries and as a
result is subject to risks of fluctuations in exchange rates of various foreign
currencies and other risks associated with foreign trade. For 1994, 1995 and
1996, the Company's foreign and United States export sales accounted for
approximately 35%, 36% and 36%, respectively, of consolidated net sales. See
Item 7, "Management's Discussion and Analysis of Financial Condition and Results
of Operations -- General" for further information concerning the possible
effects of foreign currency fluctuations and currency hedges intended to
mitigate their impact.
RELIANCE ON KEY DISTRIBUTORS
A substantial portion of the Company's sales of laboratory products is made
through the major independent distributors, which historically have been Fisher,
VWR, Baxter Scientific Products and CMS. As set forth above, these major
distributors experienced significant consolidation in 1995, with Fisher
acquiring CMS and VWR acquiring Baxter Industrial. This consolidation slowed
sales in the domestic segment of the laboratory business in 1995 and during the
first half of 1996. The softness was primarily due to consolidation of
inventories by the distributors and not due to a deterioration of end-user
demand.
Because of the significance of the Company's sales to these major
laboratory distributors, the loss of any one of them (now Fisher, VWR and
Allegiance) could have a materially adverse effect on the Company's business.
The Operating Subsidiaries in the laboratory segment do not have any contractual
relationships with such distributors. However, such subsidiaries within this
segment have long-standing relationships with these distributors and, in certain
cases, their predecessors. Although not to the same extent as the laboratory
segment, Kerr also sells through distributors. The loss of certain of Kerr's
distributors could have a material adverse effect on the Company's results of
operations or financial condition.
ITEM 2. PROPERTIES
The Company's Operating Subsidiaries operate manufacturing facilities in
the United States and certain foreign countries. The principal domestic
facilities of the Company's Operating Subsidiaries other than NNI's Nunc
facility in Naperville, Illinois, are leased.
The following table sets forth information regarding the Company's
principal properties, including those owned by the Company's subsidiaries.
Properties of less than 20,000 square feet have been omitted from this table:
<TABLE>
<CAPTION>
SUBSIDIARY/LOCATION OF FACILITY BUILDING SPACE AND USE OWNED OR LEASED
- --------------------------------------- -------------------------------------------- ---------------
<S> <C> <C>
PROPERTIES USED BY LABORATORY SEGMENT
- ---------------------------------------
NNI
Penfield, New York 266,000 sq. ft./manufacturing, warehouse and leased
headquarters
Auburn, New York 49,600 sq. ft./manufacturing, warehouse and owned
offices
New Castle, Delaware 25,900 sq. ft./manufacturing, warehouse and leased
offices
Wiesbaden, Germany 21,000 sq. ft./warehouse leased
Naperville, Illinois 103,000 sq. ft./manufacturing, warehouse and owned
office
Roskilde, Denmark 151,000 sq. ft./manufacturing and office owned
Lafayette, New Jersey 36,000 sq. ft./manufacturing, warehouse and leased
offices
Bridgewater, New Jersey 44,000 sq. ft./manufacturing, warehouse and leased
offices
</TABLE>
14
<PAGE> 18
<TABLE>
<CAPTION>
SUBSIDIARY/LOCATION OF FACILITY BUILDING SPACE AND USE OWNED OR LEASED
- --------------------------------------- -------------------------------------------- ---------------
<S> <C> <C>
Erie
Portsmouth, New Hampshire 126,000 sq. ft./manufacturing and leased
headquarters
Braunschweig, Germany 40,000 sq. ft./manufacturing owned
Romont, Switzerland 176,000 sq. ft./manufacturing owned
Aguadilla, Puerto Rico 23,000 sq. ft./manufacturing leased
West Paterson, New Jersey 20,000 sq. ft./manufacturing leased
Woburn, Massachusetts 30,000 sq. ft./manufacturing leased
East Providence, Rhode Island 35,000 sq. ft./manufacturing leased
Kalamazoo, Michigan 36,000 sq. ft./manufacturing leased
Naugatuck, Connecticut 75,000 sq. ft./manufacturing owned
Holtsville, New York 31,400 sq. ft./manufacturing leased
Wayne, New Jersey 32,500 sq. ft./manufacturing leased
Barnstead/Thermolyne
Dubuque, Iowa 180,000 sq. ft./manufacturing and leased
headquarters
PROPERTIES USED BY DENTAL SEGMENT
- --------------------------------------
Sybron Dental Specialties
Orange, California 104,000 sq. ft./headquarters, leased
administration, manufacturing and
warehouse
Kerr
Morrisburg, Ontario 30,000 sq. ft./manufacturing owned
Danbury, Connecticut 30,000 sq. ft./office, warehouse and leased
manufacturing
Romulus, Michigan 220,000 sq. ft./manufacturing leased
Scafati, Italy 39,000 sq. ft./manufacturing owned
Ormco
Mexicali, Mexico 21,000 sq. ft./office and manufacturing leased
Glendora, California 66,000 sq. ft./manufacturing leased
Redmond, Washington 29,000 sq. ft./manufacturing, warehouse and leased
offices
Uman, Yucatan, Mexico 35,000 sq. ft./manufacturing owned
</TABLE>
The Company considers its plants and equipment to be well-maintained and
suitable for their purposes. The Company, from time to time, has expanded and
will continue to expand facilities as the need arises. The Company expects to
fund such expansions through internally generated funds or borrowings under its
existing Credit Facilities, as defined in Note 7 to the consolidated financial
statements of the Company contained in Item 8 of this Annual Report. See Item 7,
"Management's Discussion and Analysis of Financial Condition and Results of
Operations -- Liquidity and Capital Resources".
ITEM 3. LEGAL PROCEEDINGS
The Company or its subsidiaries are at any one time parties to a number of
lawsuits or subject to claims arising out of their respective operations, or
their operation of businesses divested in the 1980's for which certain
subsidiaries may continue to have legal or contractual liability, including
products liability, workplace safety and environmental claims and cases, some of
which involve claims for substantial damages. The
15
<PAGE> 19
Company or its subsidiaries are vigorously defending lawsuits or claims against
them. Subject to the qualifications stated below relating to the Aqua-Tech Site
(as defined below) and the Rochester Site (as defined below), based upon the
insurance available under the Company's insurance program and the potential for
liability with respect to claims which are uninsured, the Company believes that
any liabilities which might foreseeably result from any of its pending cases and
claims would not have a material adverse effect on the results of operations or
financial condition of the Company and its subsidiaries taken as a whole. There
can be no assurance as to this, however, or that litigation having such a
material adverse effect will not arise in the future.
Among the lawsuits previously reported is one in which Kerr obtained a
judgement on a jury verdict in its favor holding that a case brought by a former
employee alleging that Kerr intentionally caused him to contract silicosis (a
lung disease) by exposing him to silica had been brought beyond the applicable
statute of limitations. The jury verdict has been confirmed by the Supreme Court
of the state in which the action was pending, and the plaintiff's appeals have
thus been exhausted.
A facility previously owned by one of the Company's subsidiaries has been
identified as a potentially responsible party ("PRP") at the Aqua-Tech site in
South Carolina (the "Aqua-Tech Site") at which an action has been conducted for
the removal of surface contaminants under the supervision of the Environmental
Protection Agency ("EPA") under the Comprehensive Environmental Response,
Compensation and Liability Act of 1980, as amended ("CERCLA"). The Company's
total contribution to such effort, which has been paid, was approximately
$46,000. The site has been placed by the EPA on the federal National Priority
List under CERCLA, which is a prerequisite to any federally-mandated requirement
for long-term remedial work at the site under CERCLA, such as would be involved
in soil and groundwater remediation. The Company is participating with a PRP
group composed of approximately 100 parties in an agreement with the EPA to
undertake a remedial investigation and feasibility study which will be used by
the EPA to determine what remedy, if any, should be required at the site. This
study is expected to be completed in early 1998. Because the study, which
involves extensive testing required to characterize the extent and nature of
contamination to determine potential remedies, has not yet been completed, an
estimate of the Company's potential liability cannot be made. However, although
CERCLA does provide for joint and several liability, because the Company's share
of waste allegedly sent to the site is reportedly not more than 1% of the total
waste sent, the Company believes any ultimate liability will not have a material
adverse effect on the results of operations or financial condition of the
Company and its subsidiaries taken as a whole.
On May 2, 1996, Combustion Engineering, Inc. ("CE"), a subsidiary of Asea
Brown Boveri Ltd. ("ABB"), commenced legal proceedings (the "CE Litigation")
against the Company with respect to the former Taylor Instruments facility in
Rochester, New York (the "Rochester Site"), a discontinued operation. The CE
Litigation, brought in the New York Supreme Court, Monroe County, New York,
relates to the previously reported claims ABB has made for reimbursement to it
of expenses associated with the remediation of alleged environmental
contamination at the Rochester Site. The Rochester Site was sold to CE in 1983
by the predecessor of a subsidiary of the Company.
See Note 13 to the consolidated financial statements of the Company
contained in Item 8 of this Annual Report, and Item 7, "Management's Discussion
and Analysis of Financial Condition and Results of Operations -- General".
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not applicable.
16
<PAGE> 20
EXECUTIVE OFFICERS OF THE REGISTRANT
Set forth below are the names, ages, positions and offices held of the
executive officers of the Company, which include the presidents of NNI, Erie,
Barnstead/Thermolyne, Sybron Dental Specialties, Kerr and Ormco. All executive
officers hold office at the pleasure of the Board of Directors.
<TABLE>
<CAPTION>
NAME AGE POSITIONS
- ---------------------------- --- ---------------------------------------------------------
<S> <C> <C>
Kenneth F. Yontz............ 52 Chairman of the Board, President and Chief Executive
Officer
Dennis Brown................ 49 Vice President -- Finance, Chief Financial Officer and
Treasurer
R. Jeffrey Harris........... 41 Vice President -- General Counsel and Secretary
David T. Della Penta........ 48 President, NNI
Frank H. Jellinek, Jr. ..... 51 President, Erie
Randy Hoff.................. 46 President, Barnstead/Thermolyne
Floyd W. Pickrell, Jr. ..... 51 President, Sybron Dental Specialties, Ormco and Kerr
</TABLE>
The following sets forth the principal occupations, as well as
directorships, for the periods specified of the executive officers, including
the presidents of the Operating Subsidiaries.
Mr. Yontz. President and Chief Executive Officer of the Company since
October 1987; Chairman of the Board since December 1987; President and Chief
Executive Officer of the Acquired Company from February 1986 until September
1992; Director of the Acquired Company from February 1986 to March 1988;
previously Group Vice President and Executive Vice President of the
Allen-Bradley Company. Director of Berg Electronics, Inc., Playtex Products,
Inc. and Thompson Minwax Co.
Mr. Brown. Joined the Company in January 1993 as Vice President -- Finance
and Chief Financial Officer and also became Treasurer of the Company in October
1993; previously served as President of Allen-Bradley Europe from March 1990 to
January 1993, and Treasurer of The Marmon Group, Inc., from January 1987 to
March 1990.
Mr. Harris. Joined the Acquired Company in 1985 as Assistant Counsel and
served as Corporate Counsel and Assistant Secretary from May 1986 until the
Company's acquisition of the Acquired Company; served as Vice President and
Assistant Secretary of the Company from October 1987 to January 1988; Vice
President -- General Counsel and Secretary of the Company since January 1988.
Mr. Della Penta. Joined the Acquired Company in 1970 and joined Nalge in
1981 as Controller, becoming Vice President -- Finance in 1982; became Vice
President -- Manufacturing of Nalge in 1986 and Vice President -- Marketing of
Nalge in 1987; appointed as Nalge's President in May 1989; appointed President
of NNI in November 1995. Director of Sear Brown Associates, Yellow Springs
Instrument, Incorporated and JAM, Inc.
Mr. Jellinek. Joined Erie in 1967 and has served as President of Erie since
1975; has from time to time held general management responsibilities for various
former businesses of the Acquired Company.
Mr. Hoff. Joined the Acquired Company in 1983 as Laboratory Group Planning
Executive, and Thermolyne Corporation in 1986 as Vice President, Sales and
Marketing. He became Vice President, Sales and Marketing of Barnstead/Thermolyne
upon its formation in 1988. In January 1995, he was appointed
Barnstead/Thermolyne's President.
Mr. Pickrell. Appointed President of Sybron Dental Specialties in August
1993; appointed President of Kerr in August 1993; joined Ormco in 1978 and has
served as Ormco's President since March 1983; previously served as Ormco's Vice
President of Marketing and as its National Sales Manager.
17
<PAGE> 21
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS
The Company has not since its inception paid any dividends on its Common
Stock. See "Management's Discussion and Analysis of Financial Condition and
Results of Operations -- Liquidity and Capital Resources" in Item 7 of this
Annual Report, and Note 7 to the consolidated financial statements of the
Company contained in Item 8 of this Annual Report, for a description of certain
restrictions on the ability of the Company to pay dividends. Subject to such
limitations, any future dividends will be at the discretion of the Company's
Board of Directors and will depend upon, among other factors, the Company's
earnings, financial condition and other requirements. The Company has no current
intention to pay cash dividends on its Common Stock.
Based upon record ownership as of December 2, 1996, the approximate number
of holders of the Company's Common Stock is 406.
The Company's Common Stock trades on the New York Stock Exchange under the
symbol "SYB". The market information set forth below is based on New York Stock
Exchange sales prices.
<TABLE>
<CAPTION>
FISCAL 1995 HIGH LOW
--------------------------------------------- ------- -------
<S> <C> <C>
First Quarter................................ $18.000 $15.563
Second Quarter............................... 18.188 16.125
Third Quarter................................ 20.375 17.625
Fourth Quarter............................... 21.438 19.688
</TABLE>
<TABLE>
<CAPTION>
FISCAL 1996 HIGH LOW
--------------------------------------------- ------- -------
<S> <C> <C>
First Quarter................................ $24.125 $18.438
Second Quarter............................... 25.000 21.875
Third Quarter................................ 27.500 23.125
Fourth Quarter............................... 29.750 24.375
</TABLE>
18
<PAGE> 22
ITEM 6. SELECTED FINANCIAL DATA
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
-------------------------------------------------------------
1992 1993 1994 1995 1996
-------- -------- -------- -------- --------
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
<S> <C> <C> <C> <C> <C>
Statement of Income Data(a):
Net sales......................... $382,595 $395,404 $439,704 $519,200 $674,457
Income before extraordinary items
and cumulative effect of
accounting change.............. 21,376 25,793 43,015 51,800 57,584
Extraordinary items............... -- (8,531)(b) -- (2,885)(b) --
Cumulative effect of accounting
change......................... -- -- (420)(c) -- --
Net income........................ 21,376 17,262 42,595 48,915 57,584
Dividends on preferred stock(d)... 12,268 -- -- -- --
Net income applicable to common
stock.......................... 9,108 17,262 42,595 48,915 57,584
Earnings per share:
Earnings per common share before
extraordinary items and
cumulative effect of accounting
change......................... .30 .57(e) .92 1.10 1.20(e)
Extraordinary items............... -- (.19) -- (.06) --
Cumulative effect of accounting
change......................... -- -- (.01) -- --
Earnings per common share......... .30 .38(e) .91 1.04 1.20(e)
</TABLE>
<TABLE>
<CAPTION>
AS OF SEPTEMBER 30,
--------------------------------------------------------
1992 1993 1994 1995 1996
-------- -------- -------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C> <C> <C>
Balance Sheet Data:
Total assets............................ $472,419 $481,291 $557,676 $852,083 $974,613
Long-term debt.......................... 270,388 249,309 223,565 406,547 481,037
Shareholders' equity.................... 101,440 126,353 176,775 227,250 283,079
</TABLE>
- ---------------
(a) Amounts include the results of acquired businesses from their respective
dates of acquisition. See Note 14 to the consolidated financial statements
of the Company contained in Item 8 of this Annual Report.
(b) Amount resulted from the refinancing of the Company's debt. See Note 7 to
the consolidated financial statements of the Company contained in Item 8 of
this Annual Report.
(c) Amount resulted from the adoption of Statement of Financial Accounting
Standards No. 109, "Accounting for Income Taxes." See Note 1(g) to the
consolidated financial statements of the Company contained in Item 8 of this
Annual Report.
(d) On May 2, 1992 the Company consummated an initial public offering of its
common stock. At that time all senior preferred stock was redeemed and all
junior preferred stock was converted to common stock.
(e) Includes a restructuring charge of $.06 and $.13 per share in fiscal 1993
and 1996, respectively. See Note 11 to the consolidated financial statements
of the Company contained in Item 8 of this report.
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
The following discussion should be read in conjunction with the Company's
consolidated financial statements and notes thereto included elsewhere herein.
The growth in the Company's 1996 sales and operating income has been
achieved through the successful implementation of management's business
strategies. Overall sales growth of 29.9% was achieved through an
19
<PAGE> 23
increase in both the domestic and international sectors. Domestic sales grew by
$97.3 million, bolstered by sales of new products and by ten domestic
acquisitions. Acquisitions accounted for approximately $85.8 million of the
domestic sales growth. International sales grew by $57.9 million, aided by
recovering international economies and the acquisition of Nunc. Acquisitions
accounted for approximately $42.6 million of the international sales growth. The
modest internal domestic growth can be attributed to softness in the Company's
core domestic laboratory business experienced primarily in the first half of
1996. Although end user demand remained healthy, demand from the Company's
largest domestic laboratory distributors was weak in the wake of significant
dealer consolidation. In 1995 the Company's principal distributors, Fisher, CMS,
VWR and Baxter Industrial, combined into two distributors through Fisher's
acquisition of CMS and VWR's acquisition of Baxter Industrial. This distributor
consolidation is believed to have been responsible for the slowness in domestic
laboratory sales during the first half of 1996 as distributor inventories were
reduced. See Item 1, "Business -- Laboratory Segment".
As discussed in Item 1, "Business -- General", management has maintained an
active program of developing and marketing both new products and product line
extensions. The Company believes that new product introductions have enabled the
Operating Subsidiaries to maintain their competitive positions. Management has
also sought out and pursued numerous acquisition opportunities, completing
twenty-nine such acquisitions since 1993, ten of which were completed by the
Company in 1996. Acquisitions completed in 1996 were as follows:
<TABLE>
<CAPTION>
APPROXIMATE ACQUISITION
COMPANY ANNUAL SALES DATE DESCRIPTION
- --------------------------- ------------- ----------- -----------------------------------------
<S> <C> <C> <C>
Analytic Technology
Corporation.............. $ 2.1 million 10/95 Manufacturer of equipment used in
conjunction with endodontic treatment.
CASCO Standards, Inc....... $ 3.2 million 11/95 Manufacturer of liquid standards as well
as calibration verification and quality
control materials used with clinical
diagnostic and testing equipment.
belle de st. claire,
inc...................... $ 2.9 million 11/95 Manufacturer of a broad line of products
for the dental laboratory.
Acutech Plastics, Inc...... $ 9.9 million 1/96 Manufacturer of pipe and tubing for
ultra-pure applications.
Naugatuck Glass Company.... $17.6 million 2/96 Manufacturer of thin glass mirrors used
primarily in the cosmetics industry.
Precision Glassworks
L.L.C.................... $ 0.5 million 5/96 Supplier of glass and mirrors to the
cosmetic and scientific markets.
Stephens Scientific........ $11.4 million 7/96 Manufacturer of solvents, imbedding
waxes, reagent grade alcohols and tissue
freezing aerosol, all products used in
histology laboratories.
Flexible Components,
Inc...................... $11.4 million 7/96 Manufacturer of flexible hoses, fittings,
and accessories used in fluid and gas
transport applications in the
pharmaceutical, biotech, food and
beverage, air, and gas industries.
Micro-Aseptic
Products, Inc............ $ 4.5 million 7/96 Marketer of infection control products,
disinfectant and decontaminant cleaners,
deodorizers, antiseptic hand and skin
cleaners and related products to the
medical and dental markets.
E&D Dental Products,
Inc...................... $ 5.4 million 8/96 Wholesale supplier of dental products.
</TABLE>
20
<PAGE> 24
These acquisitions are consistent with the Company's strategy of making
acquisitions which provide product lines that can be manufactured in existing
facilities, sold through existing sales and distribution networks, or both. The
Company intends to continue to seek out acquisition candidates consistent with
its business strategy. However, there can be no assurance of the number or size
of future acquisitions.
As described in Item 3, "Legal Proceedings", one of the Company's
subsidiaries is involved as a PRP at the Aqua-Tech Site, and another is involved
in legal proceedings with respect to environmental claims against it with
respect to the Rochester Site. Because the testing has not been done to
determine what remedy, if any, should be required at the Aqua-Tech Site, an
estimate of the Company's potential liability with respect to this site cannot
be made at this time. However, and although CERCLA does provide for joint and
several liability, because the Company's share of waste allegedly sent to the
site is reportedly not more than 1% of the total waste sent, the Company
believes that any ultimate liability with respect to the Aqua-Tech Site will not
have a material adverse effect on the results of operations or financial
condition of the Company and its subsidiaries as a whole.
With respect to the Rochester Site, as reported previously, on May 2, 1996,
Combustion Engineering, Inc. ("CE") commenced legal proceedings in the New York
Supreme Court, County of Monroe (the "CE Litigation"), against the Company with
respect to the former Taylor Instruments ("Taylor") facility in Rochester, New
York (the "Rochester Site"), a discontinued operation. According to CE's
complaint, its claims are based on an asset purchase and sale agreement dated as
of September 30, 1983, pursuant to which Taylor was sold to CE (the "1983
Agreement"), and an agreement between a subsidiary of the Company and CE dated
August 14, 1987 (the "1987 Agreement"). The complaint alleges that under the
1983 Agreement the Company retained certain liabilities for, and indemnified CE
with respect to, environmental contamination, hazards and other conditions that
existed at the time of the sale of Taylor to CE, and that under the 1987
Agreement, the Company agreed to bear 70 percent of the costs thereafter
incurred to clean up, remediate and remove mercury from the land and buildings
at the Rochester Site. CE's complaint seeks declaratory relief and claims
damages of at least $10 million with respect to expenses CE has incurred and
expects to incur to remediate and remove mercury contamination from the land and
buildings sold to CE at the Rochester Site. The complaint also seeks declaratory
relief and claims damages in excess of $1 million with respect to expenses
incurred and expected to be incurred for remediating other alleged environmental
hazards associated with the Rochester Site. Some of CE's claims relate to the
cost to demolish and dispose of the buildings at the Rochester Site, which CE
maintains it had to do because the buildings were contaminated with mercury. CE
previously informed the Company that CE claims that the Company's share of such
demolition and disposal costs is approximately $4.2 million. The Company denies
it has any liability for such costs. CE's remaining claims relate to alleged
soil and groundwater contamination, including mercury contamination, for which
the Company also denies liability. CE implemented a plan in early 1996 to assess
the extent of potential soil and groundwater contamination at the Rochester
Site, the preliminary results of which have been provided by CE to the Company.
The preliminary results indicate there is mercury and inorganic and volatile
organic compound contamination in the soil and groundwater at certain Rochester
Site locations. CE is preparing a voluntary clean-up proposal based on these
results which it plans to present to the New York Department of Environmental
Conservation (the "NYDEC") for consideration. The cost to remediate the
Rochester Site will depend upon the remediation standards incorporated into any
voluntary agreement between CE and the NYDEC. Because the clean-up standards
which may be applied have not been determined, the extent of remediation to be
undertaken, and its cost, is unknown. As a result, the Company cannot, at this
time, estimate the cost of the soil and groundwater remediation claims. The
Company previously reported that prior to beginning the Rochester Site
assessment which generated the current test results, CE had indicated to the
Company that, based upon information available to it and subject to a number of
caveats, including the lack of assessment information and the fact that clean-up
standards which may be applied to the Rochester Site have not been determined,
the cost to remediate the soil and groundwater would range from $3 million to $5
million. Because the bases for this estimate were not disclosed by CE to the
Company, the Company cannot make a judgement about how the preliminary test
results it has been provided would affect this estimate. The Company intends to
pursue insurance coverage for CE's claims and has therefore provided notice of
CE's claims to its third party liability insurance carriers. To date the
carriers have denied coverage.
For additional information regarding factors that may influence the
Company's performance, see Item 1, "Business" and Item 3, "Legal Proceedings".
21
<PAGE> 25
The Company's results of operations reflect goodwill amortization, other
amortization, and depreciation, which are non-cash charges, totaling $30.4
million, $33.7 million, and $44.1 million in 1994, 1995 and 1996, respectively.
Due to the acquisition activity and associated amortization of stepped up assets
and goodwill, the Company expects depreciation and amortization to continue to
increase through fiscal 1997. In fiscal 1998, such depreciation of stepped-up
assets associated with the Acquisition is expected to decrease by approximately
$2.9 million, primarily as a result of the completed write-off of depreciation
associated with machinery and equipment with a ten year life. As discussed below
in "Liquidity and Capital Resources", the Company's earnings before interest,
taxes, depreciation and amortization ("EBITDA") amounted to $120.5 million,
$141.7 million and $180.3 million in 1994, 1995 and 1996, respectively. EBITDA
represents, for any relevant period, net income (except that extraordinary items
and the cumulative effect on prior years of adoption of Statement of Financial
Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS 109") are
excluded) plus (i) interest expense, (ii) provision for income taxes, (iii)
depreciation, and (iv) amortization, all determined on a consolidated basis and
in accordance with generally accepted accounting principles.
Substantial portions of the Company's net sales, net income and cash flows
from operations are derived internationally. The financial position and the
results of operations from substantially all of the Company's international
operations, other than most United States export sales, are measured using the
local currency of the countries in which such operations are conducted and are
translated into United States dollars. While the reported income of foreign
subsidiaries will be impacted by a weakening or strengthening of the United
States dollar in relation to a particular local currency, the effects of foreign
currency fluctuations are partially mitigated by the fact that manufacturing
costs and other expenses of foreign subsidiaries are generally incurred in the
same currencies in which sales are generated. Such effects of foreign currency
fluctuations are also mitigated by the fact that such subsidiaries' operations
are conducted in numerous foreign countries and, therefore, in numerous foreign
currencies. In addition, the Company's United States export sales may be
impacted by foreign currency fluctuations to the relative value of the United
States dollar as foreign customers may adjust their level of purchases upward or
downward according to the weakness or strength of the United States dollar. In
order to hedge against future strengthening of the United States dollar, in June
and July 1993 and in October 1994, the Company employed currency hedges through
the purchase of a series of options. In June and July 1993, options were
purchased with a United States dollar notional amount of approximately $23.0
million at a cost of approximately $1.1 million. All of these options expired
worthless. In October 1994 the purchased options had a United States dollar
notional amount of approximately $21.2 million at a cost of approximately $0.2
million. The October 1994 options expired worthless but protected the Company
from potential detrimental effects of currency movements as compared to the
prior year. From time to time, management may employ additional currency hedges
to further mitigate the impact of foreign currency fluctuations. If currency
hedges are not employed, the Company is exposed to earnings volatility as a
result of foreign currency fluctuations.
The following table sets forth the domestic net sales and foreign and
United States export net sales by the Company in 1994, 1995 and 1996. See also
Note 15 to the consolidated financial statements of the Company contained in
Item 8 of this Annual Report.
<TABLE>
<CAPTION>
YEAR ENDED SEPTEMBER 30,
--------------------------------
1994 1995 1996
-------- -------- --------
(IN THOUSANDS)
<S> <C> <C> <C>
Domestic net sales.................................... $287,674 $332,646 $429,988
Foreign and United States export net sales............ 152,030 186,554 244,469
-------- -------- --------
Total net sales....................................... $439,704 $519,200 $674,457
======== ======== ========
</TABLE>
22
<PAGE> 26
RESULTS OF OPERATIONS
YEAR ENDED SEPTEMBER 30, 1996
COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1995
Net Sales. Net sales for the year ended September 30, 1996 were $674.5
million, an increase of $155.3 million (29.9%) from net sales of $519.2 million
for the corresponding 1995 period. Sales in the laboratory segment were $394.3
million in the 1996 period, an increase of 46.9% from the 1995 period. Increased
sales in the laboratory segment resulted primarily from: (i) sales from Nunc
following its acquisition (approximately $57.0 million), (ii) sales of products
from other acquired companies (approximately $53.8 million), (iii) an increase
in sales of existing products at NNI (approximately $6.3 million) and Erie
(approximately $1.8 million), (iv) price increases at Barnstead/Thermolyne
(approximately $2.2 million), Erie (approximately $2.1 million) and NNI
(approximately $1.9 million) and (v) increased volume from sales of new products
at NNI with respect to NALGENE products (approximately $2.2 million, primarily
their micropackaging vials and an OEM product, Roche Cobas bottles) and
Barnstead/Thermolyne (approximately $0.2 million, primarily their line of
asphalt ashing furnaces), partially offset by discontinued sales of products at
NNI's trade molding business (approximately $1.7 million) and an unfavorable
foreign currency impact at Erie (approximately $0.2 million). In the dental
segment, net sales were $280.1 million in the 1996 period, an increase of 11.7%
from the 1995 period. Increased sales in the dental segment resulted primarily
from: (i) sales of products from acquired companies (approximately $17.6
million), (ii) increased volume from sales of new products (approximately $12.8
million, primarily from the ORTHOS(TM) and copper Ni-Ti(TM) product lines
manufactured by Ormco, and Kerr's TYTIN FC(TM) Alloy) and (iii) favorable
foreign currency impacts (approximately $0.3 million), partially offset by
decreased sales of existing products (approximately $1.7 million).
Gross Profit. Gross profit for the year ended September 30, 1996, before a
restructuring charge discussed below, was $338.9 million, an increase of 30.4%
from gross profit of $259.8 million for the corresponding 1995 period. Gross
profit in the laboratory segment was $180.5 million (45.8% of net segment
sales), an increase of 50.3% from $120.1 million (44.7% of net segment sales)
during the 1995 period. Increased gross profit in the laboratory segment was
primarily from: (i) the gross profit from Nunc following its acquisition
(approximately $28.0 million), (ii) the additional gross profit from other
acquired companies (approximately $19.7 million), (iii) increased sales volume
at NNI with respect to NALGENE products (approximately $4.3 million),
Barnstead/Thermolyne (approximately $1.1 million) and Erie (approximately $0.6
million), (iv) a favorable product mix at NNI (approximately $2.4 million), Erie
(approximately $1.6 million) and Barnstead/ Thermolyne (approximately $0.8
million), (v) decreased material costs at NNI (approximately $1.5 million) and
various inventory factors at NNI (approximately $1.0 million), partially offset
by inventory factors at Erie (approximately $0.7 million). In the dental
segment, gross profit was $158.3 million (56.5% of net segment sales), an
increase of 13.3% from gross profit of $139.7 million (55.7% of net segment
sales) during the 1995 period. Increased gross profit in the dental segment was
primarily from: (i) the additional gross profit from acquired businesses
(approximately $12.4 million) and (ii) increased sales volume (approximately
$6.7 million), partially offset by increased material costs (approximately $1.0
million).
Selling, General and Administrative Expenses. Selling, general and
administrative expenses for the 1996 period, prior to a restructuring charge
discussed below, were $194.6 million (28.9% of net sales) as compared to $150.7
million (29.0% of net sales) in the 1995 period. General and administrative
expenses at the corporate level, including amortization of goodwill, were $21.7
million in 1996, representing an increase of 7.8% from $20.1 million in 1995.
Increases at the corporate level were primarily due to: (i) an increase in
insurance expense (approximately $0.8 million) and (ii) an increase in employee
benefits expense (approximately $0.2 million). Selling, general and
administrative expenses at the subsidiary level, including amortization of
intangibles, were $172.9 million, representing a $42.3 million (32.4%) increase
over the 1995 period. Increases at the subsidiary level were primarily due to:
(i) increased selling, general and administrative expenses as a result of
acquired businesses (approximately $20.7 million), (ii) increased marketing
expenses (approximately $7.3 million), (iii) increased general and
administrative expenses (approximately $6.2 million), (iv) increased
amortization of intangibles primarily as a result of the purchase of Nunc
(approximately $6.0 million), (v) increased research and development expenses
(approximately $1.4 million) and (vi) unfavorable foreign currency impacts
(approximately $0.7 million).
23
<PAGE> 27
Restructuring Charge. In March of 1996, the Company recorded a
restructuring charge of $8.3 million ($6.1 million after-tax or $0.13 per share)
for the rationalization of certain acquired companies, combination of certain
production facilities, movement of certain customer service and marketing
functions and the exiting of several product lines. Approximately $5.0 million
was charged against this reserve as of September 30, 1996. As of September 30,
1996 approximately $3.3 million of the established liability remains to be
expended and is recorded in other current liabilities. The Company expects to
charge approximately $3.0 million against the reserve in fiscal 1997 and the
remaining $0.3 million some time thereafter. Principal items in the reserve are
severance and termination costs for approximately 130 notified employees
(primarily production, sales and marketing personnel) (approximately $2.3
million), remaining lease payments and shutdown costs on exited facilities
(approximately $2.1 million), the non-cash write-off of certain fixed assets and
inventory associated with exited product lines, primarily of Sybron Dental
Specialties (approximately $2.5 million), a statutory tax penalty (approximately
$0.7 million) and other related restructuring costs (approximately $0.7
million).
Operating Income. As a result of the foregoing, operating income was $136.7
million (20.3% of net sales) for the year ended September 30, 1996, as compared
with $109.1 million (21.0% of net sales) in the 1995 period. Operating income in
the laboratory segment was $82.6 million (20.9% of net segment sales) as
compared to $55.2 million (20.6% of net segment sales) in 1995. Operating income
in the dental segment was $54.1 million (19.3% of net segment sales) in 1996 as
compared to $53.9 million (21.5% of net segment sales) in 1995. Both the
laboratory and dental segment operating income were negatively impacted in 1996
by the restructuring charge referred to above.
Interest Expense. Interest expense was $35.2 million in the 1996 period, an
increase of $12.2 million from the 1995 period. The increase resulted from a
higher average debt balance in 1996, resulting primarily from the Company's
acquisition activity.
Income Taxes. Taxes on income increased $10.2 million. This was primarily
the result of increased taxable earnings and the impact of non-deductible
goodwill associated with acquisitions.
In October 1995, the Company made a payment to the Internal Revenue Service
of approximately $14.2 million as final settlement for the tax years ended
December 31, 1986 through September 30, 1989. As a result of this settlement,
the Company increased goodwill as of September 30, 1995 by approximately $7.2
million for tax incurred prior to the acquisition of the Acquired Company in
October 1987. The remaining portion of approximately $7.0 million had been
accrued in prior years as taxes payable.
Net Income. As a result of the foregoing, the Company had net income of
$57.6 million for the year ended September 30, 1996, as compared to net income
of $48.9 million after inclusion of an extraordinary item discussed below in the
1995 period.
Depreciation and Amortization. Depreciation and amortization expense is
allocated among cost of sales, selling, general and administrative expenses and
other expense. Depreciation and amortization increased in 1996 due to additional
depreciation and amortization from the step-up of assets and goodwill recorded
from the acquisition of Nunc, as well as from additions from other acquisitions
and capital expenditures.
New Accounting Pronouncements. SFAS 123 was issued by the Financial
Accounting Standards Board in October 1995. SFAS 123 establishes financial and
reporting standards for stock-based compensation plans. Adoption is not required
by the Company until fiscal 1997. Under SFAS 123, the Company may choose to
reflect the fair value of stock options as compensation cost based on the value
of the option which is recognized over the vesting period or retain the current
approach set forth in APB Opinion 25 and expand its footnote disclosure to
provide pro forma disclosure as if it had adopted the fair value accounting
method. The Company expects to retain its current accounting methodology and
expand its footnote disclosure when SFAS 123 is adopted.
24
<PAGE> 28
RESULTS OF OPERATIONS
YEAR ENDED SEPTEMBER 30, 1995
COMPARED TO THE YEAR ENDED SEPTEMBER 30, 1994
Net Sales. Net sales for the year ended September 30, 1995 were $519.2
million, an increase of $79.5 million (18.1%) from net sales of $439.7 million
for the corresponding 1994 period. Sales in the laboratory segment were $268.4
million in the 1995 period, an increase of 20.0% from the 1994 period. Increased
sales in the laboratory segment resulted primarily from: (i) sales from the
acquisition of Nunc (approximately $11.9 million), (ii) sales of products from
other acquired companies (approximately $23.1 million), (iii) price increases at
Nalge (approximately $2.3 million), Erie (approximately $1.4 million), and at
Barnstead/Thermolyne (approximately $1.2 million), (iv) increased volume from
sales of new products at Barnstead/Thermolyne (approximately $3.2 million,
primarily their new line of asphalt ashing furnaces) and at Nalge (approximately
$1.4 million, primarily the BioProcess products and PES membranes) and (v) a
favorable foreign currency impact at Erie (approximately $2.3 million),
partially offset by a reduction in sales of existing products at Nalge
(approximately $1.9 million) and Erie (approximately $0.4 million). In the
dental segment, net sales were $250.8 million in the 1995 period, an increase of
16.1% from the 1994 period. Increased sales in the dental segment resulted
primarily from: (i) sales of products from acquired companies (approximately
$13.7 million), (ii) increased volume from sales of new products (approximately
$11.2 million, primarily from Ormco's OPTIMESH(TM), a specially treated
orthodontic bonding pad, Ormco's ORTHOS(TM) product line, Kerr's EXTRUDE MPV(R)
impression materials, and Kerr's PRODIGY(TM) hybrid composite filling
materials), (iii) favorable foreign currency impacts (approximately $7.3
million) and (iv) increased sales of existing products (approximately $2.6
million).
Gross Profit. Gross profit for the year ended September 30, 1995 was $259.8
million, an increase of 17.1% from gross profit of $221.9 million for the
corresponding 1994 period. Gross profit in the laboratory segment was $120.1
million (44.7% of net segment sales), an increase of 15.6% from $103.9 million
(46.4% of net segment sales) during the 1994 period. Increased gross profit in
the laboratory segment was primarily from: (i) the gross profit from the
acquisition of Nunc (approximately $5.9 million), (ii) the additional gross
profit from other acquisitions (approximately $10.4 million), (iii) increased
sales volume at Barnstead/Thermolyne (approximately $2.1 million), (iv) a
favorable foreign currency impact at Erie (approximately $0.7 million) and (v) a
favorable product mix at Erie (approximately $0.3 million) and
Barnstead/Thermolyne (approximately $0.3 million), partially offset by decreased
sales volume at Nalge (approximately $1.6 million) and an increase in material
costs at Erie (approximately $0.7 million) and Nalge (approximately $0.4
million). Softness in the domestic laboratory business was primarily responsible
for lower gross margins. In the dental segment, gross profit was $139.7 million
(55.7% of net segment sales), an increase of 18.4% from gross profit of $118.0
million (54.6% of net segment sales) during the 1994 period. Increased gross
profit in the dental segment was primarily from: (i) increased sales volume
(approximately $7.5 million), (ii) the additional gross profit from acquired
businesses (approximately $5.8 million), (iii) a favorable foreign currency
impact (approximately $5.8 million), (iv) decreased material costs
(approximately $1.9 million) and (v) various inventory factors (approximately
$0.7 million).
Selling, General and Administrative Expenses. Selling, general and
administrative expenses for the 1995 period were $150.7 million (29.0% of net
sales) as compared to $130.4 million (29.7% of net sales) in the 1994 period.
General and administrative expenses at the corporate level, including
amortization of goodwill, were $20.1 million in 1995, representing a decrease of
13.4% from $23.2 million in 1994. Decreases at the corporate level were
primarily due to a reallocation of insurance and employee benefits expenses.
Selling, general and administrative expenses at the subsidiary level, including
amortization of intangibles, were $130.6 million, representing a $23.4 million
(21.8%) increase over the 1994 period. Increases at the subsidiary level were
primarily due to: (i) increased selling, general and administrative expenses as
a result of acquired businesses (approximately $11.7 million), (ii) increased
marketing expenses (approximately $3.7 million), (iii) increased general and
administrative expenses (approximately $3.7 million), (iv) increased research
and development expenses (approximately $1.5 million), (v) unfavorable foreign
currency impacts (approximately $1.5 million) and (vi) increased amortization of
intangibles primarily related to the acquisition of Nunc (approximately $0.8
million).
25
<PAGE> 29
Operating Income. As a result of the foregoing, operating income was $109.1
million (21.0% of net sales) for the year ended September 30, 1995, as compared
with $91.5 million (20.8% of net sales) in the 1994 period. Operating income in
the laboratory segment was $55.2 million (20.6% of net segment sales) as
compared to $47.8 million (21.3% of net segment sales) in fiscal year 1994.
Operating income in the dental segment was $53.9 million (21.5% of net segment
sales) in 1995 as compared to $43.7 million (20.3% of net segment sales) in
1994.
Interest Expense. Interest expense was $23.0 million in the 1995 period, an
increase of $3.8 million from the 1994 period. The increase resulted from a
higher average debt balance in 1995, resulting primarily from the Company's
acquisition activity.
Income Taxes. Taxes on income increased $5.2 million. This was primarily
the result of increased taxable earnings.
In October 1995, the Company made a payment to the Internal Revenue Service
of approximately $14.2 million as final settlement for the tax years ended
December 31, 1986 through September 30, 1989. As a result of this settlement,
the Company increased goodwill as of September 30, 1995 by approximately $7.2
million for tax incurred prior to the acquisition of the Acquired Company in
October 1987. The remaining portion of approximately $7.0 million had been
accrued in prior years as taxes payable.
Extraordinary Item. As a result of the refinancing of the Company's debt in
July 1995, the Company wrote off approximately $2.9 million of unamortized
deferred financing fees net of tax benefits. The refinancing was completed on
July 31, 1995 in order to expand the Company's credit facilities and to provide
financing for the acquisition of Nunc.
Net Income. As a result of the foregoing, the Company had net income of
$48.9 million for the year ended September 30, 1995, as compared to net income
of $42.6 million in the 1994 period.
Depreciation and Amortization. Depreciation and amortization expense is
allocated among cost of sales, selling, general and administrative expenses and
other expense. Depreciation and amortization increased in 1995 due to additional
depreciation and amortization from the step-up of assets and goodwill recorded
from the acquisition of Nunc, as well as from additions from other acquisitions
and capital expenditures.
INFLATION
The Company does not believe that inflation has had a material impact on
net sales or income during any of the periods presented above. There can be no
assurance, however, that the Company's business will not be affected by
inflation in the future.
LIQUIDITY AND CAPITAL RESOURCES
As a result of the Acquisition, subsequent adoption of SFAS 109 and the
acquisitions completed since 1987, the Company increased the carrying value of
certain tangible and intangible assets consistent with generally accepted
accounting principles. Also, as a result of the permanent financing, effected in
August 1988 for the Acquisition, the Company incurred approximately $372 million
of debt. Accordingly, the Company's results of operations include a significant
level of non-cash expenses related to the depreciation of fixed assets and the
amortization of intangible assets, including goodwill. Goodwill and intangible
assets increased by $83.6 million in 1996 as a result of acquisitions. The
Company believes, therefore, that EBITDA represents the more appropriate measure
of the Company's ability to internally fund its capital requirements.
The Company's capital requirements arise principally from indebtedness
incurred in connection with the permanent financing for the Acquisition and its
subsequent refinancings, the Company's working capital needs, primarily related
to inventory and accounts receivable, the Company's capital expenditures,
primarily related to purchases of machinery and molds, the purchase of various
businesses and product lines in execution of the Company's acquisition strategy,
the periodic expansion of physical facilities, and, in the short term, payments
related to the restructuring charge (as described above). In addition, in the
event the Company should be held liable for CE's claims in the CE Litigation,
liability for which the Company denies, the Company could require capital to
satisfy such liabilities, depending upon their magnitude. See Item 3 "Legal
26
<PAGE> 30
Proceedings". With respect to the restructuring charge, as of September 30,
1996, the Company has paid approximately $2.4 million and charged an additional
$2.6 million to inventory and fixed assets. The Company intends to expend an
additional $3.0 million by the end of fiscal 1997 and $0.3 million over the
remaining terms of exited facilities leases and severance arrangements. With
respect to acquisitions, it is currently the Company's intent to continue to
pursue its acquisition strategy. If acquisitions are to continue at the
Company's historical pace, the Company may require financing beyond the capacity
of its existing Credit Facilities (as defined below). In addition, certain
acquisitions previously completed contain "earnout provisions" requiring further
payments in the future if certain financial results are achieved by the acquired
companies.
The statement contained in the immediately preceding paragraph concerning
the Company's intent to continue to pursue its acquisition strategy is a
forward-looking statement. The Company's ability to continue its acquisition
strategy is subject to a number of uncertainties, including, but not limited to,
its ability to raise capital beyond the capacity of its existing Credit
Facilities (as defined below), and the availability of suitable acquisition
candidates at reasonable prices. See "Cautionary Factors" below.
On July 31, 1995, the Company and its domestic subsidiaries entered into a
new credit agreement (the "Credit Agreement") with Chemical Bank (now known as
The Chase Manhattan Bank ("Chase")) and certain other lenders providing for a
term loan facility of $300 million (the "Term Loan Facility"), and a revolving
credit facility of $250 million (the "Revolving Credit Facility") (collectively
the "Credit Facilities"). On the same day, the Company and its subsidiaries
borrowed $300 million under the Term Loan Facility and approximately $122.5
million under the Revolving Credit Facility. Approximately $158.5 million of the
borrowed funds were used to finance the acquisition of Nunc (approximately $9.1
million of the acquisition price for Nunc was borrowed under the Company's
previous credit facilities (the "Previous Credit Facilities")). The remaining
borrowed funds of approximately $264.0 million were used to repay outstanding
amounts, including accrued interest, under the Company's Previous Credit
Facilities and to pay certain fees in connection with such refinancing. On July
9, 1996, under the First Amendment to the Credit Agreement (the "Amendment"),
the capacity of the Revolving Credit Facility was increased to $300 million, and
a competitive bid process was established as an additional option to the Company
in setting interest rates.
Payment of principal and interest with respect to the Credit Facilities and
the Sale/Leaseback (as defined later herein) are anticipated to be the Company's
largest use of funds in the future. The Credit Facilities provide for an annual
interest rate, at the option of the Company, equal to (a) the higher of (i) the
rate from time to time publicly announced by The Chase Manhattan Bank in New
York City as its prime rate, (ii) the federal funds rate plus 1/2 of 1%, and
(iii) the base CD rate plus 1%, (b) the London interbank offered rate ("LIBOR")
plus 1/2% to 1% (the "LIBOR Margin") depending upon the level of certain
financial ratios, or (c) with respect to the Revolving Credit Facility, the rate
set by the competitive bid process among the parties to the Revolving Credit
Facility established in the Amendment. In 1996, the average rates on the Term
Loan Facility and the Revolving Credit Facility (inclusive of the swap
agreements described below) were 6.3% and 6.5%, respectively.
As a result of the terms of the Credit Agreement and the agreement
governing the Previous Credit Facilities, the Company is sensitive to a rise in
interest rates. In order to reduce its sensitivity to interest rate increases,
the Company entered into five interest rate swap agreements, aggregating a
notional amount of $250 million, to hedge against a rise in interest rates. The
net interest rate paid by the Company is approximately equal to the sum of the
swap agreement rate plus the applicable LIBOR Margin. During 1996, the LIBOR
Margin was .75% or 1.0% and as of September 30, 1996, was .75%. The swap
agreement rates and duration are as follows:
<TABLE>
<CAPTION>
EXPIRATION DATE NOTIONAL AMOUNT SWAP AGREEMENT DATE SWAP AGREEMENT RATE
- ------------------------------------- --------------- ------------------- -------------------
<S> <C> <C> <C>
December 9, 1996..................... $50 million December 8, 1995 5.3475%
July 7, 1998......................... $50 million July 7, 1993 5.17%
August 13, 1999...................... $50 million August 13, 1993 5.54%
September 8, 2000.................... $50 million December 8, 1995 5.56%
September 10, 2001................... $50 million December 8, 1995 5.623%
</TABLE>
27
<PAGE> 31
On November 8, 1996, the Company entered into a forward swap agreement
which will begin on December 16, 1996. This additional swap agreement has a $50
million notional amount at a swap agreement rate of 5.64%. This agreement
expires December 15, 1997. See Note 7 to the consolidated financial statements
of the Company contained in Item 8 of this Annual Report.
Also as part of the permanent financing for the Acquisition, on December
22, 1988, the Company entered into the sale and leaseback of its principal
domestic facilities (the "Sale/Leaseback"). The annual obligation under the
Sale/Leaseback is $3.3 million, payable monthly. On the fifth anniversary of the
leases and every five years thereafter (including renewal terms), the rent will
be increased by the percentage equal to 75% of the percentage increase in the
Consumer Price Index over the preceding five years. The percentage increase to
the rent in any five-year period is capped at 15%. The next adjustment will not
occur until January 1, 1999.
The Company intends to fund its acquisitions, working capital requirements,
capital expenditure requirements, principal and interest payments, obligations
under the Sale/Leaseback, restructuring expenditures, other liabilities and
periodic expansion of facilities, to the extent available, with funds provided
by operations and short-term borrowings under the Revolving Credit Facility. To
the extent that funds are not available, particularly with respect to the
Company's acquisition strategy, the Company will have to raise additional
capital.
As set forth above, the Revolving Credit Facility provides for up to $300
million in available credit. As of September 30, 1996, there was $69.1 million
of available credit under the Revolving Credit Facility. Under the Term Loan
Facility, on October 31, 1995 the Company began to repay principal in 28
consecutive quarterly installments; $35 million was paid in 1996. Annual
payments are due as follows: $35 million, $40 million, $40 million, $50 million,
$50 million, and $50 million in the fiscal years 1997 through 2002,
respectively.
The Credit Agreement contains numerous financial and operating covenants,
including, among other things, restrictions on investments; requirements that
the Company maintain certain financial ratios; restrictions on the ability of
the Company and its subsidiaries to incur indebtedness or to create or permit
liens, to make capital expenditures, or to pay cash dividends in excess of $50.0
million plus 50% of the defined consolidated net income of the Company for each
fiscal quarter ending after June 30, 1995, less any dividends paid after June
22, 1994; restrictions on annual capital expenditures to amounts ranging from
$36.0 million to $40.0 million during the remaining term of the Credit
Agreement; and limitations on incurrence of additional indebtedness. The Credit
Agreement permits the Company to make acquisitions provided the Company
continues to satisfy all financial covenants upon any such acquisition. The
ability of the Company to meet its debt service requirements and to comply with
such covenants is dependent upon the Company's future performance, which is
subject to financial, economic, competitive and other factors affecting the
Company, many of which are beyond its control.
CAUTIONARY FACTORS
This report contains various forward-looking statements concerning the
Company's prospects that are based on the current expectations and beliefs of
management. Forward-looking statements may also be made by the Company from time
to time in other reports and documents as well as oral presentations. When used
in written documents or oral statements, the words "anticipate", "believe",
"estimate", "expect", "objective" and similar expressions are intended to
identify forward-looking statements. The statements contained herein and such
future statements involve or may involve certain assumptions, risks and
uncertainties, many of which are beyond the Company's control, that could cause
the Company's actual results and performance to differ materially from what is
expected. In addition to the assumptions and other factors referenced
specifically in connection with such statements, the following factors could
impact the business and financial prospects of the Company:
- Factors affecting the Company's international operations, including
relevant foreign currency exchange rates, which can affect the cost to
produce the Company's products or the ability to sell the Company's
products in foreign markets, and the value in United States dollars of
sales made in foreign currencies. Other factors include the Company's
ability to obtain effective hedges against fluctuations in currency
exchange rates; foreign trade, monetary and fiscal policies; laws,
regulations and other activities of foreign governments, agencies and
similar organizations; and risks associated with having major
28
<PAGE> 32
manufacturing facilities located in countries, such as Mexico, Hungary
and Italy, which have historically been less stable than the United
States in several respects, including fiscal and political stability.
- Factors affecting the Company's ability to continue pursuing its current
acquisition strategy, including the Company's ability to raise capital
beyond the capacity of its existing Credit Facilities or to use the
Company's stock for acquisitions, the cost of the capital required to
effect the Company's acquisition strategy, the availability of suitable
acquisition candidates at reasonable prices, the ability of the Company
to realize the synergies expected to result from acquisitions, and the
ability of existing Company personnel to efficiently handle increased
transitional responsibilities resulting from acquisitions.
- Factors affecting the Company's ability to profitably distribute and sell
its products, including any changes in the Company's business
relationships with its principal distributors, primarily in the
laboratory segment, competitive factors such as the entrance of
additional competitors into the Company's markets, pricing and
technological competition, and risks associated with the development and
marketing of new products in order to remain competitive by keeping pace
with advancing dental, orthodontic and laboratory technologies.
- With respect to Erie, factors affecting its Erie Electroverre S.A.
subsidiary's ability to manufacture the glass used by Erie's worldwide
manufacturing operations, including delays encountered in connection with
the periodic rebuild of the sheet glass furnace and furnace malfunctions
at a time when inventory levels are not sufficient to sustain Erie's
operations.
- Factors affecting the Company's ability to hire and retain competent
employees, including unionization of the Company's non-union employees
and changes in relationships with the Company's unionized employees.
- The risk of strikes or other labor disputes at those locations which are
unionized which could affect the Company's operations.
- Factors affecting the Company's ability to continue manufacturing and
selling those of its products that are subject to regulation by the
United States Food and Drug Administration or other domestic or foreign
governments or agencies, including the promulgation of stricter laws or
regulations, reclassification of the Company's products into categories
subject to more stringent requirements, or the withdrawal of the approval
needed to sell one or more of the Company's products.
- Factors affecting the economy generally, including the financial and
business conditions of the Company's customers and the demand for
customers' products and services that utilize Company products.
- Factors relating to the impact of changing public and private health care
budgets which could affect demand for or pricing of the Company's
products.
- Factors affecting the Company's financial performance or condition,
including tax legislation, unanticipated restrictions on the Company's
ability to transfer funds from its subsidiaries and changes in applicable
accounting principles or environmental laws and regulations.
- The cost and other effects of claims involving the Company's products and
other legal and administrative proceedings, including the expense of
investigating, litigating and settling any claims.
- Factors affecting the Company's ability to produce products on a
competitive basis, including the availability of raw materials at
reasonable prices.
- Unanticipated technological developments that result in competitive
disadvantages and create the potential for impairment of existing assets.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
29
<PAGE> 33
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
SYBRON INTERNATIONAL CORPORATION
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report.......................................................... 31
Consolidated Balance Sheets as of September 30, 1995 and 1996......................... 32
Consolidated Statements of Income for the years ended September 30, 1994, 1995 and
1996................................................................................ 33
Consolidated Statements of Shareholders' Equity for the years ended September 30,
1994, 1995 and 1996................................................................. 34
Consolidated Statements of Cash Flows for the years ended September 30, 1994, 1995 and
1996................................................................................ 35
Notes to Consolidated Financial Statements............................................ 36
</TABLE>
30
<PAGE> 34
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Shareholders
Sybron International Corporation:
We have audited the accompanying consolidated balance sheets of Sybron
International Corporation and subsidiaries as of September 30, 1995 and 1996,
and the related consolidated statements of income, shareholders' equity, and
cash flows for each of the years in the three-year period ended September 30,
1996. These consolidated financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
consolidated financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above
present fairly, in all material respects, the financial position of Sybron
International Corporation and subsidiaries as of September 30, 1995 and 1996,
and the results of their operations and their cash flows for each of the years
in the three-year period ended September 30, 1996, in conformity with generally
accepted accounting principles.
KPMG Peat Marwick LLP
Milwaukee, Wisconsin
November 8, 1996
31
<PAGE> 35
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
SEPTEMBER 30, 1995 AND 1996
(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)
<TABLE>
<CAPTION>
SEPTEMBER 30,
--------------------
1995 1996
-------- --------
<S> <C> <C>
ASSETS
Current assets:
Cash and cash equivalents............................................. $ 9,243 $ 10,874
Accounts receivable (less allowance for doubtful receivables of $2,355
and $2,429 in 1995 and 1996, respectively) (note 2)................ 109,572 127,849
Inventories (note 3).................................................. 108,675 120,317
Deferred income taxes (note 4)........................................ 10,224 11,588
Prepaid expenses and other current assets............................. 13,229 12,012
-------- --------
Total current assets.......................................... 250,943 282,640
-------- --------
Property, plant and equipment, net (notes 5 and 7)...................... 148,110 170,151
Intangible assets (note 6).............................................. 437,865 502,079
Deferred income taxes (note 4).......................................... 9,144 12,563
Other assets............................................................ 6,021 7,180
-------- --------
Total assets.................................................. $852,083 $974,613
======== ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable...................................................... $ 27,165 $ 30,398
Current portion of long-term debt (notes 7 and 8)..................... 39,635 40,603
Income taxes payable (note 4)......................................... 17,772 7,636
Accrued payroll and employee benefits (note 10)....................... 26,890 29,824
Deferred income taxes (note 4)........................................ 1,234 2,542
Other current liabilities (notes 11 and 13)........................... 25,459 27,764
-------- --------
Total current liabilities..................................... 138,155 138,767
-------- --------
Long-term debt (notes 7 and 8).......................................... 406,547 481,037
Deferred income taxes (note 4).......................................... 62,071 55,686
Other liabilities (note 10)............................................. 18,060 16,044
Commitments and contingent liabilities (notes 8, 10 and 13)
Shareholders' equity (note 12):
Preferred stock, $0.01 par value; authorized 20,000,000 shares........ -- --
Common stock, $0.01 par value; authorized 110,000,000 shares, issued
46,529,992 and 46,924,588 shares in 1995 and 1996, respectively.... 465 469
Equity rights, 1,098 and 698 rights at $1.09 per right in 1995 and
1996, respectively................................................. 1 1
Additional paid-in capital............................................ 172,774 179,954
Retained earnings..................................................... 54,261 111,845
Cumulative foreign currency translation adjustment.................... 220 (9,189)
Treasury common stock, 2,402 and 1,528 shares at cost in 1995 and
1996, respectively................................................. (1) (1)
Minimum pension liability adjustment (note 10)........................ (470) --
-------- --------
Total shareholders' equity.................................... 227,250 283,079
-------- --------
Total liabilities and shareholders' equity.................... $852,083 $974,613
======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
32
<PAGE> 36
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
FOR THE YEARS ENDED SEPTEMBER 30, 1994, 1995 AND 1996
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
1994 1995 1996
-------- -------- --------
<S> <C> <C> <C>
Net sales..................................................... $439,704 $519,200 $674,457
Cost of sales:
Cost of product sold........................................ 214,195 255,779 331,761
Restructuring charge (note 11).............................. -- -- 2,223
Depreciation of purchase accounting adjustments............. 3,636 3,631 3,846
-------- -------- --------
Total cost of sales........................................... 217,831 259,410 337,830
-------- -------- --------
Gross profit.................................................. 221,873 259,790 336,627
Selling, general and administrative expenses.................. 117,735 137,110 174,852
Restructuring charge (note 11)................................ -- -- 5,307
Depreciation and amortization of purchase accounting
adjustments................................................. 12,650 13,556 19,735
-------- -------- --------
Operating income.............................................. 91,488 109,124 136,733
-------- -------- --------
Other income (expense):
Interest expense (note 10).................................. (19,218) (23,036) (35,237)
Amortization of deferred financing fees..................... (851) (825) (286)
Other, net.................................................. (543) (353) (284)
-------- -------- --------
Income before income taxes, extraordinary item and cumulative
effect of change in accounting principle.................... 70,876 84,910 100,926
Income taxes (note 4)......................................... 27,861 33,110 43,342
-------- -------- --------
Income before extraordinary item and cumulative effect of
change in accounting principle.............................. 43,015 51,800 57,584
Extraordinary item -- Write-off of unamortized deferred
financing fees (net of income tax benefits of $1,699) (note
7).......................................................... -- (2,885) --
Cumulative effect on prior years of adoption of Statement of
Financial Accounting Standards No. 109 (note 1(g)).......... (420) -- --
-------- -------- --------
Net income.................................................... $ 42,595 $ 48,915 $ 57,584
======== ======== ========
Earnings per common share:
Income before extraordinary item and cumulative effect of
change in accounting principle........................... $ .92 $ 1.10 $ 1.20
Extraordinary item.......................................... -- (.06) --
Cumulative effect on prior years of adoption of Statement of
Financial Accounting Standards No. 109................... (.01) -- --
-------- -------- --------
Net income.................................................. $ .91 $ 1.04 $ 1.20
======== ======== ========
</TABLE>
See accompanying notes to consolidated financial statements.
33
<PAGE> 37
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
FOR THE YEARS ENDED SEPTEMBER 30, 1994, 1995 AND 1996
(IN THOUSANDS, EXCEPT SHARE DATA)
<TABLE>
<CAPTION>
CUMULATIVE
RETAINED FOREIGN MINIMUM
ADDITIONAL EARNINGS CURRENCY TREASURY PENSION TOTAL
COMMON EQUITY PAID-IN (ACCUMULATED TRANSLATION COMMON LIABILITY SHAREHOLDERS'
STOCK RIGHTS CAPITAL DEFICIT) ADJUSTMENT STOCK ADJUSTMENT EQUITY
------ ------ ---------- ------------ ----------- ------ ---------- -------------
<S> <C> <C> <C> <C> <C> <C> <C> <C>
Balance at September 30,
1993....................... $462 $ 2 $166,063 $(37,248) $(2,235) $ (2) $ (689) $ 126,353
Shares issued in connection
with the exercise of
269,304 stock options...... 2 -- 980 (1) -- -- -- 981
Tax benefits related to stock
options.................... -- -- 3,884 -- -- -- -- 3,884
Net income................... -- -- -- 42,595 -- -- -- 42,595
Foreign currency translation
adjustment................. -- -- -- -- 2,273 -- -- 2,273
Amount related to recording
minimum pension
liability.................. -- -- -- -- -- -- 689 689
---- --- -------- -------- ------- --- ----- --------
Balance at September 30,
1994....................... 464 2 170,927 5,346 38 (2) -- 176,775
Shares issued in connection
with the exercise of
135,268 stock options...... 1 -- 1,550 -- -- -- -- 1,551
Conversion of 294 equity
rights to common stock..... -- (1) -- -- -- 1 -- --
Tax benefits related to stock
options.................... -- -- 297 -- -- -- -- 297
Net income................... -- -- -- 48,915 -- -- -- 48,915
Foreign currency translation
adjustment................. -- -- -- -- 182 -- -- 182
Amount related to recording
minimum pension
liability.................. -- -- -- -- -- -- (470) (470)
---- --- -------- -------- ------- --- ----- --------
Balance at September 30,
1995....................... 465 1 172,774 54,261 220 (1) (470) 227,250
Shares issued in connection
with the exercise of
393,722 stock options...... 4 -- 5,635 -- -- -- -- 5,639
Tax benefits related to stock
options.................... -- -- 1,545 -- -- -- -- 1,545
Net income................... -- -- -- 57,584 -- -- -- 57,584
Foreign currency translation
adjustment................. -- -- -- -- (9,409) -- -- (9,409)
Amount related to recording
minimum pension
liability.................. -- -- -- -- -- -- 470 470
---- --- -------- -------- ------- --- ----- --------
Balance at September 30,
1996....................... $469 $ 1 $179,954 $111,845 $(9,189) $ (1) -- $ 283,079
==== === ======== ======== ======= === ===== ========
</TABLE>
See accompanying notes to consolidated financial statements.
34
<PAGE> 38
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED SEPTEMBER 30, 1994, 1995 AND 1996
(IN THOUSANDS)
<TABLE>
<CAPTION>
1994 1995 1996
-------- --------- ---------
<S> <C> <C> <C>
Cash flows from operating activities:
Net income................................................ $ 42,595 $ 48,915 $ 57,584
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation........................................... 17,145 19,619 24,394
Amortization........................................... 13,256 14,108 19,719
Loss (gain) on sales of property, plant and
equipment............................................ 141 (159) 266
Provision for losses on doubtful receivables........... 998 503 1,129
Inventory provisions................................... 960 1,810 2,845
Deferred income taxes.................................. (3,350) (4,780) (6,981)
Extraordinary item..................................... -- 2,885 --
Cumulative effect of change in accounting principle.... 420 -- --
Changes in assets and liabilities, net of effects of
businesses acquired:
Increase in accounts receivable...................... (7,059) (15,861) (11,743)
Increase in inventories.............................. (11,006) (13,930) (7,642)
(Increase) decrease in prepaid expenses and other
current assets.................................... 1,025 (4,863) 1,192
Increase (decrease) in accounts payable.............. (1,621) 658 655
Increase (decrease) in income taxes payable.......... (530) 772 (14,340)
Increase in accrued payroll and employee benefits.... 1,394 2,181 2,134
Increase (decrease) in other current liabilities..... (6,407) 5,605 (2,285)
Net change in other assets and liabilities........... 6,947 1,166 (86)
-------- --------- ---------
Total adjustments................................. 12,313 9,714 9,257
-------- --------- ---------
Net cash provided by operating activities............ 54,908 58,629 66,841
Cash flows from investing activities:
Capital expenditures...................................... (20,587) (22,311) (37,737)
Proceeds from sales of property, plant and equipment...... 349 453 3,735
Net payments for businesses acquired...................... (17,350) (237,075) (105,987)
-------- --------- ---------
Net cash used in investing activities................ (37,588) (258,933) (139,989)
Cash flows from financing activities:
Repayment of retired credit facilities.................... -- (261,750) --
Proceeds from new term loan facilities.................... -- 300,000 --
Proceeds from new revolving credit facilities............. -- 122,500 --
Principal payments on long-term debt...................... (26,346) (22,680) (36,397)
Proceeds from the exercise of stock options............... 981 1,551 5,639
Refinancing fees.......................................... (736) (1,230) --
Net change in revolving credit facilities................. (1,000) 51,500 106,100
Other..................................................... 555 5,527 1,043
-------- --------- ---------
Net cash provided by (used in) financing
activities........................................ (26,546) 195,418 76,385
Effect of exchange rate changes on cash and cash
equivalents............................................... 939 2,935 (1,606)
Net increase (decrease) in cash and cash equivalents........ (8,287) (1,951) 1,631
Cash and cash equivalents at beginning of year.............. 19,481 11,194 9,243
-------- --------- ---------
Cash and cash equivalents at end of year.................... $ 11,194 $ 9,243 $ 10,874
======== ========= =========
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest............................................... $ 19,190 $ 18,893 $ 41,225
======== ========= =========
Income taxes........................................... $ 26,263 $ 31,523 $ 48,224
======== ========= =========
Capital lease obligations incurred........................ $ 1,071 $ 1,167 $ 1,028
======== ========= =========
</TABLE>
See accompanying notes to consolidated financial statements.
35
<PAGE> 39
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED SEPTEMBER 30, 1994, 1995 AND 1996
(DOLLARS IN THOUSANDS, EXCEPT PER SHARE DATA)
(1) SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Sybron International Corporation manufactures value-added products for the
laboratory and professional orthodontic and dental markets in the United States
and abroad. The Company's laboratory business provides plastic labware,
microscope slides, consumables, temperature control apparatus and water
purification systems to industrial, academic, clinical, governmental and
biotechnology laboratories. The Company's orthodontic and dental businesses
provide orthodontic appliances and related products to orthodontists and a
diversified line of consumable products to dentists.
(a) Principles of Consolidation and Fiscal Year End
The consolidated financial statements reflect the accounts of Sybron
International Corporation and its subsidiaries. The term "Company" as used
herein refers to Sybron International Corporation and its subsidiaries, and
their respective predecessors, unless the context otherwise requires. All
significant intercompany balances and transactions have been eliminated. The
Company's fiscal year ends on September 30. The fiscal years ended September 30,
1994, 1995 and 1996 are hereinafter referred to as "1994", "1995" and "1996",
respectively.
(b) Cash Equivalents
For purposes of reporting cash flows, cash and cash equivalents include
investments in debt obligations with original maturities of three months or
less.
(c) Inventories
Inventories are stated at the lower of cost or market. Certain domestic
inventories of approximately $56,000 and $79,600 at September 30, 1995 and 1996,
respectively, are valued on the last-in, first-out (LIFO) method.
(d) Property, Plant and Equipment
Property, plant and equipment are stated at cost less accumulated
depreciation. Depreciation is provided over the estimated useful lives of
depreciable assets (5 to 45 years for land improvements, buildings and building
improvements, and 3 to 12 years for machinery and equipment) using the
straight-line method.
(e) Intangible Assets
Intangible assets are recorded at cost and are amortized, using the
straight-line method, over their estimated useful lives. Excess cost over net
asset value acquired (goodwill) and trademarks are amortized over 40 years;
proprietary technology and other intangibles are amortized over 7 to 17 years.
The Company assesses the recoverability of its goodwill by determining whether
the amortization of the goodwill balance over its remaining life can be
recovered through projected undiscounted future cash flows of the acquired
businesses. If projected future cash flows indicate that unamortized goodwill
will not be recovered, an adjustment would be made to reduce the net goodwill to
an amount equal to projected future cash flows discounted at the Company's
incremental borrowing rate. Cash flow projections are based on trends of
historical performance and management's estimate of future performance, giving
consideration to existing and anticipated competitive and economic conditions.
(f) Revenue Recognition
The Company recognizes revenue on the accrual basis of accounting upon
shipment of products.
36
<PAGE> 40
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(g) Income Taxes
Effective October 1, 1993, the Company adopted the provisions of Statement
of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS
109"). Under the asset and liability method of SFAS 109, deferred tax assets and
liabilities are recognized for future tax consequences attributable to
differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases and operating loss and tax credit
carryforwards. Deferred tax assets and liabilities are measured using enacted
tax rates expected to apply to taxable income in the years in which those
temporary differences are expected to be recovered or settled. The effect on
deferred tax assets and liabilities of a change in tax rates is recognized in
income in the period that includes the enactment date.
The adoption of SFAS 109 resulted in increases in intangible and other
assets of approximately $48,000, increases in deferred taxes and other
liabilities of approximately $48,420, and a decrease in net income of
approximately $420. The income effect is reported separately as the cumulative
effect of a change in accounting principle in the consolidated statement of
income for 1994.
(h) Research and Development Costs
Research and development costs are charged to selling, general and
administrative expenses in the year they are incurred. Research and development
costs for 1994, 1995 and 1996 were approximately $9,523, $11,020 and $13,702,
respectively.
(i) Foreign Currency Translation
The functional currency for the Company's foreign operations is the
applicable local currency. The translation from the applicable foreign
currencies to United States dollars is performed for balance sheet accounts
using current exchange rates in effect at the balance sheet date and for revenue
and expense accounts using a weighted average exchange rate during the period.
The gains or losses, net of applicable deferred income taxes, resulting from
such translations are included in shareholders' equity. Gains and losses
resulting from foreign currency transactions are included in net income. Foreign
currency transaction losses for 1994, 1995 and 1996 were approximately $649,
$372, and $493, respectively.
(j) Pensions
The Company and its subsidiaries have various pension plans covering
substantially all employees. United States and Canadian pension obligations are
funded by payments to pension fund trustees. Other foreign pensions are funded
as expenses are incurred. The Company's policy is generally to fund the minimum
amount required under the Employee Retirement Income Security Act of 1974 for
plans subject thereto.
(k) Earnings Per Common Share
For purposes of calculating earnings per common share, the Company uses the
weighted-average number of common and common equivalent shares including common
stock equivalents outstanding during the year applied to net income. The
weighted-average number of shares outstanding for 1994, 1995 and 1996 was
approximately 46,572,000, 46,978,000 and 47,917,000, respectively. Common stock
equivalents considered in the computation of primary earnings per share for
1994, 1995 and 1996 were approximately 234,000, 562,000 and 1,184,000,
respectively. Primary and fully diluted earnings per share amounts in 1994, 1995
and 1996 were the same.
(l) Reclassifications
Certain 1994 and 1995 amounts as originally reported have been reclassified
to conform with the 1996 presentation.
37
<PAGE> 41
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(m) Advertising Costs
Advertising costs included in selling, general and administrative expenses
are expensed as incurred and were $9,286, $8,762 and $9,659 in 1994, 1995 and
1996, respectively.
(n) Use of Estimates
Management of the Company has made a number of estimates and assumptions
relating to the reporting of assets and liabilities and the disclosure of
contingent liabilities to prepare these financial statements in conformity with
generally accepted accounting principles. Actual results could differ from those
estimates.
(2) BUSINESS AND CREDIT CONCENTRATIONS
Many of the Company's laboratory products were sold through four major
distributors and, until October 1994, to an original equipment manufacturer. In
1995, the four major distributors consolidated into two major distributors. In
1994, no single distributor or such manufacturer accounted for more than ten
percent of the Company's net sales. After the consolidation in distributors, the
remaining two distributors each accounted for approximately 12% of net sales in
1995 and 12% and 10% of the Company's net sales in 1996. Accounts receivable
from these distributors comprised approximately 23% and 24% of the outstanding
consolidated accounts receivable balances at September 30, 1995 and 1996,
respectively. (see note 15)
(3) INVENTORIES
Inventories at September 30, 1995 and 1996 consist of the following:
<TABLE>
<CAPTION>
1995 1996
-------- --------
<S> <C> <C>
Raw materials and supplies.................................. $ 30,314 $ 27,140
Work in process............................................. 22,660 35,579
Finished goods.............................................. 60,046 62,276
LIFO reserve................................................ (4,345) (4,678)
-------- --------
$108,675 $120,317
======== ========
</TABLE>
(4) INCOME TAXES
Total income tax expense for the years ended September 30, 1994, 1995 and
1996 is allocated as follows:
<TABLE>
<CAPTION>
1994 1995 1996
------- ------- -------
<S> <C> <C> <C>
Income from continuing operations.................... $27,861 $33,110 $43,342
Extraordinary item................................... -- (1,699) --
Shareholders' equity for compensation expense for tax
purposes in excess of amounts recognized for
financial reporting purposes....................... (3,884) (297) (1,545)
------- ------- -------
$23,977 $31,114 $41,797
======= ======= =======
</TABLE>
38
<PAGE> 42
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Income tax expense attributable to income from continuing operations
consists of:
<TABLE>
<CAPTION>
CURRENT DEFERRED TOTAL
------- -------- -------
<S> <C> <C> <C>
Year ended September 30, 1994:
United States, state and local..................... $22,361 $ (3,678) $18,683
Foreign............................................ 8,850 328 9,178
------- ------- -------
$31,211 $ (3,350) $27,861
======= ======= =======
Year ended September 30, 1995:
United States, state and local..................... $26,326 $ (3,940) $22,386
Foreign............................................ 11,564 (840) 10,724
------- ------- -------
$37,890 $ (4,780) $33,110
======= ======= =======
Year ended September 30, 1996:
United States, state and local..................... $38,808 $ (3,722) $35,086
Foreign............................................ 11,515 (3,259) 8,256
------- ------- -------
$50,323 $ (6,981) $43,342
======= ======= =======
</TABLE>
The domestic and foreign components of income before income taxes,
extraordinary item and cumulative effect of change in accounting principle are
as follows:
<TABLE>
<CAPTION>
1994 1995 1996
------- ------- --------
<S> <C> <C> <C>
United States....................................... $49,917 $59,370 $ 86,189
Foreign............................................. 20,959 25,540 14,737
------- ------- -------
Income before income taxes, extraordinary item, and
cumulative effect of change in accounting
principle......................................... $70,876 $84,910 $100,926
======= ======= =======
</TABLE>
Income tax expense attributable to income from continuing operations was
$27,861, $33,110 and $43,342 in 1994, 1995 and 1996, respectively, and differed
from the amounts computed by applying the United States federal income tax rate
of 35 percent to pretax income from continuing operations in 1994, 1995 and 1996
as a result of the following:
<TABLE>
<CAPTION>
1994 1995 1996
------- ------- -------
<S> <C> <C> <C>
Computed "expected" tax expense...................... $24,807 $29,719 $35,324
Increase (reduction) in income taxes resulting
from:
Change in beginning of year valuation allowance for
deferred tax assets allocated to income tax
expense......................................... (1,292) (2,631) (1,815)
Amortization of goodwill........................... 1,911 2,010 3,016
State and local income taxes, net of federal income
tax benefit..................................... 2,843 2,389 4,155
Foreign income taxed at rates higher than United
States federal income........................... 2,696 4,567 3,103
Foreign tax credits utilized in excess of United
States tax on foreign earnings.................. (2,075) (653) (678)
Other, net......................................... (1,029) (2,291) 237
------- ------- -------
$27,861 $33,110 $43,342
======= ======= =======
</TABLE>
39
<PAGE> 43
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The significant components of deferred income tax benefit attributable to
income from continuing operations for 1994, 1995 and 1996 are as follows:
<TABLE>
<CAPTION>
1994 1995 1996
------- ------- -------
<S> <C> <C> <C>
Deferred tax benefit (exclusive of the effects of
other components listed below)..................... $(2,058) $(2,324) $(5,087)
Charge in lieu of taxes resulting from the
recognition of foreign tax credits previously
benefited for financial statement purposes......... 2,709 -- --
Decrease in the valuation allowance for deferred tax
assets............................................. (4,001) (2,456) (1,894)
------- ------- -------
$(3,350) $(4,780) $(6,981)
======= ======= =======
</TABLE>
The tax effects of temporary differences that give rise to significant
portions of the deferred tax assets and deferred tax liabilities at September
30, 1995 and 1996 are presented below.
<TABLE>
<CAPTION>
1995 1996
-------- --------
<S> <C> <C>
Deferred tax assets:
Inventories............................................... $ 1,477 $ 1,883
Compensation.............................................. 1,221 1,661
Sale/Leaseback............................................ 7,545 7,452
Employee benefits......................................... 4,571 4,071
Foreign tax credit carryforwards.......................... 2,773 2,013
Net operating loss carryforwards.......................... 6,703 5,569
Warranty and other accruals............................... 4,554 9,084
-------- --------
Total gross deferred tax assets................... 28,844 31,733
Less valuation allowance.......................... (9,476) (7,582)
-------- --------
Net deferred tax assets........................... 19,368 24,151
-------- --------
Deferred tax liabilities:
Depreciation.............................................. (10,111) (10,253)
Purchase accounting....................................... (51,651) (44,883)
Other..................................................... (1,543) (3,092)
-------- --------
Total gross deferred tax liabilities.............. (63,305) (58,228)
-------- --------
Net deferred tax liability........................ $(43,937) $(34,077)
======== ========
</TABLE>
The valuation allowance for deferred tax assets as of October 1, 1994 was
$11,932. The net change in the total valuation allowance for the years ended
September 30, 1995 and 1996 was a decrease of $2,456 and $1,894, respectively.
In assessing the realizability of deferred tax assets, management considers
whether it is more likely than not that some portion or all of the deferred tax
assets will not be realized. The ultimate realization of deferred tax assets is
dependent upon the generation of future taxable income during the periods in
which those temporary differences become deductible. Management considers the
scheduled reversal of deferred tax liabilities, projected future taxable income
and tax planning strategies in making this assessment.
Subsequently recognized tax benefits relating to the valuation allowance
for deferred tax assets as of September 30, 1996 will be allocated as follows:
<TABLE>
<CAPTION>
1996
------
<S> <C>
Income tax benefit reported in the consolidated statement of income..... $5,569
Additional paid-in capital.............................................. 2,013
------
$7,582
======
</TABLE>
40
<PAGE> 44
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
At September 30, 1996, the Company has approximately $2,013 of foreign tax
credit carryforwards which expire in 1998. These carryforwards will be credited
to additional paid-in capital when realized as additional benefit from the
exercise of stock options. The Company has an aggregate of $2,400 of foreign net
operating loss carryforwards from certain foreign jurisdictions of which $1,700
expire from 2002 through 2006 and $700 may be carried forward indefinitely. The
Company has an aggregate of $108,000 of various state net operating losses, the
majority of which expire between 2002 and 2007.
Accumulated earnings of foreign subsidiaries at September 30, 1994, 1995
and 1996 of approximately $22,000, $21,000 and $25,000, respectively, have been
reinvested in the business and no provision for income taxes has been made for
the repatriation of these earnings.
In October 1995, the Company made a payment to the Internal Revenue Service
of $14,184 as final settlement for the tax years ended December 31, 1986 through
September 30, 1989. As a result of this settlement, the Company increased
goodwill as of September 30, 1995 by $7,171 for tax incurred prior to the
acquisition of Sybron Corporation in October 1987. The remaining portion of
$7,013 had been accrued in prior years as taxes payable.
(5) PROPERTY, PLANT AND EQUIPMENT
Major classifications of property, plant and equipment at September 30,
1995 and 1996 are as follows:
<TABLE>
<CAPTION>
1995 1996
-------- --------
<S> <C> <C>
Land and land improvements.................................. $ 9,289 $ 11,383
Buildings and building improvements......................... 65,258 77,689
Machinery and equipment..................................... 163,697 185,623
Construction in progress.................................... 13,363 18,885
-------- --------
251,607 293,580
Less: Accumulated depreciation.............................. 103,497 123,429
-------- --------
$148,110 $170,151
======== ========
</TABLE>
Commitments for purchases of equipment were approximately $902 at September
30, 1996. Machinery and equipment includes capitalized leases, net of
amortization, totaling $1,993 and $1,736 at September 30, 1995 and 1996,
respectively. (see note 8)
(6) INTANGIBLE ASSETS
Intangible assets at September 30, 1995 and 1996 are as follows:
<TABLE>
<CAPTION>
1995 1996
-------- --------
<S> <C> <C>
Excess cost over net asset value acquired (goodwill)........ $383,136 $464,685
Proprietary technology...................................... 37,140 37,140
Trademarks.................................................. 46,611 46,611
Other....................................................... 69,496 71,517
-------- --------
536,383 619,953
Less: Accumulated amortization.............................. 98,518 117,874
-------- --------
$437,865 $502,079
======== ========
</TABLE>
The increases in intangible assets from 1995 to 1996 were primarily due to
acquisitions.
41
<PAGE> 45
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(7) LONG-TERM DEBT
Long-term debt at September 30, 1995 and 1996 consists of the following:
<TABLE>
<CAPTION>
1995 1996
-------- --------
<S> <C> <C>
Term Loan Facility.......................................... $300,000 $265,000
Revolving Credit Facility................................... 119,000 225,100
Sale/Leaseback Obligation................................... 21,863 21,582
Capital leases and other (see note 8)....................... 5,319 9,958
-------- --------
446,182 521,640
Less: Current portion of long-term debt..................... 39,635 40,603
-------- --------
$406,547 $481,037
======== ========
</TABLE>
THE 1995 REFINANCING: On July 31, 1995, the Company and its domestic
subsidiaries entered into a new credit agreement (the "Credit Agreement") with
Chemical Bank (now known as The Chase Manhattan Bank ("Chase")) and certain
other lenders providing for a term loan facility of $300,000 (the "Term Loan
Facility"), and a revolving credit facility of $250,000 (the "Revolving Credit
Facility"; collectively, the "Credit Facilities"). On the same day, the Company
borrowed $300,000 under the Term Loan Facility and approximately $122,500 under
the Revolving Credit Facility. Approximately $158,500 of the borrowed funds were
used to finance the acquisition of Nunc (approximately $9,100 of the acquisition
price for Nunc had been borrowed under the Previous Credit Facilities, as
defined below). The remaining borrowed funds of approximately $264,000 were used
to repay outstanding amounts, including accrued interest, under the Company's
Previous Credit Facilities and to pay certain fees in connection with such
refinancing. On July 9, 1996, under the First Amendment to the Credit Agreement
(the "Amendment"), the Revolving Credit Facility was increased to $300,000 and a
competitive bid process was added as an option to the Company in setting
interest rates. The transaction described above, including the Amendment, is
referred to as the "1995 Refinancing".
In connection with the 1995 Refinancing, the Company wrote off as an
extraordinary item approximately $4,584 ($2,885 after tax) consisting of
unamortized deferred financing fees.
THE 1993 REFINANCING: On July 1, 1993, the Company and its domestic
operating subsidiaries entered into a credit agreement (the "Previous Credit
Agreement") with Chemical Bank and certain other lenders providing for a term
loan facility of $250,000 (the "Previous Term Loan Facility"), and a revolving
credit facility of $75,000 (the "Previous Revolving Credit Facility";
collectively, the "Previous Credit Facilities"). On the same date, the Company's
operating subsidiaries borrowed $85,000 under the Previous Term Loan Facility
and the Company borrowed $2,500 under the Previous Revolving Credit Facility.
These borrowings were used to repay the balance outstanding under a 1988 term
loan agreement and 1988 revolving credit agreements (collectively, the "1988
Credit Agreements") in the amount of $82,800. The borrowings were also used to
pay approximately $4,700 in lenders' fees.
On August 15, 1993, the Company's operating subsidiaries borrowed the
remaining $165,000 available under the Previous Term Loan Facility and, together
with borrowings by the Company under the Previous Revolving Credit Facility,
redeemed the Company's 13 1/4% Senior Subordinated Notes (the "Notes"). The
aggregate redemption price of the Notes, which included $160,000 in principal, a
redemption premium of 4.968%, and accrued interest to the date of redemption,
was approximately $178,500.
The transactions described herein pursuant to which borrowings were made
under the Previous Credit Facilities to pay off amounts outstanding under the
1988 Credit Agreements and the Notes are referred to herein as the "1993
Refinancing."
On June 22, 1994, the Previous Credit Agreement was amended to, among other
things, reduce the interest rate on borrowings thereunder (as described below),
modify the restrictions on the Company's ability
42
<PAGE> 46
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
to pay dividends (also described below), and release all collateral securing the
borrowings thereunder other than the pledge of certain capital stock of the
Company's subsidiaries.
TERM LOAN FACILITY: Borrowings under the Term Loan Facility are required to
be repaid in 28 consecutive quarterly installments of principal. Payments of
$35,000 were made in 1996. Remaining annual payments are due as follows: $35,000
in fiscal 1997, $40,000 in fiscal 1998, $40,000 in fiscal 1999, $50,000 in
fiscal 2000, $50,000 in fiscal 2001, and $50,000 in fiscal 2002.
In addition, the Company is required to further retire the principal amount
of borrowings under the Term Loan Facility (and then the Revolving Credit
Facility) with proceeds from borrowings other than from the Credit Facilities
exceeding certain amounts, and with proceeds from certain asset sales not in the
ordinary course of business. Borrowings under the Term Loan Facility (and the
Revolving Credit Facility) are secured by the capital stock of the Company's
domestic subsidiaries, and by 65% of the stock held by the domestic subsidiaries
in their direct foreign subsidiaries. The Credit Facilities provide for an
annual interest rate, at the option of the Company, equal to (a) the higher of
(i) the rate from time to time publicly announced by Chase in New York City as
its prime rate, (ii) the federal funds rate plus 1/2 of 1%, and (iii) the base
CD rate plus 1%, (b) the London interbank offered rate ("LIBOR") plus 1/2% to 1%
(the "LIBOR Margin") depending upon the level of certain financial ratios, or
(c) with respect to the Revolving Credit Facility, the rate set by a competitive
bid process among the parties to the Revolving Credit Facility established in
the Amendment.
As of September 30, 1996, the Company has five interest rate swap
agreements outstanding aggregating a notional amount of $250,000. The net
interest rate paid by the Company is approximately equal to the sum of the swap
agreement rate plus the applicable LIBOR Margin. During 1996, the LIBOR Margin
was .75% or 1.0% and, as of September 30, 1996, was .75%. The swap agreement
rates and duration are as follows:
<TABLE>
<CAPTION>
EXPIRATION DATE NOTIONAL AMOUNT SWAP AGREEMENT DATE SWAP AGREEMENT RATE
------------------------------ --------------- ------------------- -------------------
<S> <C> <C> <C>
December 9, 1996.............. $50,000 December 8, 1995 5.3475%
July 7, 1998.................. $50,000 July 7, 1993 5.17%
August 13, 1999............... $50,000 August 13, 1993 5.54%
September 8, 2000............. $50,000 December 8, 1995 5.56%
September 10, 2001............ $50,000 December 8, 1995 5.623%
</TABLE>
On November 8, 1996, the Company entered into a forward swap agreement
which will begin on December 16, 1996. The additional swap has a $50,000
notional amount at a swap agreement rate of 5.64%. This agreement expires
December 15, 1997. The Company's risk with regard to the swaps is limited to the
respective counterparty's (Bank of America, Illinois and The Long-Term Credit
Bank of Japan, Ltd.) ability to meet the payment terms of the contract. All
interest expense for all debt is calculated using the interest method.
The Credit Agreement contains numerous financial and operating covenants,
including, among other things: restrictions on investments; requirements that
the Company maintain certain financial ratios; restrictions on the ability of
the Company and its subsidiaries to create or permit liens, or to pay dividends
or make other restricted payments (as defined) in excess of $50,000 plus 50% of
the defined consolidated net income of the Company for each fiscal quarter
ending after June 30, 1995, less any dividends paid or other restricted payments
made after June 22, 1994; restrictions on annual capital expenditures to amounts
ranging from $36,000 to $40,000 during the term of the Credit Agreement; and
limitations on incurrence of additional indebtedness.
REVOLVING CREDIT FACILITY: Prior to June 22, 1994, the Company paid a
commitment fee of 1/2% per year on the average unused portion of the commitments
under the Previous Revolving Credit Facility. After June 22, 1994, the
commitment fee was reduced to 3/8% per year on the average unused portion of the
commitments under the Previous Revolving Credit Facility and the Revolving
Credit Facility, with the ability to reduce the amount to 1/4% when certain
financial criteria are met. The Revolving Credit Facility also
43
<PAGE> 47
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
provides for the issuance of standby letters of credit and commercial letters of
credit on behalf of the Company's subsidiaries as required in the ordinary
course of business as part of the working capital line. Borrowings under the
Revolving Credit Facility bear interest on the same terms as those under the
Term Loan Facility described above. The Revolving Credit Facility term expires
on August 16, 2002.
The Company paid fees on the average unused portion of credit commitments
under the Previous Revolving Credit Facility and the Revolving Credit Facility
of approximately $322, $185 and $234 in 1994, 1995 and 1996, respectively. The
Company paid fees of approximately $52, $46 and $60 for standby letters of
credit under the Previous Revolving Credit Facility, and the Revolving Credit
Facility in 1994, 1995 and 1996, respectively. Standby letters of credit were
approximately $3,527, $4,688 and $4,355 at September 30, 1994, 1995 and 1996,
respectively.
SALE/LEASEBACK: On December 22, 1988, the Company completed the sale and
leaseback (the "Sale/Leaseback") of its principal domestic manufacturing and
office facilities with an unaffiliated third party. The proceeds of $22,500 (net
of approximately $1,100 in fees) were used to retire debt. The transaction has
been accounted for as a financing for financial statement purposes and as a sale
for income tax purposes. The financing obligation is being amortized over the
initial 25-year lease term.
The Company pays all costs of maintenance and repair, insurance, taxes, and
all other expenses associated with the properties. In addition, each of the
leases is unconditionally guaranteed by the Company.
The initial term of each lease is 25 years with five five-year renewal
options. The initial aggregate annual payments under the leases were $2,879
payable monthly in advance. On the fifth anniversary of the leases and every
five years thereafter (including renewal terms), the rent is increased by the
percentage equal to 75% of the percentage increase in the Consumer Price Index
over the preceding five years. The percentage increase to the rent in any
five-year period will be capped at 15%. Beginning January 1, 1994, annual
payments increased to $3,311. The next adjustment will not occur until January
1, 1999.
Under the terms of the Sale/Leaseback, the Company is not permitted to pay
dividends with respect to its Common Stock in excess of 50% of: (a) its total
consolidated net income (as defined) earned since September 1, 1988 through the
fiscal quarter ended prior to the payment of the dividend, plus (b) the
aggregate net proceeds of the sale of the Company's capital stock after December
1988.
The Company has the option to purchase the facilities according to the
terms of any bona fide offer received by the lessor from a third party (the
"Third Party Offer") at any time during the term of the leases. The purchase
price upon exercise of the option will be an amount equal to the purchase price
contained in the Third Party Offer.
In the event of a breach of certain covenants which include, subject to
certain exceptions, restrictions on the Company's and its subsidiaries'
incurrence of certain additional indebtedness, payment of dividends or the
making of other distributions or the repurchase of the Company's capital stock,
or the creation of liens on their respective properties, the Company must cause
each subsidiary to make a rejectable offer to the lessor to purchase its
facility. If the lessor accepts the rejectable offer, each subsidiary will pay
to the lessor a formula price based upon the lessor's equity in the property and
the lessor's pre-payment premium to its lender. The Company may also be
obligated to repurchase the property upon the occurrence of certain other
events.
44
<PAGE> 48
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
As of September 30, 1996, maturities of long-term debt, including capital
leases, are as follows:
<TABLE>
<CAPTION>
FISCAL
------
<S> <C>
1997.................................................................. $ 40,603
1998.................................................................. 41,297
1999.................................................................. 40,971
2000.................................................................. 51,555
2001.................................................................. 50,641
Thereafter............................................................ 296,573
--------
$521,640
========
</TABLE>
(8) LEASE COMMITMENTS
As of September 30, 1996, minimum rentals, excluding rent payments under
the Sale/Leaseback described in note 7, under capital and noncancellable
operating leases consisting primarily of machinery and equipment, and building
leases are:
<TABLE>
<CAPTION>
FISCAL CAPITAL OPERATING
------ ------- ---------
<S> <C> <C>
1997........................................................... $ 1,050 $ 5,920
1998........................................................... 701 4,909
1999........................................................... 306 3,356
2000........................................................... 71 2,740
2001........................................................... -- 2,308
Thereafter..................................................... -- 10,967
------ -------
2,128 $30,200
=======
Less amounts representing interest............................. 322
------
Present value of net minimum lease payments.................... 1,806
Less current portion........................................... 868
------
Long-term obligations under capital leases..................... $ 938
======
</TABLE>
Amortization of assets held under capital leases is included with
depreciation expense.
Rental expense under operating leases (net of sublease rental income of
$120, $18 and $107 in 1994, 1995 and 1996, respectively) was $3,032, $4,411 and
$6,918 in 1994, 1995 and 1996, respectively.
(9) DISCLOSURES ABOUT FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amounts of financial instruments approximate fair value due to
the short maturity of those instruments except as follows:
Long-Term Debt
TERM LOAN FACILITY AND REVOLVING CREDIT FACILITY. Because interest rates on
both the Term Loan Facility and the Revolving Credit Facility float at market
interest rates, their carrying value approximates their fair value.
SALE/LEASEBACK. The fair value was determined by estimating the interest
rate at which the Company could refinance the Sale/Leaseback given the same
maturity period.
45
<PAGE> 49
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Interest Rate Swap Agreements
The fair values of interest rate swap agreements are obtained from dealer
quotes. These values represent the estimated amount the Company would collect if
the agreements were terminated as quoted by the bank with which the Company
executed the swap agreements.
<TABLE>
<CAPTION>
SEPTEMBER 30, 1995 SEPTEMBER 30, 1996
---------------------- ----------------------
REPORTED ESTIMATED REPORTED ESTIMATED
AMOUNT FAIR VALUE AMOUNT FAIR VALUE
-------- ---------- -------- ----------
<S> <C> <C> <C> <C>
Long-term debt.......................... $446,182 $ 456,338 $521,640 $ 531,176
Interest rate swap agreements........... -- 2,228 -- 5,593
</TABLE>
(10) EMPLOYEE BENEFIT PLANS
PENSION PLANS: The Company has defined benefit pension plans covering
approximately 90 percent of United States employees. The benefits are generally
based on various formulas, the principal factors of which are years of service
and compensation. The Company's funding policy is to generally make the minimum
annual contributions required by applicable regulations. However, in 1994, 1995
and 1996, the Company funded additional special cash contributions of $1,439,
$98 and $962, respectively. Such contributions were made to increase the funding
level for a pension plan with accumulated benefits in excess of plan assets. The
1995 adjustment to recognize minimum pension liability reflects the excess of
the unfunded accumulated benefit obligations over accrued pension costs. This
excess was partially offset by an intangible asset with the remainder reflected
as an adjustment to shareholders' equity.
The following table sets forth the plans' funded status and amounts
recognized in the Company's consolidated balance sheets for 1995 and 1996 for
its United States and Canadian pension plans:
<TABLE>
<CAPTION>
1995 1996
-------------------------- --------------------------
PLANS PLANS PLANS PLANS
WHOSE WHOSE WHOSE WHOSE
ASSETS ACCUMULATED ASSETS ACCUMULATED
EXCEED BENEFITS EXCEED BENEFITS
ACCUMULATED EXCEED ACCUMULATED EXCEED
BENEFITS ASSETS BENEFITS ASSETS
----------- ----------- ----------- -----------
<S> <C> <C> <C> <C>
Actuarial present value of benefit
obligations:
Vested benefit obligation........ $ 2,883 $35,519 $37,505 $ 516
======= ======= ======= =======
Accumulated benefit obligation... $ 3,381 $40,817 $46,380 $ 628
======= ======= ======= =======
Projected benefit obligation..... $ 4,432 $47,221 $52,942 $ 1,692
Plan assets at fair value.......... 5,316 38,374 51,089 --
------- ------- ------- -------
Plan assets in excess of (less
than) projected benefit
obligation....................... 884 (8,847) (1,853) (1,692)
Unrecognized net loss.............. 707 3,376 462 762
Unrecognized prior service cost.... 266 (147) (104) 300
Unrecognized transition obligation
(asset).......................... (544) 937 293 --
Adjustment required to recognize
minimum pension liability........ -- (1,577) -- --
Remaining excess of fair value of
plan assets over projected
benefit obligation recognized as
a result of the 1987 acquisition
of Sybron Corporation............ 710 3,358 3,901 --
------- ------- ------- -------
Pension asset (liability)
recognized in the consolidated
balance sheets................... $ 2,023 $(2,900) $ 2,699 $ (630)
======= ======= ======= =======
</TABLE>
46
<PAGE> 50
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Net periodic pension cost for 1994, 1995 and 1996 includes the following
components:
<TABLE>
<CAPTION>
1994 1995 1996
------- ------- -------
<S> <C> <C> <C>
Service cost -- benefits earned during the year...... $ 2,571 $ 2,268 $ 2,885
Interest cost on projected benefit obligation........ 3,228 3,425 3,800
Actual return on assets.............................. (586) (6,876) (5,823)
Net amortization and deferral........................ (2,613) 3,508 1,427
------- ------- -------
Net periodic pension cost............................ $ 2,600 $ 2,325 $ 2,289
======= ======= =======
Assumptions used are:
Discount rate...................................... 8.5% 7.5% 7.75%
Rate of increase in compensation levels............ 5% 4% 4%
Expected long-term rate of return on assets........ 10% 10% 10%
</TABLE>
SAVINGS PLANS: Substantially all employees in the United States are
eligible to participate in contributory savings plans maintained by the Company
under Section 401(k) of the Internal Revenue Code of 1986, as amended (the
"Code"). Company matching contributions under the plan, net of forfeitures, were
approximately $1,021, $1,204 and $2,016 for 1994, 1995 and 1996, respectively.
POSTRETIREMENT HEALTH CARE PLANS: In addition to providing pension
benefits, the Company provides certain health care benefits for eligible retired
employees which are funded as costs are incurred. Certain employees who reached
the age of 55 prior to January 1, 1996, will become eligible for these benefits
if they reach retirement age while working for the Company. The Company accrues,
as current costs, the future lifetime retirement benefits for both qualifying
active and retired employees and their dependents. The postretirement health
care plans for subsidiaries of the Company and certain divested operations are
generally contributory, with retiree contributions adjusted annually. In 1986,
the Company instituted a policy with respect to postretirement medical premiums
where the Company's contributions were frozen at the levels equal to the
Company's contribution on December 31, 1988. This policy applies to
postretirement health care plans for all subsidiaries of the Company and certain
divested operations except where collective bargaining agreements prohibited
such changes in policy.
The following table sets forth the postretirement plans' status as shown in
the Company's consolidated balance sheets at September 30, 1995 and 1996.
<TABLE>
<CAPTION>
1995 1996
------- -------
<S> <C> <C>
Accumulated postretirement benefit obligation:
Retirees........................................................ $11,341 $10,930
Fully eligible plan participants................................ 2,484 3,906
------- -------
Accumulated postretirement benefit obligation................... 13,825 14,836
Estimated loss not yet recognized............................... (1,487) (3,233)
------- -------
Accumulated postretirement benefit obligation recognized in the
consolidated balance sheets................................... $12,338 $11,603
======= =======
</TABLE>
Net periodic postretirement benefit cost recognized in the consolidated
statements of income include the following components:
<TABLE>
<CAPTION>
1994 1995 1996
------ ------ ------
<S> <C> <C> <C>
Service cost -- benefits attributed to service during the year.... $ 161 $ 139 $ 145
Interest cost on accumulated postretirement benefit obligation.... 1,098 1,136 985
Net amortization and deferral..................................... 87 6 7
------ ------ ------
Net periodic postretirement benefit cost.......................... $1,346 $1,281 $1,137
====== ====== ======
</TABLE>
47
<PAGE> 51
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The weighted-average discount rate used in determining the net periodic
benefit cost was 7.5%, 8.5% and 7.5% in 1994, 1995 and 1996, respectively. The
weighted-average discount rate used in determining the accumulated
postretirement benefit obligation was 8.5%, 7.5% and 7.75% in 1994, 1995 and
1996, respectively. The assumed average inflation rate of medical costs over the
life of the benefits was 7%, 6.5% and 5.5% in 1994, 1995 and 1996, respectively.
An increase of one percentage point in the per capita cost of health care
costs associated with the plans for which the Company contributions are not
frozen would increase the accumulated postretirement benefit obligation as of
September 30, 1996 by approximately $950 and the aggregate of the service,
interest and net amortization and deferral cost components of net periodic
postretirement benefit cost by approximately $23, $54 and $46, respectively.
Because the majority of the postretirement plans are remaining liabilities
from certain divested operations and more than 80% of the 1994, 1995 and 1996
net periodic postretirement benefit costs relate to interest costs, the Company
has classified such interest costs as interest expense. This results in a
non-cash increase in interest expense of approximately $1,098, $1,136 and $985
in 1994, 1995 and 1996, respectively.
(11) RESTRUCTURING CHARGE
In March 1996, the Company recorded a restructuring charge of $8,277
($6,087 after tax or $.13 per share) for the rationalization of certain acquired
companies, combination of certain production facilities, movement of certain
customer service and marketing functions, and the exiting of several product
lines. The restructuring charge has been classified as a component of cost of
sales ($2,223), selling, general and administrative expenses ($5,307) and income
tax expense ($747). Principal items included in the reserve are severance and
termination costs for approximately 130 notified employees (primarily
production, sales and marketing personnel) (approximately $2,300), remaining
lease payments and shut down costs on exited facilities (approximately $2,100),
the non-cash write-off of certain fixed assets and inventory associated with
exited product lines, primarily at Sybron Dental Specialties (approximately
$2,500), a statutory tax penalty (approximately $750) and other related
restructuring costs (approximately $650). As of September 30, 1996, the Company
has made cash payments of approximately $2,400 and has written-off approximately
$2,600 of fixed assets and inventory relating to the restructuring reserve. As
of September 30, 1996, this reserve totaled approximately $3,300 and is recorded
in other current liabilities. The Company expects to incur cash payments of
approximately $3,000 in fiscal 1997. The remaining amount of $300 relates to
long-term leases and severance arrangements which will be paid some time
thereafter.
(12) CAPITAL STOCK
In 1992, the Company entered into a shareholders agreement with H&H/Sybron
Partners, L.P., Hicks & Haas Incorporated, DLJ Capital Corporation, Thomas O.
Hicks and Robert B. Haas, and certain of the executive officers of the Company
that became effective on May 14, 1992. The shareholders agreement grants to the
parties thereto (other than the Company) certain rights to sell a portion of the
shares of Common Stock owned by the parties as part of certain transfers by any
other party thereto and grants certain rights of first refusal (including to the
Company) with respect to certain transfers by the parties thereto. Such
agreement also grants certain demand and piggy-back registration rights to the
parties thereto. DLJ Capital Corporation effectively is no longer a party to
this agreement because it has sold all of the Common Stock of the Company held
by it which was subject to the agreement.
STOCK OPTION PLANS: The Company has five stock option plans, four of which
are active. As of September 30, 1996, there were options with respect to 6,892
shares of Common Stock outstanding under the 1988 Stock Option Plan (the "1988
Plan"), and there were options with respect to 3,998 shares available for grant
under such plan; there were no options outstanding with respect to the 1989
Stock Option Plan (the "1989 Plan"), and there were no options remaining
available for grant under such plan; there were options with respect to 80,000
shares of Common Stock outstanding under the 1990 Stock Option Plan (the "1990
48
<PAGE> 52
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Plan") and there were 20,000 shares remaining available for grant under such
plan; there were options with respect to 3,814,654 shares of Common Stock
outstanding under the Amended and Restated 1993 Long-Term Incentive Plan (the
"1993 Plan") and there were 702,644 shares remaining available for grant under
such plan; and there were options with respect to 90,000 shares of Common Stock
outstanding under the Amended and Restated 1994 Outside Directors' Stock Option
Plan (the "Outside Directors' Plan") and there were 110,000 shares remaining
available for grant under such plan. Changes in stock options outstanding are as
follows:
<TABLE>
<CAPTION>
NUMBER PRICE
OF SHARES PER SHARE
--------- ---------------
<S> <C> <C>
Options outstanding at September 30, 1993............. 1,116,240 $.50-$12.72
Granted............................................. 1,187,742 $15.00-$16.69
Exercised........................................... (269,304) $.50-$12.72
Cancelled and available for reissue................. (64,250) $12.72-$16.69
---------
Options outstanding at September 30, 1994............. 1,970,428 $1.14-$16.69
Granted............................................. 1,895,730 $16.69-$20.03
Exercised........................................... (135,268) $4.30-$16.69
Cancelled and available for reissue................. (48,722) $12.00-16.69
---------
Options outstanding at September 30, 1995............. 3,682,168 $4.30-$20.03
Granted............................................. 759,988 $12.72-$28.875
Exercised........................................... (393,722) $4.30-$19.0625
Cancelled and available for reissue................. (56,888) $12.72-$23.09
---------
Options outstanding at September 30, 1996............. 3,991,546 $11.97-$28.875
Options exercisable at September 30, 1996............. 1,221,442 $11.97-$23.09
Options available for grant at September 30, 1996..... 836,642
=========
</TABLE>
1988, 1989, 1990 and 1993 Plans
No options may be granted under the plans after ten years from the date the
plans are approved by the shareholders of the Company. Options granted pursuant
to the plans shall be either incentive options which are intended to meet the
requirements of section 422 of the Code or nonstatutory options. The exercise
price of the options will be determined by the Compensation/Stock Option
Committee. The exercise price of any incentive option shall not be less than the
fair market value per share of the Common Stock on the date of the grant of such
option. An optionee under the plans must pay the full option price of an option
either (i) in cash, (ii) with the Compensation/Stock Option Committee's consent,
by delivering shares of Common Stock already owned by an optionee, (iii) except
under the 1993 Plan, with the Compensation/Stock Option Committee's consent, by
withholding from the shares of Common Stock otherwise to be issued that number
of shares having a fair market value equal to the exercise price, or (iv) in any
combination of the foregoing.
With respect to the options granted prior to May 14, 1992 under the 1990
Plan, all of the shares purchased under such nonstatutory options were deemed to
have been vested no later than May 14, 1993, the first anniversary of the
Company's public offering of shares of common stock on May 14, 1992. With
respect to options granted under the 1990 Plan after May 14, 1992, and with
respect to options granted under the 1993 Plan, the options vest in equal annual
installments on each of the first four anniversaries following the date of
grant, except with respect to one grant under the 1993 Plan for which the
options vested in equal annual installments on each of the first two
anniversaries following the date of grant.
49
<PAGE> 53
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
Outside Directors' Plan
The Outside Directors' Plan, which became effective on January 19, 1994,
provides for the automatic granting of nonstatutory stock options to those of
the Company's directors who qualify as "outside directors" at the time of grant.
Following each annual meeting of shareholders prior to September 30, 1998, the
plan's expiration date (unless earlier terminated), each outside director is
automatically granted an option to purchase 6,000 shares of Common Stock at an
exercise price equal to the fair market value of the Common Stock on the date of
grant. Each option granted under the Outside Directors' Plan becomes exercisable
six months after the date of grant, regardless of whether the grantee is still a
director of the Company on such date. All rights to exercise an option granted
under the Outside Directors' Plan terminate upon the earlier of ten years from
the date of grant or two years from the date the grantee ceases to be a director
of the Company. The exercise price must be paid in full at the time of exercise,
and such payment may be made in cash, by delivering shares of Common Stock which
the optionee or the optionee's spouse or both have beneficially owned for at
least six months prior to the time of exercise, or through a combination of cash
and such delivered Common Stock.
EQUITY RIGHTS: As of September 30, 1996, the Company holds 1,528 shares of
treasury stock for delivery to equity right holders who have not yet surrendered
their certificates. Equity right holders are entitled to receive 2.1875 shares
of common stock upon surrender of such certificates.
(13) COMMITMENTS AND CONTINGENT LIABILITIES
The Company or its subsidiaries are at any one time parties to a number of
lawsuits or subject to claims arising out of their respective operations, or
their operation of businesses divested in the 1980's for which certain
subsidiaries may continue to have legal or contractual liability, including
products liability, workplace safety and environmental claims and cases, some of
which involve claims for substantial damages. The Company or its subsidiaries
are vigorously defending lawsuits or claims against them. The Company has
provided reserves for the estimated liability and legal expenses at September
30, 1995 and 1996, respectively, that may result from certain of these claims.
Subject to the qualifications stated below relating to the Aqua-Tech Site (as
defined below) and the Rochester Site (as defined below), based upon the
insurance available under the Company's insurance program and the potential for
liability with respect to claims which are uninsured, the Company believes that
any liabilities which might foreseeably result from any of its pending cases and
claims would not have a material adverse effect on the results of operations or
financial condition of the Company and its subsidiaries taken as a whole. There
can be no assurance as to this, however, or that litigation having such a
material adverse effect will not arise in the future.
One of the Company's subsidiaries has been identified as a potentially
responsible party at the Aqua-Tech Site in South Carolina (the "Aqua-Tech
Site"), which has been placed on the federal National Priority List under the
Comprehensive Environmental Response, Compensation and Liability Act of 1980, as
amended ("CERCLA"). The Company has also been informed by Asea Brown Boveri
("ABB") of environmental claims against it with respect to a site in Rochester,
New York (the "Rochester Site") which was previously operated as the Taylor
Instrument Division by a predecessor of a subsidiary of the Company. Because the
testing has not been done to determine what remedy, if any, should be required
at the Aqua-Tech Site, an estimate of the Company's potential liability with
respect to this site cannot be made at this time. However, and although CERCLA
does provide for joint and several liability, because the Company's share of
waste allegedly sent to the site is reportedly not more than 1% of the total
waste sent, the Company believes that any ultimate liability with respect to the
Aqua-Tech Site will not have a material adverse effect on the results of
operations or financial condition of the Company and its subsidiaries as a
whole.
On May 2, 1996, Combustion Engineering, Inc. ("CE") commenced legal
proceedings in the New York Supreme Court, County of Monroe (the "CE
Litigation"), against the Company with respect to the former Taylor Instruments
("Taylor") facility at the Rochester Site, a discontinued operation. According
to CE's complaint, its claims are based on an asset purchase and sale agreement
dated as of September 30, 1983,
50
<PAGE> 54
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
pursuant to which Taylor was sold to CE (the "1983 Agreement"), and an agreement
between a subsidiary of the Company and CE dated August 14, 1987 (the "1987
Agreement"). The complaint alleges that under the 1983 Agreement the Company
retained certain liabilities for, and indemnified CE with respect to,
environmental contamination, hazards and other conditions that existed at the
time of the sale of Taylor to CE, and that under the 1987 Agreement, the Company
agreed to bear 70 percent of the costs thereafter incurred to clean up,
remediate and remove mercury from the land and buildings at the Rochester Site.
CE's complaint seeks declaratory relief and claims damages of at least $10,000
with respect to expenses CE has incurred and expects to incur to remediate and
remove mercury contamination from the land and buildings sold to CE at the
Rochester Site. The complaint also seeks declaratory relief and claims damages
in excess of $1,000 with respect to expenses incurred and expected to be
incurred for remediating other alleged environmental hazards associated with the
Rochester Site. Some of CE's claims relate to the cost to demolish and dispose
of the buildings at the Rochester Site, which CE maintains it had to do because
the buildings were contaminated with mercury. CE previously informed the Company
that CE claims that the Company's share of such demolition and disposal costs is
approximately $4,200. The Company denies it has any liability for such costs.
CE's remaining claims relate to alleged soil and groundwater contamination,
including mercury contamination, for which the Company also denies liability. CE
implemented a plan in early 1996 to assess the extent of potential soil and
groundwater contamination at the Rochester Site, the preliminary results of
which have been provided by CE to the Company. The preliminary results indicate
there is mercury and inorganic and volatile organic compound contamination in
the soil and groundwater at certain Rochester Site locations. CE is preparing a
voluntary clean-up proposal based on these results which it plans to present to
the New York Department of Environmental Conservation (the "NYDEC") for
consideration. The cost to remediate the Rochester Site will depend upon the
remediation standards incorporated into any voluntary agreement between CE and
the NYDEC. Because the clean-up standards which may be applied have not been
determined, the extent of remediation to be undertaken, and its cost, is
unknown. As a result, the Company cannot, at this time, estimate the cost of the
soil and groundwater remediation claims. The Company previously reported that
prior to beginning the Rochester Site assessment which generated the current
test results, CE had indicated to the Company that, based upon information
available to it and subject to a number of caveats, including the lack of
assessment information and the fact that clean-up standards which may be applied
to the Rochester Site have not been determined, the cost to remediate the soil
and groundwater would range from $3,000 to $5,000. Because the bases for this
estimate were not disclosed by CE to the Company, the Company cannot make a
judgment about how the preliminary test results it has been provided would
affect this estimate. The Company intends to pursue insurance coverage for CE's
claims and has therefore provided notice of CE's claims to its third party
liability insurance carriers. To date the carriers have denied coverage.
(14) ACQUISITIONS
The Company has completed 28 acquisitions since the beginning of 1994. The
acquired companies are all engaged in businesses related to the laboratory or
dental segments of the Company or use a process in manufacturing which is
similar to the Company's existing businesses.
1994
During 1994, the Company completed four acquisitions, Demetron Research
Corp. ("Demetron"), Labindustries, E.T.M. Corporation ("ETM") and Allesee
Orthodontic Appliances, Inc. ("AOA"), none of which individually or combined
were considered material for disclosure of pro forma effects. All acquisitions
were accounted for as purchases. The results of the acquisitions were included
as of the date they were acquired. The following unaudited table outlines sales
and operating income for the most recent available twelve-month period prior to
acquisition, and total assets at the most recent available date prior to
acquisition, for each of the acquired companies.
51
<PAGE> 55
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
UNAUDITED
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
COMPANY ACQUIRED DATE SALES INCOME (LOSS) ASSETS ACQUISITION
- ---------------------------------------- ------------ ------ ------------- ------ -----------
<S> <C> <C> <C> <C> <C>
January
Demetron................................ 1994........ $9,934 $ 1,387 $4,214 Stock
Labindustries........................... April 1994.. 3,055 (57) 1,557 Asset
ETM..................................... June 1994... 5,523 3 2,397 Stock
AOA..................................... June 1994... 3,351 247 838 Stock
</TABLE>
The aggregate purchase price of these acquisitions, including earnouts paid
subsequent to September 30, 1994, was approximately $18,575 including fees and
expenses. The Company may be subject to a future purchase price adjustment of up
to $150 based upon an earnout provision under one of the purchase and sale
agreements, which, if achieved, is payable in 1997.
1995
During 1995, the Company completed twelve acquisitions at an aggregate
purchase price, including earnout provisions paid subsequent to September 30,
1995, of approximately $242,872, including fees and expenses. The Company may be
subject to future purchase price adjustments based upon earnout provisions under
certain of the purchase and sale agreements. Such earnout provisions applying to
the 1995 acquisitions aggregate a maximum remaining potential payout of
approximately $19,523. Earnout provisions are subject to the achievement of
certain financial goals. Remaining earnouts, if achieved, are payable in the
years 1997 through 2000. Other than the acquisition of Nunc (as defined below),
none of the acquisitions individually or combined were considered material for
disclosure of pro forma effects. All acquisitions were accounted for as
purchases. The results of the acquisitions were included as of the date they
were acquired. The following unaudited table outlines sales and operating income
for the most recent available twelve-month period prior to acquisition, and
total assets at the most recent available date prior to acquisition, for each of
the acquired companies, except Nunc.
UNAUDITED
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
COMPANY ACQUIRED DATE SALES INCOME (LOSS) ASSETS ACQUISITION
- ------------------------------------ -------------- ------- ------------- ------ -----------
<S> <C> <C> <C> <C> <C>
Gold Seal........................... October 1994 * * * Asset
Ever Ready Thermometer Co., Inc. ... November 1994 $ 4,081 $ 314 $1,872 Asset
Owl Scientific, Inc. ............... January 1995 4,221 243 1,341 Asset
Sani-Tech, Inc. .................... February 1995 11,349 1,453 4,739 Asset
Metrex Research Corporation......... March 1995 7,651 (41) 5,386 Asset
Ormco GmbH.......................... April 1995 7,436 1,169 4,137 Stock
Excellence in Endodontics, Inc. .... April 1995 1,991 711 693 Stock
Richard-Allan Scientific Company.... May 1995 9,014 2,161 1,648 Asset
Biomolecular, Inc. ................. August 1995 5,287 (415) 4,777 Stock
New England Reagent Laboratory,
Inc. ............................. September 1995 2,983 4 1,139 Asset
Secure Medical Products............. September 1995 3,308 1,032 646 Asset
</TABLE>
- ---------------
* The Company acquired the Gold Seal(R) product line of microscope slides.
Because the Company provided the microscope slides to the seller prior to the
acquisition, this information is not applicable.
On July 31, 1995, the Company acquired the stock of Nunc A/S, Nunc Inc. and
Nunc GmbH (collectively referred to as "Nunc") from BTR plc for a purchase price
(including estimated fees and expenses) of approximately $171,000. The following
unaudited pro forma financial information reflects the
52
<PAGE> 56
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
combined results of operations of the Company and Nunc for the years ended
September 30, 1994 and September 30, 1995 as if the transaction had been
consummated on October 1, 1993.
<TABLE>
<CAPTION>
(UNAUDITED)
1994 1995
-------- --------
<S> <C> <C>
Net sales....................................................... $497,484 $571,598
======== ========
Gross profit.................................................... 250,674 284,504
Selling, general and administrative expenses.................... 146,769 164,851
-------- --------
Operating income................................................ $103,905 $119,653
======== ========
Income before income taxes, extraordinary item and cumulative
effect of accounting change................................... $ 73,994 $ 86,971
Income taxes.................................................... 29,269 33,953
-------- --------
Income before extraordinary item and cumulative effect of
accounting change............................................. $ 44,725 $ 53,018
======== ========
Earnings per share before extraordinary item and cumulative
effect of accounting change................................... $ .96 $ 1.13
======== ========
</TABLE>
The above unaudited pro forma financial information is not necessarily
indicative either of the results of operations that would have occurred had the
acquisition taken place at the beginning of 1994 or of future results of
operations of the combined companies.
1996
During 1996, the Company completed ten acquisitions at an aggregate
purchase price of approximately $99,965, including fees and expenses. The
Company may be subject to future purchase price adjustments based upon earnout
provisions under certain of the purchase and sale agreements. Such earnout
provisions applying to the 1996 acquisitions aggregate a maximum total potential
payout of approximately $10,500. Earnout provisions are subject to the
achievement of certain financial goals. Earnouts, if achieved, are payable in
the years 1997 through 2001. All acquisitions were accounted for as purchases.
The results of the acquisitions were included as of the date they were acquired.
The following unaudited table outlines sales and operating income for the most
recent available twelve-month period prior to acquisition, and total assets at
the most recent available date prior to acquisition, for each of the acquired
companies.
UNAUDITED
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
COMPANY ACQUIRED DATE SALES INCOME ASSETS ACQUISITION
- --------------------------------------- ------------- ------- --------- ------- -----------
<S> <C> <C> <C> <C> <C>
Analytic Technology Corporation........ October 1995 $ 2,086 $ 470 $ 811 Asset
CASCO Standards, Inc................... November 1995 3,202 340 1,100 Asset
belle de st. claire, inc............... November 1995 2,858 210 1,529 Asset
Acutech Plastics, Inc.................. January 1996 9,888 1,912 5,894 Stock
Naugatuck Glass Company................ February 1996 17,553 2,070 14,503 Stock
Precision Glassworks, L.L.C............ May 1996 524 29 34 Asset
Stephens Scientific.................... July 1996 11,370 5,389 732 Asset
Flexible Components, Inc............... July 1996 11,426 1,839 4,401 Asset
Micro-Aseptic Products, Inc............ July 1996 4,546 478 837 Asset
E&D Dental Products, Inc............... August 1996 5,438 281 1,518 Stock
</TABLE>
Subsequent to September 30, 1996, the Company completed two acquisitions.
The following unaudited table outlines the sales and operating income for the
most recent available twelve-month period prior to each
53
<PAGE> 57
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
acquisition, and total assets at the most recent available date prior to
acquisition, for each of the acquired businesses.
UNAUDITED
<TABLE>
<CAPTION>
OPERATING TOTAL TYPE OF
COMPANY ACQUIRED DATE SALES INCOME ASSETS ACQUISITION
- ----------------------------------------- ------------ ------- --------- ------- -----------
<S> <C> <C> <C> <C> <C>
Pure Fit, Inc. .......................... October 1996 $ 2,705 $ 931 $ 1,041 Stock
D&W, Inc. ............................... October 1996 289 * * Asset
</TABLE>
- ---------------
* The Company acquired the customer list and certain cutting machines of D&W,
Inc. Operating income and total assets are not applicable.
(15) SEGMENT INFORMATION
The Company's operating subsidiaries are engaged in the manufacture and
sale of dental and laboratory products in the United States and other countries.
Dental products include orthodontic appliances, dental supplies and intra-oral
instrumentation. Laboratory products include labware, general laboratory
equipment, water treatment equipment, heating and stirring apparatus and glass
specialty items. Inter-business segment sales are not material. Information on
these business segments is summarized as follows:
<TABLE>
<CAPTION>
1994 1995 1996
-------- -------- --------
<S> <C> <C> <C>
Net sales:
Dental...................................................... $215,953 $250,803 $280,133
Laboratory.................................................. 223,751 268,397 394,324
-------- -------- --------
Total net sales............................................. $439,704 $519,200 $674,457
======== ======== ========
Operating income:
Dental...................................................... $ 43,713 $ 53,945 $ 54,139
Laboratory.................................................. 47,775 55,179 82,594
-------- -------- --------
Total operating income...................................... $ 91,488 $109,124 $136,733
======== ======== ========
Depreciation and amortization expense:
Dental...................................................... $ 11,432 $ 12,233 $ 13,951
Laboratory.................................................. 17,639 20,093 29,226
Corporate................................................... 1,330 1,401 936
-------- -------- --------
Total depreciation and amortization expense................. $ 30,401 $ 33,727 $ 44,113
======== ======== ========
Capital expenditures:
Dental...................................................... $ 8,270 $ 11,801 $ 11,640
Laboratory.................................................. 9,484 10,917 18,426
Corporate................................................... 3,904 760 8,699
-------- -------- --------
Total capital expenditures.................................. $ 21,658 $ 23,478 $ 38,765
======== ======== ========
Identifiable assets:
Dental...................................................... $256,669 $290,571
Laboratory.................................................. 532,732 620,746
-------- --------
Total identifiable assets................................... 789,401 911,317
Corporate................................................... 62,682 63,296
-------- --------
Total assets................................................ $852,083 $974,613
======== ========
</TABLE>
Corporate assets include cash, miscellaneous receivables, and other
non-current assets.
54
<PAGE> 58
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
The Company's international operations are conducted principally in Europe.
Inter-geographic sales are made at prices approximating market.
<TABLE>
<CAPTION>
1994 1995 1996
-------- -------- --------
<S> <C> <C> <C>
Net Sales:
United States:
Customers............................................... $287,674 $332,646 $429,988
Inter-geographic........................................ 9,211 17,541 33,506
-------- -------- --------
296,885 350,187 463,494
-------- -------- --------
Europe:
Customers............................................... 84,190 105,545 143,895
Inter-geographic........................................ 37,062 46,860 61,579
-------- -------- --------
121,252 152,405 205,474
-------- -------- --------
All other areas:
Customers............................................... 67,840 81,009 100,574
Inter-geographic........................................ 11,915 9,781 11,988
-------- -------- --------
79,755 90,790 112,562
Inter-geographic sales.................................... (58,188) (74,182) (107,073)
-------- -------- --------
Total net sales......................................... $439,704 $519,200 $674,457
======== ======== ========
Operating income:
United States........................................... $ 76,047 $ 85,073 $115,537
Europe.................................................. 8,732 15,212 11,776
All other areas......................................... 6,709 8,839 9,420
-------- -------- --------
Total operating income.................................... $ 91,488 $109,124 $136,733
======== ======== ========
Accounts receivable:
United States........................................... $ 73,179 $ 90,408
Europe.................................................. 25,949 28,323
All other areas......................................... 10,444 9,118
-------- --------
Total accounts receivable............................... $109,572 $127,849
======== ========
Identifiable assets:
United States........................................... $536,715 $666,311
Europe.................................................. 234,153 223,249
All other areas......................................... 18,533 21,757
-------- --------
Total identifiable assets............................... 789,401 911,317
Other corporate assets.................................. 62,682 63,296
-------- --------
Total assets............................................ $852,083 $974,613
======== ========
</TABLE>
55
<PAGE> 59
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS -- (CONTINUED)
(16) QUARTERLY FINANCIAL INFORMATION (UNAUDITED)
<TABLE>
<CAPTION>
FIRST SECOND THIRD FOURTH TOTAL
QUARTER QUARTER QUARTER QUARTER YEAR
-------- -------- -------- -------- --------
<S> <C> <C> <C> <C> <C>
1995
Net sales................................. $111,728 $127,936 $129,763 $149,773 $519,200
======== ======== ======== ======== ========
Gross profit.............................. $ 55,583 $ 64,610 $ 65,222 $ 74,375 $259,790
======== ======== ======== ======== ========
Income before extraordinary item.......... $ 9,947 $ 13,505 $ 13,799 $ 14,549 $ 51,800
Extraordinary item........................ -- -- -- (2,885) (2,885)
-------- -------- -------- -------- --------
Net income................................ $ 9,947 $ 13,505 $ 13,799 $ 11,664 $ 48,915
======== ======== ======== ======== ========
Per Share:
Income before extraordinary item.......... $ .21 $ .29 $ .29 $ .31 $ 1.10
Extraordinary item........................ -- -- -- (.06) (.06)
-------- -------- -------- -------- --------
Net income................................ $ .21 $ .29 $ .29 $ .25 $ 1.04
======== ======== ======== ======== ========
1996
Net sales................................. $146,862 $170,851 $171,096 $185,648 $674,457
======== ======== ======== ======== ========
Gross profit.............................. $ 72,850 $ 82,157 $ 85,478 $ 96,142 $336,627
======== ======== ======== ======== ========
Net income................................ $ 11,722 $ 10,540 $ 17,105 $ 18,217 $ 57,584
======== ======== ======== ======== ========
Earnings per share:....................... $ .25 $ .22 $ .36 $ .38 $ 1.20
======== ======== ======== ======== ========
</TABLE>
Gross profit for the second quarter of 1996 was adjusted to reflect a
reclassification of approximately $2,223 of the restructuring charge to cost of
sales. The effect was to reduce gross profit by $2,223. Net income remains
unchanged from the amount previously reported in the March 31, 1996 quarterly
report on Form 10-Q.
56
<PAGE> 60
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
FINANCIAL DISCLOSURE
None
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
The information called for by Item 10 of Form 10-K with respect to
directors and executive officers is incorporated herein by reference to such
information included in the Company's Proxy Statement for the Annual Meeting of
Shareholders to be held January 22, 1997, under the caption "Election of
Directors" and "Section 16(a) Beneficial Ownership Reporting Compliance", and to
the information under the caption "Executive Officers of the Registrant" in Part
I hereof.
ITEM 11. EXECUTIVE COMPENSATION
The information called for by Item 11 of Form 10-K is incorporated herein
by reference to such information included in the Company's Proxy Statement for
the Annual Meeting of Shareholders to be held January 22, 1997, under the
captions "Executive Compensation" and "Election of Directors -- Directors'
Compensation".
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
The information called for by Item 12 of Form 10-K is incorporated herein
by reference to such information included in the Company's Proxy Statement for
the Annual Meeting of Shareholders to be held January 22, 1997, under the
caption "Security Ownership of Certain Beneficial Owners and Management".
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
Not applicable.
57
<PAGE> 61
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES AND REPORTS ON FORM 8-K
(a) Documents Filed. The following documents are filed as part of this
Annual Report or incorporated by reference as indicated:
1. The consolidated financial statements of Sybron International
Corporation and its subsidiaries filed under Item 8:
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report.......................................... 31
Consolidated Balance Sheets as of September 30, 1995 and 1996......... 32
Consolidated Statements of Income for the years ended September 30,
1994, 1995 and 1996................................................. 33
Consolidated Statements of Shareholders' Equity for the years ended
September 30, 1994, 1995 and 1996................................... 34
Consolidated Statements of Cash Flows for the years ended September
30, 1994, 1995 and 1996............................................. 35
Notes to Consolidated Financial Statements............................ 36
</TABLE>
2. Financial Statement Schedules.
The following report and financial statement schedule should be read in
conjunction with the consolidated financial statements set forth in Item 8:
<TABLE>
<CAPTION>
PAGE
----
<S> <C>
Independent Auditors' Report.......................................... S-1
Schedule II -- Valuation and Qualifying Accounts...................... S-2
</TABLE>
Schedules other than those listed above are omitted because they are not
applicable or because the required information is given in the consolidated
financial statements and notes thereto.
3. Exhibits and Exhibit Index.
See the Exhibit Index included as the last part of this report, which is
incorporated herein by reference. Each management contract and compensatory plan
or arrangement required to be filed as an exhibit to this report is identified
in the Exhibit Index by an asterisk following its exhibit number.
(b) Reports on Form 8-K.
No reports on Form 8-K were filed by the Company during the fourth quarter
of its 1996 fiscal year.
58
<PAGE> 62
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
December 20, 1996 SYBRON INTERNATIONAL CORPORATION
By /s/ KENNETH F. YONTZ
------------------------------------------
Kenneth F. Yontz, Chairman of the Board,
President, and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Principal Executive Officer:
/s/ KENNETH F. YONTZ Chairman of the Board,
------------------------------- President and Chief Executive Officer
Kenneth F. Yontz
December 20, 1996
Principal Financial Officer and
Principal Accounting Officer:
/s/ DENNIS BROWN Vice President -- Finance,
-------------------------------- Chief Financial Officer and Treasurer
Dennis Brown
December 20, 1996
All of the members of the Board of Directors:
Don H. Davis, Jr. /s/ R. JEFFREY HARRIS
Robert B. Haas -------------------------------------
Thomas O. Hicks R. Jeffrey Harris,
Joe L. Roby Attorney and Agent for each member of
Richard W. Vieser the Board of Directors of
Kenneth F. Yontz Sybron International Corporation
under
Powers of Attorney
dated December 6, 1996
December 20, 1996
59
<PAGE> 63
INDEPENDENT AUDITORS' REPORT
The Board of Directors and Shareholders
Sybron International Corporation:
Under date of November 8, 1996, we reported on the consolidated balance
sheets of Sybron International Corporation and subsidiaries as of September 30,
1995 and 1996, and the related consolidated statements of income, shareholders'
equity, and cash flows for each of the years in the three-year period ended
September 30, 1996, which are included in the 1996 Annual Report on Form 10-K.
In connection with our audits of the aforementioned consolidated financial
statements, we also audited the related financial statement schedule as listed
in Item 14. This financial statement schedule is the responsibility of the
Company's management. Our responsibility is to express an opinion on the
financial statement schedule based on our audits.
In our opinion, such financial statement schedule, when considered in
relation to the basic consolidated financial statements taken as a whole,
presents fairly, in all material respects, the information set forth therein.
KPMG Peat Marwick LLP
Milwaukee, Wisconsin
November 8, 1996
S-1
<PAGE> 64
SCHEDULE II
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
VALUATION AND QUALIFYING ACCOUNTS
FOR THE YEARS ENDED SEPTEMBER 30, 1994, 1995 AND 1996
(IN THOUSANDS)
<TABLE>
<CAPTION>
ADDITIONS
------------------------
BALANCE AT CHARGED TO CHARGED TO
BEGINNING COSTS AND OTHER BALANCE AT
DESCRIPTION OF YEAR EXPENSES ACCOUNTS DEDUCTIONS END OF YEAR
- ------------------------------------------ ------------ ---------- ---------- ---------- -----------
<S> <C> <C> <C> <C> <C>
Year ended September 30, 1994
Deducted from asset accounts:
Allowance for doubtful receivables... $2,579 $ 998 $216(d) $ 332(a) $ 3,461
====== ====== ==== ====== ======
Inventory reserves................... $2,833 $ 960 $367(d) $ 665(b) $ 3,495
====== ====== ==== ====== ======
Legal reserves.......................... $2,029 $2,036 $ 19(d) $1,633(c) $ 2,451
====== ====== ==== ====== ======
Year ended September 30, 1995
Deducted from asset accounts:
Allowance for doubtful receivables... $3,461 $ 503 $283(d) $1,892(a) $ 2,355
====== ====== ==== ====== ======
Inventory reserves................... $3,495 $1,810 $792(d) $2,513(b) $ 3,584
====== ====== ==== ====== ======
Legal reserves.......................... $2,451 $2,371 $ -- $1,416(c) $ 3,406
====== ====== ==== ====== ======
Year ended September 30, 1996
Deducted from asset accounts:
Allowance for doubtful receivables... $2,355 $1,129 $207(d) $1,262(a) $ 2,429
====== ====== ==== ====== ======
Inventory reserves................... $3,584 $2,845 $756(d) $1,304(b) $ 5,881
====== ====== ==== ====== ======
Legal reserves.......................... $3,406 $1,066 $ -- $1,047(c) $ 3,425
====== ====== ==== ====== ======
</TABLE>
- ---------------
Note: Above additions and deductions include the effects of foreign currency
rate changes.
(a) Uncollectible accounts written off, net of recoveries.
(b) Inventory written off.
(c) Net disbursements.
(d) Reserves of acquired businesses.
S-2
<PAGE> 65
SYBRON INTERNATIONAL CORPORATION
(THE "REGISTRANT")
(COMMISSION FILE NO. 1-11091)
EXHIBIT INDEX
TO
1996 ANNUAL REPORT ON FORM 10-K
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
3.1 -- Articles of Incorporation of the Registrant Exhibit B to the 1994
Annual Meeting Proxy
Statement of Sybron
Corporation dated
December 17, 1993 ("1994
Proxy Statement")
3.2 -- Bylaws of the Registrant Exhibit C to the 1994
Proxy Statement
4.1 -- Articles of Incorporation and Bylaws of the Exhibits 3.1 and 3.2
Registrant hereto
4.2 -- Amended and Restated Credit Agreement dated Exhibit 4.1 to the
as of July 31, 1995 (the "Credit Agreement"), Registrant's Current
among Sybron International Corporation and Report on Form 8-K dated
certain of its subsidiaries, the several July 31, 1995 ("7/31/95
Lenders from time to time parties thereto, 8-K")
Chemical Securities Inc. as Arranger, and
Chemical Bank, as Administrative Agent for
the Lenders
4.3 -- Form of Revolving Credit Note, dated as of Exhibit 4.2 to the
July 31, 1995, executed pursuant to the 7/31/95 8-K
Credit Agreement
4.4 -- Form of Term Note, dated as of July 31, 1995, Exhibit 4.3 to the
executed pursuant to the Credit Agreement 7/31/95 8-K
4.5 -- Form of Swing Line Note, dated as of July 31, Exhibit 4.4 to the
1995, executed pursuant to the Credit 7/31/95 8-K
Agreement
4.6 -- Form of Amended and Restated Parent Pledge Exhibit 4.5 to the
Agreement, dated as of July 31, 1995, 7/31/95 8-K
executed pursuant to the Credit Agreement
4.7 -- Form of Amended and Restated Subsidiaries Exhibit 4.6 to the
Guarantee, dated as of July 31, 1995, 7/31/95 8-K
executed pursuant to the Credit Agreement
4.8 -- Form of Amended and Restated Subsidiaries Exhibit 4.7 to the
Pledge Agreement, dated as of July 31, 1995, 7/31/95 8-K
executed pursuant to the Credit Agreement
</TABLE>
EI-1
<PAGE> 66
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
4.9 -- First Amendment, dated as of July 9, 1996, to Exhibit 4.1 to the
the Amended and Restated Credit Agreement, Registrant's Form 10-Q
dated as of July 31, 1995 (as amended, for the quarterly period
supplemented or otherwise modified from time ended June 30, 1996 (the
to time, the "Credit Agreement"), among the "6/30/96 10-Q")
Registrant and certain of its subsidiaries,
the several Lenders from time to time parties
thereto, Chase Securities Inc. (formerly
known as Chemical Securities Inc.), as
Arranger, and Chemical Bank (now known as
Chase Manhattan Bank), as Administrative
Agent for the Lenders
4.10 -- Form of Revolving Credit Note, dated as of Exhibit 4.2 to the
July 9, 1996, executed pursuant to the Credit 6/30/96 10-Q
Agreement
4.11 -- Form of CAF Advance Note, dated as of July 9, Exhibit 4.3 to the
1996, executed pursuant to the Credit 6/30/96 10-Q
Agreement
4.12 -- Amended and Restated Parent Pledge Agreement, Exhibit 4.4 to the
dated as of July 9, 1996, executed pursuant 6/30/96 10-Q
to the Credit Agreement
4.13 -- Form of Amended and Restated Subsidiaries Exhibit 4.5 to the
Guarantee, dated as of July 9, 1996, executed 6/30/96 10-Q
pursuant to the Credit Agreement
4.14 -- Form of Amended and Restated Subsidiaries Exhibit 4.6 to the
Pledge Agreement, dated as of July 9, 1996, 6/30/96 10-Q
executed pursuant to the Credit Agreement
10.1* -- Form of Employment Agreement with each of the Exhibit 10(a) to Sybron
following executive officers: Corporation's Form 10-K
Kenneth F. Yontz, for the fiscal year ended
Dennis Brown, September 30, 1993 ("1993
R. Jeffrey Harris, 10-K")
Floyd W. Pickrell, Jr.,
Frank H. Jellinek, Jr. and
Randy A. Hoff
10.2 -- Shareholders Agreement, dated as of May 6, Exhibit 10(f-2) to Sybron
1992, between Sybron Corporation and certain Corporation's
shareholders Registration Statement on
Form S-1 (No. 33-52614)
10.3* -- 1988 Stock Option Plan Exhibit 10(q) to Sybron
Corporation's
Registration Statement on
Form S-1 (No. 33-20829)
10.4* -- 1990 Stock Option Plan Exhibit 10(q-2) to Sybron
Corporation's
Registration Statement on
Form S-1 (No. 33-20829)
10.5* -- 1993 Long-Term Incentive Plan Exhibit A to the 1993
Annual Meeting Proxy
Statement of Sybron
Corporation dated
December 18, 1992
</TABLE>
EI-2
<PAGE> 67
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
10.6* -- 1994 Outside Directors' Stock Option Plan Exhibit D to the 1994
Proxy Statement
10.7* -- Amendment to the 1988 Stock Option Plan Exhibit 10(q-4) to Sybron
Corporation's Form 10-K
for the fiscal year ended
September 30, 1992 ("1992
10-K")
10.8* -- Amendment to the 1990 Stock Option Plan Exhibit 10(q-6) to the
1992 10-K
10.9* -- Form of Nonstatutory Stock Option Agreement Exhibit 10(r) to Sybron
under the 1988 Stock Option Plan Corporation's
Registration Statement on
Form S-1 (No. 33-20829)
10.10* -- Form of Nonstatutory Stock Option Agreement Exhibit 10(s-1) to Sybron
under the 1990 Stock Option Plan Corporation's
Registration Statement on
Form S-1 (No. 33-20829)
10.11* -- Form of Nonstatutory Stock Option Agreement Exhibit 10(u) to the 1993
under the 1993 Long-Term Incentive Plan 10-K
10.12* -- Form of Indemnity Agreement with each of the Exhibit 10(v) to the 1993
executive officers and directors identified 10-K
on the schedule thereto
10.13 -- Lease Agreement dated December 21, 1988 Exhibit 10(bb) to Sybron
between CPA:7 and CPA:8, as landlord, and Corporation's
Ormco Corporation; as tenant Registration Statement on
Form S-1 (No. 33-24640)
10.14 -- Lease Agreement dated December 21, 1988 Exhibit 10(cc) to Sybron
between CPA:7 and CPA:8, as landlord, and Corporation's
Barnstead Thermolyne Corporation, as tenant Registration Statement on
Form S-1 (No. 33-24640)
10.15 -- Lease Agreement dated December 21, 1988 Exhibit 10(dd) to Sybron
between CPA:7 and CPA:8, as landlord, and Corporation's
Kerr Manufacturing Company, as tenant Registration Statement on
Form S-1 (No. 33-24640)
10.16 -- Lease Agreement dated December 21, 1988 Exhibit 10(ee) to Sybron
between CPA:7 and CPA:8, as landlord, and Corporation's
Erie Scientific Company, as tenant Registration Statement on
Form S-1 (No. 33-24640)
10.17 -- Lease Agreement dated December 21, 1988 Exhibit 10(ff) to Sybron
between CPA:7 and CPA:8, as landlord, and Corporation's
Nalge Nunc International Corporation Registration Statement on
(formerly Nalge Company), as tenant File S-1 (No. 33-24640)
10.18 -- Guaranty and Suretyship Agreement dated Exhibit 10(gg) to Sybron
December 21, 1988 between Sybron Corporation Corporation's
and CPA:7 and CPA:8 Registration Statement on
Form S-1 (No. 33-24640)
</TABLE>
EI-3
<PAGE> 68
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
10.19 -- Tenant Agreement dated December 21, 1988 Exhibit 10(rr) to Sybron
between New England Mutual Life Insurance Corporation's
Company, as lender, and CPA:7 and CPA:8, as Registration Statement on
landlord, and Ormco Corporation, as tenant Form S-1 (No. 33-24640)
10.20 -- Tenant Agreement dated December 21, 1988 Exhibit 10(ss) to Sybron
between New England Mutual Life Insurance Corporation's
Company, as lender, and CPA:7 and CPA:8, as Registration Statement on
landlord, and Barnstead Thermolyne Form S-1 (No. 33-24640)
Corporation, as tenant
10.21 -- Tenant Agreement dated December 21, 1988 Exhibit 10(tt) to Sybron
between New England Mutual Life Insurance Corporation's
Company, as lender, and CPA:7 and CPA:8, as Registration Statement on
landlord, and Kerr Manufacturing Company, as Form S-1 (No. 33-24640)
tenant
10.22 -- Tenant Agreement dated December 21, 1988 Exhibit 10(uu) to Sybron
between New England Mutual Life Insurance Corporation's
Company, as lender, and CPA:7 and CPA:8, as Registration Statement on
landlord, and Erie Scientific Company, as Form S-1 (No. 33-24640)
tenant
10.23 -- Tenant Agreement dated December 21, 1988 Exhibit 10(vv) to Sybron
between New England Mutual Life Insurance Corporation's
Company, as lender, and CPA:7 and CPA:8, as Registration Statement on
landlord, and Nalge Nunc International Form S-1 (No. 33-24640)
Corporation (formerly Nalge Company), as
tenant
10.24 -- Sale and Leaseback Agreement dated December Exhibit 10(ww) to Sybron
21, 1988 between Sybron Corporation and New Corporation's
England Mutual Life Insurance Company, as Registration Statement on
lender Form S-1 (No. 33-24640)
10.25 -- Environmental Risk Agreement dated December Exhibit 10(xx) to Sybron
21, 1988 from Sybron Corporation and Ormco Corporation's
Corporation, as indemnitors, to New England Registration Statement on
Mutual Life Insurance Company, as lender, and Form S-1 (No. 33-24640)
CPA:7 and CPA:8, as borrowers
10.26 -- Environmental Risk Agreement dated December Exhibit 10(yy) to Sybron
21, 1988 from Sybron Corporation and Corporation's
Barnstead Thermolyne Corporation, as Registration Statement on
indemnitors, to New England Mutual Life Form S-1 (No. 33-24640)
Insurance Company, as lender, and CPA:7 and
CPA:8, as borrowers
10.27 -- Environmental Risk Agreement dated December Exhibit 10(zz) to Sybron
21, 1988 from Sybron Corporation and Kerr Corporation's
Manufacturing Company, as indemnitors, to New Registration Statement on
England Mutual Life Insurance Company, as Form S-1 (No. 33-24640)
lender, and CPA:7 and CPA:8, as borrowers
10.28 -- Environmental Risk Agreement dated December Exhibit 10(aaa) to Sybron
21, 1988 from Sybron Corporation and Erie Corporation's
Scientific Company, as indemnitors, to New Registration Statement on
England Mutual Life Insurance Company, as Form S-1 (No. 33-24640)
lender, and CPA:7 and CPA:8, as borrowers
</TABLE>
EI-4
<PAGE> 69
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
10.29 -- Environmental Risk Agreement dated December Exhibit 10(bbb) to Sybron
21, 1988 from Sybron Corporation and Nalge Corporation's
Nunc International Corporation (formerly Registration Statement on
Nalge Company), as indemnitors, to New Form S-1 (No. 33-24640)
England Mutual Life Insurance Company, as
lender, and CPA:7 and CPA:8, as borrowers
10.30* -- Life insurance policy for Kenneth F. Yontz, Exhibit 10(eee) to Sybron
executive officer of the Registrant Corporation's
Registration Statement on
Form S-1 (No. 33-45948)
10.31* -- Life insurance policy for Frank H. Jellinek, Exhibit 10(eee-1) to
Jr., executive officer of the Registrant Sybron Corporation's
Registration Statement on
Form S-1 (No. 33-45948)
10.32* -- Life insurance policy for Floyd W. Pickrell, Exhibit 10(eee-4) to
Jr., executive officer of the Registrant Sybron Corporation's
Registration Statement on
Form S-1 (No. 33-45948)
10.33* -- Life insurance policy for David T. Della Exhibit 10(eee-3) to
Penta, executive officer of the Registrant Sybron Corporation's
Registration Statement on
Form S-1 (No. 33-45948)
10.34* -- Life insurance policy for R. Jeffrey Harris, Exhibit 10(rr) to the
executive officer of the Registrant 1993 10-K
10.35 -- Lease Agreement, as amended, with respect to Exhibit 10(fff) to Sybron
Ormco Corporation's manufacturing facility in Corporation's
Glendora, CA Registration Statement on
Form S-1 (No. 33-20829)
10.36* -- Employment Agreement, dated Exhibit 10(ggg) to Sybron
February 24, 1992, with David T. Della Penta, Corporation's
executive officer of the Registrant Registration Statement on
Form S-1 (No. 33-45948)
10.37* -- Amended and Restated 1993 Long-Term Incentive Exhibit A to the
Plan Registrant's 1995 Annual
Meeting Proxy Statement
dated December 16, 1994
("1995 Proxy Statement")
10.38* -- Senior Executive Incentive Compensation Plan, Exhibit B to the 1995
effective October 1, 1994 Proxy Statement
10.39* -- Life insurance policy for Dennis Brown, Exhibit 10.42 to the
executive officer of the Registrant Registrant's Form 10-K
for the fiscal year ended
September 30, 1995 ("1995
10-K")
10.40* -- Life insurance policy for Randy A. Hoff, Exhibit 10.43 to the 1995
executive officer of the Registrant 10-K
10.41* -- Amended and Restated 1994 Outside Directors' X
Stock Option Plan
</TABLE>
EI-5
<PAGE> 70
<TABLE>
<CAPTION>
INCORPORATED HEREIN FILED
EXHIBIT NO. DESCRIPTION BY REFERENCE TO HEREWITH
- ----------- --------------------------------------------- ------------------------- --------
<S> <C> <C> <C> <C>
10.42* -- Amended and Restated Senior Executive Exhibit A to the
Incentive Compensation Plan Registrant's 1997 Annual
Meeting Proxy Statement
dated December 20, 1996
11 -- Statement regarding computation of per share X
earnings
21 -- Subsidiaries of the Registrant X
23 -- Consent of KPMG Peat Marwick LLP X
24 -- Powers of Attorney of directors of the X
Registrant
27 -- Financial Data Schedule X
</TABLE>
- ---------------
* Denotes management contract or executive compensation plan or arrangement
required to be filed as an exhibit pursuant to Item 14(c) of Form 10-K.
EI-6
<PAGE> 1
EXHIBIT 10.41
SYBRON INTERNATIONAL CORPORATION
AMENDED AND RESTATED
1994 OUTSIDE DIRECTORS' STOCK OPTION PLAN
EFFECTIVE AS OF JANUARY 25, 1995
I. INTRODUCTION
1.01 PURPOSE. This plan shall be known as the Sybron International
Corporation Amended and Restated 1994 Outside Directors' Stock Option Plan (the
"Plan"). The purpose of the Plan is to provide an incentive for Outside
Directors of Sybron International Corporation to improve corporate performance
on a long-term basis. It is intended that the Plan and its operation comply with
the provisions of Rule 16b-3 under the Securities Exchange Act of 1934 (or any
successor rule). If any provision of the Plan or any grant hereunder would
disqualify the Plan or such grant under, or would not comply with, Rule 16b-3
(or any successor rule), such provision or grant shall be construed or deemed
amended to conform to Rule 16b-3.
1.02 EFFECTIVE DATE. The Plan first became effective on January 19, 1994,
upon approval by the Company's stockholders at the Company's 1994 annual
meeting.
II. PLAN DEFINITIONS
2.01 DEFINITIONS. For Plan purposes, except where the context clearly
indicates otherwise, the following terms shall have the meanings set forth
below:
(a) "Board" shall mean the Board of Directors of the Company.
(b) "Committee" shall have the meaning ascribed to such term in
Section 4.01 hereof.
(c) "Company" shall mean Sybron International Corporation, a Wisconsin
corporation, or any successor thereto as provided in Section 6.07
hereof, and, as the context may require, Sybron Corporation, a
Delaware corporation, the Company's predecessor prior to the
Delaware-to-Wisconsin change of domicile merger effective January
31, 1994.
(d) "Company Stock" shall mean the Company's Common Stock, par value
$0.01 per share, and such other stock and securities as may be
substituted therefor pursuant to Section 3.02 hereof.
(e) "Director" shall mean any individual who is a member of the Board.
(f) "Fair Market Value" means the average of the highest and lowest
quoted selling prices for the Company Stock on the relevant date,
or (if there were no sales on such date) the weighted average of
the means between the highest and lowest quoted selling prices on
the nearest day before and the nearest day after the relevant
date, as reported in The Wall Street Journal or a similar
publication selected by the Committee.
(g) "Grantee" shall mean any person who has been granted an option
under the Plan.
(h) "Outside Director" shall mean a Director who is not also an active
full-time employee of the Company or a corporation in which the
Company owns, directly or indirectly, a voting stock interest of
more than fifty percent (50%).
III. SHARES SUBJECT TO OPTION
3.01 AVAILABLE SHARES. The total number of shares of Company Stock that may
be issued under the Plan shall not exceed One Hundred Thousand (100,000) shares.
Shares subject to and not issued under an option which expires, terminates, or
is cancelled for any reason under the Plan shall again become available for
granting of options.
3.02 CHANGES IN COMMON STOCK. If any stock dividend is declared upon the
Company Stock, or if there is any stock split, stock distribution, or other
recapitalization of the Company with respect to the Company
1
<PAGE> 2
Stock, resulting in a split or combination or exchange of shares, the aggregate
number and kind of shares which may thereafter be granted under the Plan shall
be proportionately and appropriately adjusted and the number and kind of shares
then subject to options under the Plan and the per share option price therefor
shall be proportionately and appropriately adjusted, without any change in the
aggregate purchase prices to be paid therefor.
IV. ADMINISTRATION
4.01 ADMINISTRATION BY THE COMMITTEE. The Plan shall be administered by the
Compensation/Stock Option Committee (the "Committee") of the Board (or any
successor committee) which shall have the power, subject to and within the
limits of the express provisions of the Plan, to exercise such powers and to
perform such acts as are deemed necessary or expedient to promote the best
interests of the Company with respect to the Plan. The Committee shall have no
discretion as to the amount, price, timing or exercisability of any option
granted under this Plan.
V. STOCK OPTIONS
5.01 OPTION AGREEMENTS. Each option granted under the Plan shall be
evidenced by a stock option agreement between the Company and the Grantee which
shall contain the terms and conditions required by this Article V, and such
other terms and conditions, not inconsistent herewith, as the Committee may deem
appropriate in each case. The holder of an option shall not have any rights as a
stockholder with respect to the shares covered by an option until such shares
have been delivered to him or her.
5.02 OPTION GRANT SIZE AND GRANT DATE.
(a) Automatic Grants. Upon the first meeting of the Board following
the Company's 1994, 1995, 1996, 1997 and 1998 annual meetings of
stockholders, each person then serving the Company as an Outside
Director shall automatically be granted a nonqualified stock
option to purchase Three Thousand (3,000) shares, subject to
adjustment under Section 3.02 hereof.
(b) Special Rule. If at any time there are not sufficient available
shares under the Plan to grant each Outside Director an option to
purchase the number of shares provided above, each Outside
Director shall receive an option to purchase an equal number of
the remaining available shares, determined by dividing the
remaining available shares by the number of Outside Directors.
5.03 EXERCISE PRICE. The price at which each share of Company Stock covered
by an option may be purchased shall be one hundred percent (100%) of the Fair
Market Value of the Company Stock on the date the option is granted.
5.04 PERIOD FOR EXERCISE OF OPTIONS. Each stock option granted under this
Plan shall become exercisable six months from the date of grant, regardless of
whether the Grantee is still a Director on such date. All rights to exercise an
option shall terminate upon the earlier of (a) ten (10) years from the date the
option is granted, or (b) two (2) years from the date the Grantee ceases to be a
Director.
5.05 METHOD OF EXERCISE. Subject to Section 5.04, each option may be
exercised in whole or in part from time to time as specified in the stock option
agreement. Each Grantee may exercise an option by giving written notice of the
exercise to the Company, specifying the number of shares to be purchased,
accompanied by payment in full of the exercise price therefor. The exercise
price may be paid in cash, by check, or by delivering shares of Company Stock
which have been beneficially owned by the Grantee, the Grantee's spouse, or both
of them for a period of at least six months prior to the time of exercise
("Delivered Stock") or a combination of cash and Delivered Stock. Delivered
Stock shall be valued at its Fair Market Value determined as of the date of
exercise of the option. No Grantee shall be under any obligation to exercise any
option hereunder.
5.06 LIMITATION ON PLAN AMENDMENTS. The option grants hereunder are
intended to be formula awards for the purposes of Rule 16b-3 under the
Securities Exchange Act of 1934 (or any successor rule). Accordingly, the
provisions of this Article V may not be amended more than once every six months.
2
<PAGE> 3
VI. GENERAL
6.01 NONTRANSFERABILITY. No option granted under the Plan shall be
transferable or assignable except by last will and testament or the laws of
descent and distribution. During the Grantee's lifetime, options shall be
exercisable only by the Grantee or by the Grantee's guardian or legal
representative. In the event of the Grantee's death, the Grantee's beneficiary
designated pursuant to Section 6.08 hereof or, in the absence of any such
designation, the personal representative of the Grantee's estate or the person
or persons to whom the option is transferred by will or the laws of descent and
distribution may exercise the option in accordance with its terms.
6.02 GENERAL RESTRICTION. Each option shall be subject to the requirement
that if at any time the Board shall determine, in its discretion, that the
listing, registration, or qualification of securities upon any securities
exchange or under any state or federal law, or the consent or approval of any
government regulatory body, is necessary or desirable as a condition of, or in
connection with, the granting of such option or the issue or purchase of
securities thereunder, such option may not be exercised in whole or in part
unless such listing, registration, qualification, consent or approval shall have
been effected or obtained free of any conditions not acceptable to the Board.
6.03 EXPIRATION AND TERMINATION OF THE PLAN. Options may be granted under
the Plan at any time and from time to time, prior to September 30, 1998, the
date on which the Plan will expire, except as to options then outstanding under
the Plan, which shall remain in effect until they have been exercised or have
expired. The Plan may be abandoned or terminated at any time by the Board except
with respect to any options then outstanding under the Plan.
6.04 AMENDMENT, MODIFICATION AND TERMINATION. With approval of the Board,
at any time and from time to time, the Committee may terminate, amend, or modify
the Plan. However, no such amendment, modification, or termination of the Plan
may be made without the approval of the stockholders of the Company, if such
approval is required by the Internal Revenue Code of 1986, as amended, by the
insider trading rules of Section 16 of the Securities Exchange Act of 1934, by
any national securities exchange or system on which the Company Stock is then
listed or reported, or by a regulatory body having jurisdiction with respect
thereto. No termination, amendment, or modification of the Plan shall in any
material manner adversely affect any option previously granted under the Plan,
without the written consent of the Grantee holding such option.
6.05 WITHHOLDING TAXES.
(a) The Company shall have the power and the right to deduct or
withhold, or require a Grantee to remit to the Company, an amount
sufficient to satisfy any federal, state and local taxes required
by law to be withheld with respect to any grant, exercise, or
payment made under or as a result of the Plan.
(b) With respect to tax withholding which may be required upon the
exercise of options, Grantees may elect, subject to the approval
of the Committee, to satisfy such withholding requirement, in
whole or in part, by having the Company withhold shares of Company
Stock having a Fair Market Value on the date the tax is to be
determined, equal to the minimum marginal total tax which could be
imposed on the transaction. All elections shall be irrevocable,
made in writing, signed by the Grantee, and comply with the
applicable requirement set forth in (c) below.
(c) The Grantee must either:
(i) Deliver written notice of the stock withholding election to the
Committee at least six (6) months prior to the date specified
by the Grantee on which the exercise of the option is to occur;
or
(ii) Make the stock withholding election in connection with an
exercise of an option which occurs during a Window Period.
3
<PAGE> 4
For this purpose, "Window Period" means the period beginning on the
third (3rd) business day following the date of public release of the
Company's quarterly sales and earnings information, and ending on the
twelfth (12th) business day following such date.
6.06 CONSTRUCTION. Except as otherwise required by applicable federal laws,
the Plan shall be governed by, and construed in accordance with, the laws of the
state of the Company's incorporation.
6.07 SUCCESSORS. All obligations of the Company under the Plan shall be
binding on any successor to the Company, whether the existence of such successor
is the result of a direct or indirect purchase, merger, consolidation, or
otherwise, of all or substantially all of the business and/or assets of the
Company.
6.08 BENEFICIARY DESIGNATION. Each Grantee may, from time to time, name any
beneficiary or beneficiaries (who may be named contingently or successively) who
shall be entitled to exercise his or her options in accordance with their terms
in the event of his or her death before he or she exercises all of his or her
outstanding options. Each such designation shall revoke all prior designations
by the same Grantee, shall be in a form prescribed by the Company, and will be
effective only when filed by the Grantee in writing with the Human Resource
Department of the Company during the Grantee's lifetime.
4
<PAGE> 1
EXHIBIT 11
SYBRON INTERNATIONAL CORPORATION AND SUBSIDIARIES
COMPUTATION OF PER SHARE EARNINGS
(IN THOUSANDS, EXCEPT PER SHARE DATA)
<TABLE>
<CAPTION>
YEARS ENDED SEPTEMBER 30,
-----------------------------
1994 1995 1996
------- ------- -------
<S> <C> <C> <C>
Earnings:
Income before extraordinary item and cumulative effect of
change in accounting principle.............................. $43,015 $51,800 $57,584
Extraordinary item............................................. -- (2,885) --
Cumulative effect of change in accounting principle............ (420) -- --
------- ------- -------
Net income..................................................... $42,595 $48,915 $57,584
======= ======= =======
Primary:
Shares:
Weighted average common shares.............................. 46,338 46,416 46,733
Common equivalent shares.................................... 234 562 1,184
------- ------- -------
46,572 46,978 47,917
======= ======= =======
Per Share:
Earnings before extraordinary item and cumulative effect of
change in accounting principle............................ $ .92 $ 1.10 $ 1.20
Extraordinary item.......................................... -- (.06) --
Cumulative effect of change in accounting principle......... (.01) -- --
------- ------- -------
Net earnings................................................ $ .91 $ 1.04 $ 1.20
======= ======= =======
Fully diluted:
Shares:
Weighted average common shares.............................. 46,338 46,416 46,733
Common equivalent shares.................................... 286 600 1,316
------- ------- -------
46,624 47,016 48,049
======= ======= =======
Per Share:
Earnings before extraordinary item and cumulative effect of
change in accounting principle............................ $ .92 $ 1.10 $ 1.20
Extraordinary item.......................................... -- (.06) --
Cumulative effect of change in accounting principle......... (.01) -- --
------- ------- -------
Net earnings................................................ $ .91 $ 1.04 $ 1.20
======= ======= =======
</TABLE>
<PAGE> 1
EXHIBIT 21
LIST OF SUBSIDIARIES
JURISDICTION OF
---------------
COMPANY NAME INCORPORATION OR ORGANIZATION
------------ -----------------------------
1. Allesee Orthodontic Appliances, Inc. Wisconsin
2. Barnstead Thermolyne Corporation Delaware
3. Bedford Mirror, Inc. Connecticut
4. belle de st. claire, inc. Wisconsin
5. CASCO Standards, Inc. Wisconsin
6. Erie Electroverre SA Switzerland
7. Erie Scientific Company Delaware
8. Erie Scientific Company of Puerto Rico Delaware
9. Erie Scientific Hungary Kft. Hungary
10. Erie-Watala Glass Company Limited Hong Kong
11. Ever Ready Thermometer Co., Inc. Wisconsin
12. Flexible Components, Inc. Wisconsin
13. Gerhard Menzel Glasbearbeitungswerk
GmbH & Co. KG Germany
14. Kerr Australia Pty. Ltd. Australia
15. Kerr Corporation Delaware
16. Kerr GmbH Germany
17. Kerr Italia S.p.A. Italy
18. Kerr UK Limited England
19. Metavac, Inc. Connecticut
20. Metrex Research Corporation Wisconsin
21. Nalge Nunc International Corporation Delaware
22. Nalge (Europe) Limited England
23. The Naugatuck Glass Company Connecticut
24. New England Reagent Laboratory, Inc. Wisconsin
25. Nunc A/S Denmark
26. Nunc GmbH & Co. KG Germany
27. Ormco Corporation Delaware
28. Ormco de Mexico SA de CV Mexico
29. Ormco (Europe) AG Switzerland
30. Ormco Pty. Ltd. Australia
31. Ormex SA de CV Mexico
32. Pure Fit, Inc. Wisconsin
33. Richard-Allan Scientific Company Wisconsin
34. SDS de Mexico SA de CV Mexico
35. Sani-Tech, Inc. Wisconsin
36. Sybron Canada Limited Canada
37. Sybron Dental Specialties, Inc. Delaware
38. Sybron Dental Specialties Japan, Inc. Japan
<PAGE> 1
EXHIBIT 23
CONSENT OF KPMG PEAT MARWICK LLP
The Board of Directors and Shareholders
Sybron International Corporation:
We consent to incorporation by reference in the registration statements
(Nos. 33-54434, 33-54436, 33-74112, 33-80098 and 33-94822) on Form S-8 and the
registration statement (No. 33-68690) on Form S-3 of Sybron International
Corporation of our reports dated November 8, 1996, relating to the consolidated
balance sheets of Sybron International Corporation and subsidiaries as of
September 30, 1995 and 1996, and the related consolidated statements of income,
shareholders' equity, and cash flows and the related financial statement
schedule for each of the years in the three-year period ended September 30,
1996, which reports appear in the September 30, 1996 Annual Report on Form 10-K
of Sybron International Corporation.
KPMG Peat Marwick LLP
Milwaukee, Wisconsin
December 19, 1996
<PAGE> 1
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"); and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K Annual
Report for the fiscal year ended September 30, 1996, and any amendment(s)
thereto, filed with the Securities and Exchange Commission pursuant to the
requirements of the Act, the undersigned hereby ratifying and confirming all
that said attorneys and agents, or either of them, shall do or cause to be done
by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these presents
as of the 6th day of December, 1996.
/s/ Kenneth F. Yontz
---------------------
Kenneth F. Yontz
<PAGE> 2
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"); and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K Annual
Report for the fiscal year ended September 30, 1996, and any amendment(s)
thereto, filed with the Securities and Exchange Commission pursuant to the
requirements of the Act, the undersigned hereby ratifying and confirming all
that said attorneys and agents, or either of them, shall do or cause to be done
by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these presents
as of the 6th day of December, 1996.
/s/ Joe L. Roby
----------------
Joe L. Roby
<PAGE> 3
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"); and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K Annual
Report for the fiscal year ended September 30, 1996, and any amendment(s)
thereto, filed with the Securities and Exchange Commission pursuant to the
requirements of the Act, the undersigned hereby ratifying and confirming all
that said attorneys and agents, or either of them, shall do or cause to be done
by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these presents
as of the 6th day of December, 1996.
/s/ Thomas O. Hicks
--------------------
Thomas O. Hicks
<PAGE> 4
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"), and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K Annual
Report for the fiscal year ended September 30, 1996, and any amendment(s)
thereto, filed with the Securities and Exchange Commission pursuant to the
requirements of the Act, the undersigned hereby ratifying and confirming all
that said attorneys and agents, or either of them, shall do or cause to be done
by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these presents
as of the 6th day of December, 1996.
/s/ Robert B. Haas
-------------------
Robert B. Haas
<PAGE> 5
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"); and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K Annual
Report for the fiscal year ended September 30, 1996, and any amendment(s)
thereto, filed with the Securities and Exchange Commission pursuant to the
requirements of the Act, the undersigned hereby ratifying and confirming all
that said attorneys and agents, or either of them, shall do or cause to be done
by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these presents
as of the 6th day of December, 1996.
/s/ Richard W. Vieser
----------------------
Richard W. Vieser
<PAGE> 6
EXHIBIT 24
POWER OF ATTORNEY
The undersigned, a director of Sybron International Corporation, hereby
constitutes and appoints R. Jeffrey Harris and Dennis Brown, or either of them,
his true and lawful attorneys and agents, each with full power and authority to
act as such without the other, to do any and all acts and things and to execute
any and all instruments which either one of said attorneys and agents may deem
necessary or advisable to enable said Corporation to comply with the Securities
Exchange Act of 1934 as amended (the "Act"); and including specifically, but
without limitation of the foregoing, full power and authority to each of said
attorneys and agents to sign the name of the undersigned to the Form 10-K
Annual Report for the fiscal year ended September 30, 1996, and any
amendment(s) thereto, filed with the Securities and Exchange Commission
pursuant to the requirements of the Act, the undersigned hereby ratifying and
confirming all that said attorneys and agents, or either of them, shall do or
cause to be done by virtue hereof.
IN WITNESS WHEREOF, the undersigned has signed and delivered these
presents as of the 6th day of December, 1996.
/s/ Don H. Davis, Jr.
-----------------------
Don H. Davis, Jr.
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY INFORMATION EXTRACTED FROM THE CONSOLIDATED
FINANCIAL STATEMENTS OF SYBRON INTERNATIONAL CORPORATION FOR THE YEAR ENDED
SEPTEMBER 30, 1996 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH
FINANCIAL STATEMENTS
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> YEAR
<FISCAL-YEAR-END> SEP-30-1996
<PERIOD-START> OCT-01-1995
<PERIOD-END> SEP-30-1996
<CASH> 10,874
<SECURITIES> 0
<RECEIVABLES> 127,849
<ALLOWANCES> 2,429
<INVENTORY> 120,317
<CURRENT-ASSETS> 282,640
<PP&E> 170,151
<DEPRECIATION> 123,429
<TOTAL-ASSETS> 974,613
<CURRENT-LIABILITIES> 138,767
<BONDS> 521,640
0
0
<COMMON> 469
<OTHER-SE> 282,610
<TOTAL-LIABILITY-AND-EQUITY> 974,613
<SALES> 674,457
<TOTAL-REVENUES> 674,457
<CGS> 337,830
<TOTAL-COSTS> 199,894
<OTHER-EXPENSES> 284
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 35,523
<INCOME-PRETAX> 100,926
<INCOME-TAX> 43,342
<INCOME-CONTINUING> 57,584
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 57,584
<EPS-PRIMARY> 1.20
<EPS-DILUTED> 1.20
</TABLE>
